Notice of Annual General Meeting in Thule Group AB

RIGHT TO ATTEND Shareholders who wish to attend the AGM must: –         be recorded in the share register kept by Euroclear Sweden AB (the Swedish Central Securities Depository) on Thursday 20 April 2017, and –         notify the company of their intention to attend the AGM by Thursday 20 April 2017, preferably before 4.00 p.m. CET. In order to participate in the AGM, shareholders with nominee-registered shares should request their bank or broker to have the shares temporarily owner-registered with Euroclear Sweden AB by Thursday 20 April 2017. Shareholders are therefore requested to notify their nominees in due time before the said date. NOTICE OF ATTENDANCENotice of attendance shall be made in writing to Thule Group AB, “AGM”, Fosievägen 13,SE-214 31 Malmö, Sweden, by telephone +46 40 635 9099, or on the company’s website, www.thulegroup.com. The notice of attendance shall state name, personal (or corporate) identity number, shareholding, telephone number and name of advisor, if any. Shareholders represented by proxy should submit a power of attorney to the company prior to the AGM. A proxy form is available at the company and on the company’s website. Representatives of a legal entity shall present a copy of the certificate of registration or similar document of authorisation. PROPOSAL FOR AGENDA 1. Opening of the Meeting 2. Election of Chairman of the Meeting 3. Preparation and approval of the voting list 4. Approval of the agenda 5. Election of person(s) to approve the minutes 6. Determination of compliance with the rules of convocation 7. The CEO’s report 8. Report on the work of the Board of Directors, including the work and functions of the Remuneration Committee and the Audit Committee appointed by the Board 9. Presentation of(a) the Annual Report and the Auditor’s Report(b) the Consolidated Accounts and the Group Auditor’s Report(c) the statement by the auditor on the compliance of the Guidelines for Remuneration to Senior Executives(d) the Board’s proposal for distribution of the Company’s profit and the Board’s reasoned statement thereon10. Resolution regarding(a)adoption of the Income Statement and the Balance Sheet as well as the Consolidated Income Statement and the Consolidated Balance Sheet(b) dispositions in respect of the company’s profit according to the adopted Balance Sheet and determination of the record date for dividend(c) discharge from liability of the Board of Directors and CEO11. Establishment of the number of Board members12. Establishment of fees to the Board members13. Election of the Board of Directors and the Chairman of the Board14. Establishment of the auditor’s fee15. Election of auditor16. Resolution regarding Guidelines for Remuneration to Senior Executives17. Resolution regarding an incentive program for executive management and key persons by way of (A) directed issue of subscription warrants, (B) approval of transfer of subscription warrants and (C) payment of retention bonus18. Closing of the Meeting PROPOSALS BY THE NOMINATION COMMITTEE (item 2 and 11-15)According to the resolution of the General Meeting, the Nomination Committee in respect of the AGM shall consist of representatives of the four largest shareholders registered in the share register kept by Euroclear Sweden AB as at 30 September every year and the Chairman of the Board. Accordingly, the Nomination Committee has consisted of Anders Oscarsson (appointed by AMF Försäkring och Fonder), Charlotta Faxén (appointed by Lannebo Fonder), Per Trygg (appointed by SEB Fonder), Johan Hernander (appointed by Nordea Fonder) and Stefan Jacobsson, in his capacity as Chairman of the Board of Thule Group. The Nomination Committee has proposed as follows:Chairman of the AGM: Stefan Jacobsson, Chairman of the Board, is proposed to be elected Chairman of the AGM. Board of Directors: The number of Board members shall be six, without any deputies. Re-election shall be made of the board members Stefan Jacobsson, Bengt Baron, Hans Eckerström, Liv Forhaug and Heléne Mellquist and new election of Eva Elmstedt. David Samuelson and Lilian Fossum Biner have declined re-election. Stefan Jacobsson shall be re-elected Chairman of the Board. Board member proposed for new election:Eva Elmstedt, born 1960, has a B.Sc. in Economics and Computer Science from the United States and Stockholm School of Economics. Eva Elmstedt has vast operational experience from more than 30 years in leading positions on a global level within Services, IT and Telecom, including from Nokia, Ericsson, the operator 3 and Semcon. The last two years, Eva Elmstedt’s principal occupation has been as professional board member and she is currently board member in Addtech AB (publ), ProAct IT Group AB (publ), Gunnebo AB (publ), Axiell AB and KnowIT AB (publ). Board and Committee fees: Board fees, excluding remuneration for Committee work, shall, unchanged, be paid by SEK 850,000 to the Chairman of the Board and SEK 325,000 to each of the Board members elected by the AGM. Work in the Audit Committee shall be remunerated by SEK 175,000 to the Chairman of the Audit Committee and SEK 60,000 to each of the other members. Work in the Remuneration Committee shall be remunerated by SEK 75,000 to the Chairman of the Remuneration Committee and SEK 35,000 to each of the other members. Auditor and Auditor’s fee: PricewaterhouseCoopers AB shall be elected auditor for the period until the end of the 2018 Annual General Meeting, in accordance with the recommendation of the Audit Committee. The auditor’s fee shall be paid according to approved invoice.  DIVIDEND (item 10 (b)) The Board and the CEO have proposed that a dividend of SEK 10.90 per share for 2016 shall be declared, whereof SEK 3.40 per share is ordinary dividend and SEK 7.50 is extraordinary dividend. It is proposed that the dividend shall be paid in two partial payments for a more favourable adaptation to the group’s cash flow profile. The Board has proposed 28 April 2017 as record date for the first payment of SEK 9.20 and 6 October 2017 as record date for the second payment of SEK 1.70. If the AGM resolves in accordance with the proposal, the first payment by Euroclear is expected to start on 4 May 2017 and the second payment on 11 October 2017.  GUIDELINES FOR REMUNERATION TO SENIOR EXECUTIVES (item 16) The Board proposes that the AGM resolves to adopt unchanged guidelines for the remuneration senior executives, in accordance with the following. The remuneration of senior executive management is to comprise fixed salary, possible variable salary, pension and other benefits. The total remuneration package should be based on market terms, be competitive and reflect the individual’s performance and responsibilities as well as, with respect to share based incentive schemes, the value growth of the Thule Group share benefitting the shareholders. The variable salary may comprise annual incentives in cash and long-term incentives in cash, shares and/or share-based instruments in Thule Group AB. Variable salary in cash is conditional upon the fulfillment of defined and measurable goals and should be maximized up to 75 per cent of the annual fixed salary for the CEO and for the other executive management up to 60 per cent. Terms and conditions for variable salary should be designed so that the Board, if exceptional economic circumstances prevail, has the option of limiting or refraining from payment of variable salary if such a measure is considered reasonable. Pension benefits should be defined contribution. Normally, severance payment is made when employment is terminated by Thule Group. Members of the Group Management generally have a period of notice of not more than 12 months, in combination with severance pay corresponding to 6-12 months fixed salary. No severance payment will be made when employment is terminated by the employee. The Board is to have the right to depart from the guidelines resolved on by the Annual General Meeting if, in an individual case, there are special reasons for this.  THE BOARD’S PROPOSAL FOR RESOLUTION ON INCENTIVE PROGRAM (item 17) The Board of Directors of Thule Group AB (publ) (the ”Company”) proposes that the general meeting resolves on an incentive program for executive management and key employees in the group based on issue and transfer of subscription warrants (the “Warrants Program 2017/2020”), on the following conditions. A.    Issue of subscription warrantsA maximum of 2,250,000 subscription warrants shall be issued. The right to subscribe for the subscription warrants shall, with deviation from the shareholders’ preferential right, vest in the Company’s wholly-owned subsidiary Thule AB, with right and obligation for the subsidiary to transfer the subscription warrants to executive management and key employees within Thule Group and its subsidiaries. Thule AB shall not be entitled to dispose of the subscription warrants in any other way. The subscription warrants shall be issued free of charge to Thule AB.Subscription for the subscription warrants shall be made on a separate subscription list on 30 June 2017 at the latest, with a right for the Board to extend the subscription period. Each subscription warrant shall entitle to subscription for one (1) new share in the Company. Subscription for shares by virtue of the subscription warrants may be effected as from 15 May 2020 up to and including 15 December 2020. The subscription price per share shall correspond to 118 per cent of the volume weighted mean value according to Nasdaq Stockholm’s official price list for share in the Company during the period from 27 April 2017 up to and including 4 May 2017. If, at the time of subscription, the share price most recently paid for a share in the Company at the closing of the stock exchange on the business day immediately preceding the subscription exceeds 162.3 per cent of the average share price upon which the subscription price has been determined, in accordance with the above, the subscription price shall be increased correspondingly by an amount equivalent to the amount of said closing price that exceeds 162.3 per cent of the average share price upon which the subscription price has been determined.A share, which has been issued upon subscription, will entitle to dividends for the first time on the first record date for dividend occurring after subscription of shares through exercise of warrants has been executed.The reasons for the deviation from the shareholders’ preferential right are that the Board is of the opinion that an incentive program which offers executive management and key employees the opportunity to take part in an increase in value of the Company will enhance the commitment and responsibility, and results in an increased motivation to work for a favorable financial development of the Company. An incentive program is also expected to improve the possibilities to recruit and retain competent, motivated and committed employees.  B.    Transfer of subscription warrantsThe subscription warrants shall be transferred by Thule AB, on one or several occasions, to employees within Thule Group and its subsidiaries, in accordance with the guidelines stated below. Transfer shall be made at market value at the time of transfer, to be established by Öhrlings PricewaterhouseCoopers AB, as an independent valuation institute, by application of the Black & Scholes valuation method. First allotment of subscription warrants shall be made to the CEO with a minimum of 125,000 and a maximum of 375,000 subscription warrants, to the CFO and President Region Americas with a minimum of 62,500 and a maximum of 187,500 subscription warrants per person and to other executive management and key employees (currently 8 persons) with a minimum of 43,750 and a maximum of 125,000 subscription warrants per person. The first allotment is expected to take place during May 2017. There will be no over-subscription.The total number of subscription warrants issued in Warrants Program 2017/2020 exceeds the number of subscription warrants expected to be allotted in the first allotment. The subscription warrants remaining after the first allotment may be allotted to future employees or employees who have been promoted at market value, applicable from time to time, in accordance with the allotment principles stated above, whereby the above stated number of employees in each category may be changed. Transfer of subscription warrants to future employees may not occur after the annual general meeting 2018. Right to allotment in the Warrants Program 2017/2020 requires that the employee, at the time for allotment, holds its position or has signed an agreement regarding it and has not, at such time, informed or been informed that the employment will be terminated.  C.    Retention bonusAs part of the Warrants Program 2017/2020, participants receive a retention bonus in the form of a gross salary addition from the Company that in total amounts to the amount paid by the participant for its subscription warrants, provided that the participant at the time of payment remains in its position (or equivalent) within the group and has not terminated its employment. The bonus is payable in connection with the ordinary salary payment in December 2020. The Board may, if necessary in individual cases, resolve on alternative payment schedules.  Participants in other jurisdictionsFor participants in jurisdictions other than Sweden, it is implied that the further transfer of the subscription warrants is legally possible and that further transfer, in the Board’s opinion, can be carried out with reasonable administrative and financial efforts at their established market value. The Board shall have the right to adjust the terms of the Warrants Program 2017/2020 to the extent required in order for allotment and exercise of subscription warrants to participants in other jurisdictions, to the extent practically possible, to be carried out under the same conditions imposed by the Warrants Program 2017/2020. Costs, dilution etc.The Company’s cost for the “retention bonus” to the participants is estimated, at full initial participation, including social security contributions, and at an assumed market value for the subscription warrants on the allotment date of SEK 8.40 per warrant, to amount to a maximum of approximately SEK 23.5 million. In addition, the Company may be charged minor costs for social security contributions for subscription warrants to participants in other jurisdictions. Other than that, the Warrants Program 2017/2020 is not expected to entail any significant costs for the Company. For that reason, no measures to secure the program has been taken.Assuming that all 2,250,000 subscription warrants in the Warrants Program 2017/2020 are exercised for subscription of new shares, the Company’s share capital will increase by a maximum of SEK 25,146.80, resulting in a maximum dilution effect equivalent to approximately 2.2 per cent calculated as the number of new shares in proportion to the number of existing shares. The key figure earnings per share for the full year 2016 had in such case been affected such that the result per share had been reduced by approximately SEK 0.08 from SEK 6.69 to SEK 6.61. The above is subject to re-calculations of the subscription warrants in accordance with the customary terms stated in the complete terms and conditions. Current incentive programThere are currently 1,666,666 issued subscription warrants within an incentive program for executive management and key employees in series 2014/2018, of which 1,302,889 subscription warrants have been allotted, which corresponds to a dilution of approximately 1.3 per cent, calculated as the number of new shares in proportion to the number of existing shares. Subscription warrants in series 2014/2018 can be exercised during 2018. The subscription price is currently SEK 88, however if at the time of subscription of new shares, the share price most recently paid for a share in the Company at the closing of the stock exchange on the business day immediately preceding the subscription exceeds 164 per cent of the subscription price, the subscription price shall be increased by an amount equivalent to the amount of said subscription price that exceeds 164 per cent of the subscription price. Eight persons that holds subscription warrants in series 2014/2018 are also intended to be included in Warrants Program 2017/2020. The preparation of the proposalThe proposal from the Board has been prepared by the Board’s Remuneration Committee and the Board. The company’s four largest shareholders, AMF Försäkring & Fonder, Lannebo Fonder, Nordea Fonder and SEB Fonder, has undertaken to support the proposal. Majority requirementThe resolution of the general meeting above is proposed to be adopted as one joint resolution. A valid resolution requires that shareholders representing at least nine tenths (9/10) of the votes cast and shares represented at the general meeting support the resolution. DOCUMENTS AND OTHER INFORMATION   The company’s financial statements, auditor’s report and other documents pursuant to item 9 and the Board’s complete proposals for the resolutions under item 16 and 17 will be available at the company and on the company’s website, www.thulegroup.com, from 5 April 2017 at the latest and will be sent to shareholders upon request. Copies will also be available at the AGM. The Board and the CEO shall at the AGM, if any shareholder so requests and the Board believes that it can be done without significant harm to the company, provide information regarding circumstances that may affect the assessment of an item on the agenda, circumstances that can affect the assessment of the company’s or its subsidiaries’ financial position and the company’s relation to other companies within the group. The total number of shares and votes in the company amounts to 102,072,910. The company holds no own shares.

Naturvårdsverket to become tenant in newly started project in Hammarby Sjöstad

More and more companies are discovering the attractiveness of the southern parts of Stockholm. The district has good communications, extensive cycle tracks, unique environments engulfed in history and immediate surroundings in strong development. At Trikåfabriken 9, Naturvårdsverket has found premises that suits its business development and demands on a new way of working. The building will be environmentally certified, with a green lease.  -          “We are extremely happy to have found a solution that suits Naturvårdsverket so well. Choosing to move to Hammarby Sjöstad is further proof of the attractiveness of the area.  We see how customers appreciate the industrial history of the area and the high level of service available, which is largely due to the mixture of residential and office properties in a dense district,” says Klaus Hansen Vikström, Vice President and Director of Business Development at Fabege. Fabege is now starting on the Trikåfabriken 9 project, with an estimated investment of around SEK 450 million. The extension will have a frame made of wood, a renewable material with low environmental impact that also binds carbon dioxide. The building is being planned to meet the requirements for environmental certification to BREEAM-SE, level ‘very good’, and will have a leasable area of over 16,000 sqm when completed. As a result of the green lease contract, the parties have agreed on a common environmental agenda for the premises, which for example, includes the selection of materials, renewable energy and sorting at source. -          “Fabege has worked intensively with sustainability for many years and Naturvårdsverket’s demands on environmentally certified premises, green lease contracts and extensive cycle parking align fully with our own values,” says Andreas Malmsäter, Director of Letting Operations and Marketing at Fabege. Tenant & Partner have served as advisors to Naturvårdsverket during the process. For more information about Trikåfabriken 9: www.trikafabriken9.se (In Swedish only) Fabege AB (publ)  

Recipharm partners with Sato to manufacture product for Japanese market

Sato, based in Tokyo and founded in 1915, is providing effective, safe and high quality products. Emla™ Patch is used as a local anaesthetic product and will be launched under the business area of ethical pharmaceuticals at Sato. Recipharm’s facility in Karlskoga, Sweden will produce and deliver to Sato. After a successful launch in Japan, it is expected that the annual volumes of Emla™ Patch to Sato will be a significant addition to the present production at the Karlskoga facility. Ingela Palmkvist, General Manager at Recipharm in Karlskoga says: “We first established a business relationship with Sato in 2012 and this new supply agreement extends our partnership further. We are looking forward to the launch in Japan and cooperating with Sato in developing the business, to the benefit of both companies.” Contact informationIngela Palmkvist, General Manager, ingela.palmkvist@recipharm.com, +46 (0)586 68 293Erik Haeffler, Vice President Manufacturing Services & Head of CSR, erik.haeffler@recipharm.com, + 46 (0)8 6025 285  For media enquiries, please contact Lindsay Baldry at ramarketing: lindsay@ramarketingpr.com, + 44 (0)191 222 1242, ramarketingpr.com, Twitter: @ramarketingpr, Facebook: /ramarketingpr, Linkedin: /ramarketing About RecipharmRecipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing around 5 000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s turnover is approximately SEK 5.3 billion and the Company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.For more information on Recipharm and our services, please visit www.recipharm.com  About Sato PharmaceuticalsSato Pharmaceuticals was founded in 1915 and is based in Tokyo, Japan, with branches in Europe, US and Canada. Sato Pharmaceutical’s main priority has been to serve customer health by providing OTC products that are precisely designed to fit the real needs of the market. The company has kept this focus over the years by creating an ongoing series of top products as it continues to grow and succeed. The goal is to help people to live healthier, happier lives. Sato Pharmaceuticals celebrated its 100th anniversary in 2015. Based on the corporate philosophy of Healthcare Innovation, Sato will work to contribute to consumers’ health by providing products such as OTC and ethical pharmaceuticals. For further information, please visit www.sato-seiyaku.co.jp         *TM owned by AstraZeneca Pharmaceuticals: EMLA product licensed to Sato in Japan and trademark used under license from AstraZeneca

Tele2 to create a more energy efficient 4G network – only Swedish operator in global initiative

Sweden has high ambitions when it comes to the energy objectives for 2020. To mention a few of them, the total energy consumption should be reduced by 20 percent and more than 50 percent of Sweden’s energy should come from renewable sources. For Tele2 Sweden, it is the nationwide 4G network that consumes most energy, as it accounts for about 70 percent of the company’s total energy consumption. Tele2 is currently working to streamline the energy consumption of the 4G network and secure the network sustainability for the future. Amongst other things, the company is testing a solution where the base station power amplifier is turned off when the station has no data to transmit. Other innovations will also be evaluated, for example shutting down one or more antenna ports at low load and smart measures to extend the battery life of the base stations during power outages. Samuel Skott, CEO of Tele2 Sweden, comments: ”We are proud that Tele2, as the only Swedish operator, has started an extensive energy efficiency project to contribute to the climate goals. It is natural for us to take a leading role and to drive and challenge our industry towards a greater sustainability thinking.” Tele2 is also, as the only Swedish operator, a part of the international initiative SooGreen that has support from Vinnova and aims to create a greener telecom industry. Within the initiative, Tele2 will work together with KTH to spread knowledge on how the telecom sector can become more sustainable in the future. For more information, please contact:Angelica Gustafsson, Head of Public Relations, Tele2 AB, Phone: +46 704 26 41 42Erik Strandin Pers, Head of Investor Relations, Tele2 AB, Phone: +46 733 41 41 88 TELE2 IS ONE OF EUROPE'S FASTEST GROWING TELECOM OPERATORS, ALWAYS PROVIDING CUSTOMERS WITH WHAT THEY NEED FOR LESS. We have 17 million customers in 9 countries. Tele2 offers mobile services, fixed broadband and telephony, data network services, content services and global IoT solutions. Ever since Jan Stenbeck founded the company in 1993, it has been a tough challenger to the former government monopolies and other established providers. Tele2 has been listed on the NASDAQ OMX Stockholm since 1996. In 2016, Tele2 had net sales of SEK 28 billion and reported an operating profit (EBITDA) of SEK 5.3 billion. For definitions of meas­ures, please see the last page of the Annual report 2015.

Voucher increases for Academedia amounts to 2.3% in Sweden

Voucher decisions have now been recieved for 89 percent of the student base which gives a stable increase for the Swedish operations. Average voucher increases for 2017 are for AcadeMedias Swedish operations 2.3 percent. For the Norwegian Preschools in the Espira Group 1.9 percent. The increases are in line with the figures provided in AcadeMedia's latest quarterly report. Voucher increases have been calculated based on voucher resolutions per municipality and are weighted by AcadeMedia student mix in each segment. Voucher increase by segmentThe voucher increase in the Pre- and compulsory schoolsegment amounts to 1.8 percent on for Preschool and 2.4 percent for Compulsory school. The average voucher increase has been weighted by child and municipality mix. In the Pre- and compulsory school segment 3 percent of revenues derive from perental fees according to the maximum fee regulation. The maximum parental fee is adjusted annually by the National Agency for Education. For 2017, the increase was 3.7 percent. The voucher increase for the Upper secondary school segment amounts to 2.7 percent on average. Voucher increases have been calculated based on the obtained decisions and are weighted with AcadeMedias student and program mix. As previously communicated, the municipal contributions for the Norwegian preschools have increased on average by 1.9 percent weighted by child and municipality mix. There is a maximum parental fee system also in Norway. The parental fees amount to about 16 percent of revenue and are adjusted annually with a index that for 2017 has been set to 2.8 percent. What is school vouchers?Revenues in AcadeMedias three school segments consists mainly of a municipal contribution per student "school vouchers". Vouchers in Sweden are calculated based on the municipality's budgeted cost for its educational activities in each school form, age group and study program. The total cost is divided by the budgeted number of children or students in the respective form of education to obtain  voucher per child/student. According to Swedish law resource allocation must be equal between students in municipality run schools and independent schools. This means that if the actual outcome in the municipal accounts show a higher cost per student, the independent schools should be compensated. In Norway, the vouchers are calculated based on the actual municipal cost for the latest financial year (2015) and adjusted with a cost index for 2016 and 2017. The index amounts to 5.2 percent for both years together. Components related to real estate cost are also adjusted to reflect each property's age, which means higher contributions for new properties and lower for older properties. Actual financial results in the municipal accounts are reconciled against the indexed amount and the variance is adjusted the following year. For more information, please contact:Eola Änggård Runsten, CFOTelephone:+46 8 794 4240E-mail: eola.runsten@academedia.se Christian Hall, Investor RelationsTelephone: +46 763 111 242E-mail: christian.hall@academedia.se About AcadeMediaAcadeMedia creates opportunities for people to develop. Our 12,500 employees at 550 preschools, compulsory schools, upper secondary schools and adult education centres share a common focus on quality and development. Our 140,000 children and students are provided with a high quality education, giving them the best conditions to attain both their learning objectives and their full potential as individuals. AcadeMedia is Northern Europe´s largest education company, with locations/facilities/presence in Sweden, Norway and Germany. Our size gives us the capacity to be a robust, long term partner to the communities we serve. More information about AcadeMedia is available on www.academedia.se

EnQuest PLC Preliminary Results

ENQUEST PLC, 21 March 2017. Results for the year ended 31 December 2016*.    Kraken on track and 2017 guidance reiterated   Magnus/SVT acquisition progressing to plan    2016 results highlights · Production averaged 39,751 Boepd in 2016, up 8.7% on 2015 · 2016 unit operating costs of $24.6/bbl compared to $29.7/bbl in 2015 · 2016 cash capex of $609.2 million compared to $751.1 million in 2015 · Revenue of $849.6 million and EBITDA** of $477.1 million, reflecting EnQuest’s strong operational performance and hedging activities  · Cash generated from operations of $408.3 million, up from $221.7 million in 2015 · Net 2P reserves of 215 MMboe at the end of 2016, 5.9% up on the 203 MMboe at the end of 2015 · Comprehensive financial restructuring significantly improved EnQuest’s liquidity position · Net debt at the year end, was $1,796.5 million, compared to $1,548.0 million at the end of 2015 2017 update and outlook · The Kraken development continues under budget and on track for first oil in Q2 2017 · EnQuest’s confirms 2017 average production guidance, in the range of 45,000 Boepd to 51,000 Boepd for the full year – dependent on the timing of Kraken first oil · EnQuest also remains on course to reduce average unit opex further in 2017 to be within the range of $21/bbl to 25/bbl including Kraken production, driven by further cost reductions across the supply chain.  Cash capex is set to be in the range $375 million to $425 million in 2017, the majority of which is being invested in the Kraken development · Hedging of c.6 million barrels for 2017, at an average of c.$51/bbl · Total debt facilities of c.$2.1 billion remain in place  · The proposed EnQuest acquisition of interests in the Magnus oil field and the Sullom Voe terminal was announced on 24 January.  Transition activities have begun and are ongoing; the process is expected to take 6-12 months, with no cash outlay for EnQuest   * Unless otherwise stated, all figures are on a business performance basis and are in US dollars.   Click on, or paste the following link into your web browser, to view the associated PDF document. http://www.rns-pdf.londonstockexchange.com/rns/0116A_1-2017-3-20.pdf This information is provided by RNSThe company news service from the London Stock Exchange END

Gunnebo Makes a Strong Impression at EuroShop 2017

Gunnebo’s stand, which was based on the theme “Time for an Adventure”, focused on the consumer’s journey and demonstrated how retailers could save time and money by using smarter security solutions. One of the dominant themes at EuroShop 2017 was the continuing digitalisation in retail and in keeping with this, Gunnebo presented a preview of its Gunnebo Retail Solution (GRS) to a selection of invited customers from around the world. The preview was extremely well-received and sparked interested discussion about the many gains to be made from connected retail security. GRS, which is currently under development, is an open platform for in-store digitalisation. It connects store systems to give retailers actionable data on the shop floor – via a single application. By adding intelligence to that information, GRS enables improvements to efficiency, productivity, store security and profitability. The stand also showcased other areas where retailers can make improvements to operational processes and security procedures, from cash management to loss prevention. About EuroShop 2017 EuroShop is the world’s premier retail event and is held every three years in Germany. The 2017 edition was the largest to date with over 113,000 visitors and 2,368 stands filling the exhibition halls in Düsseldorf. Visit the official EuroShop website at http://www.euroshop-tradefair.com/. GUNNEBO AB (publ)Group Communications For further information, please contact: Karin Wallström, SVP Marketing & Communicationstel: 46 10 2095 026, karin.wallstrom@gunnebo.com www.gunnebogroup.com 

Cxense invests in mporium – supporting strategic partnership, technology adoption and distribution

Oslo, Norway – 21 March 2017 – Cxense ASA (Cxense) (OSE: CXENSE) today announced that it has made an investment of GBP 0.65 million in mporium Group plc (mporium) (AIM:MPM) through participation in a GBP 3.05 million private placement to strengthen mporium’s balance sheet and growth capacity. In May 2015 Cxense and mporium formed a strategic partnership enabling mporium to upgrade its technology platform with Cxense advanced, real-time technology. As part of this strategic partnership between the two companies, mporium issued 100,000,000 shares to Cxense valued at 2p each. As consideration mporium received a three-year license agreement from Cxense, GBP 0.5 million in cash and 53,113 Cxense shares. On 18 July 2016, Cxense acquired a further 8,790,403 shares at a price per share of 7.5p in a private placement. In the private placement announced today Cxense has subscribed a total of 4,333,000 shares, each at a price of 15p. After the investment, Cxense holds 113,123,403 shares in mporium with a weighted average subscription price of 2.9p. On 20 March 2017, the closing share price of mporium was 14.88p. Over the last six months, Cxense and mporium have collaborated more closely to combine the Cxense data management- and personalization platform with mporium’s IMPACT solution for management of digital advertising campaigns on mobile devices. mporium will bring the combined offering to its direct customers as well as advertising agency partners, and the partners will together develop new markets for their combined offering. “The mporium IMPACT solution cleverly identifies and acts on those micro-moments where digital advertising campaigns are the most effective, and thus helps to optimize the campaign efficiency and make the most out of an advertiser’s budget. Combining mporium’s IMPACT solution with Cxense’s real-time technology, brands and their advertising agencies obtain a more powerful technology solution at hand to achieve successful digital advertising campaigns on mobile devices” says Aleksander Øhrn, Cxense CTO. “By combining Cxense’s data management and personalization technology with mporium IMPACT solution, mporium gets a one-stop-shop offering for advertising campaigns targeting mobile device users. The combined offering is uniquely powerful in its abilities to both capture and convert interest from users to increased sales. mporium will expand the distribution of Cxense’s technology and solutions, both through sales towards ecommerce direct customers, as well as through their digital agency partner channel. We do this because we want more revenue from strategic partnerships” says John T. Sviland, Cxense Chief Business Development Officer. About mporium: mporium, is a “mobile native” technology company that enables brands, and the agencies that serve them, to achieve better outcomes from digital advertising campaigns. Uniquely, mporium uses proprietary technology to achieve successful digital advertising campaigns on mobile devices, from brand advertising to direct response. Based in the UK, mporium Group plc is quoted on AIM, the junior market of the London Stock Exchange plc. About Cxense: Cxense (pronounced "see-sense") enables the world's leading media, e-commerce and consumer brands to take control of their audience data to deliver more engaging and personalized user experiences. Businesses using Cxense's advanced real-time analytics, data management (DMP), advertising, search and personalization technology gain more engaged users, increased digital revenue and higher sales conversions. Cxense is headquartered in Oslo, Norway, with offices worldwide. Customers include the Wall Street Journal, USA Today (Gannett), Grupo Clarin, El Pais, Bonnier, Naspers, Ebay, The Golf Channel, PGA, NBA, NFL, ABC News, FOX Sports, Singapore Press Holdings, South China Morning Post, AEON, DMM, Rakuten and many more. For more information: www.cxense.com, Twitter: @Cxense. Cxense is listed on the Oslo Stock Exchange with the ticker 'CXENSE.' Investor Relations Contact: Jørgen Loeng, Chief Financial Officer Email: jorgen.loeng@cxense.com Mobile: +47 906 60 062 Technology Contact: Aleksander Øhrn, Chief Technology Officer Email: aleksander.ohrn@cxense.com  Mobile: +47 479 37 222

Farstad Shipping ASA – Subscription period of the subsequent offering ends today

NOT FOR PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, CANADA, JAPAN, SWITZERLAND OR THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA). Ålesund, Norway, 21 March 2017 – Reference is made to previous announcements of Farstad Shipping ASA ("Farstad" or the "Company") concerning the subsequent offering in the Company announced on 13 March 2017 (the "Subsequent Offering"). The subscription period for the Subsequent Offering of 142,857,142 new shares in the Company (the "Offer Shares") at a subscription price of NOK 0.35 per Offer Share expires today, 21 March 2017, at 16:30 hours, Oslo time. The Subsequent Offering is directed towards eligible shareholders and eligible bondholders as further set out in the Company's stock exchange announcement dated 13 March 2017 and on such terms and conditions as set in the prospectus dated 13 March 2017 that has been prepared by the Company inter alia for the Subsequent Offering (the "Prospectus"). Please note that subscription rights that are not used to subscribe for Offer Shares before the expiry of the subscription period will have no value and will lapse without compensation to the holder. The Subsequent Offering is managed by ABG Sundal Collier ASA and Pareto Securities AS (the "Managers"). The Prospectus, including the subscription form, is available at www.farstad.com, www.abgsc.no and www.paretosec.com and is also available free of charge at the business offices of the Company at Skansekaia 4A, 6002 Ålesund, Norway and may be obtained by contacting one of the Managers. Subscriptions may be made by duly completing and delivering the subscription form, in accordance with the terms and conditions set out in the Prospectus, to one of the subscription offices set out therein. Subscribers who are Norwegian citizens may also subscribe for Offer Shares by following the link on www.abgsc.no or www.paretosec.com, which will redirect the subscriber to the VPS online subscription system. In order to use the online subscription system, the subscriber must have, or obtain, a VPS account number. All online subscribers must verify that they are Norwegian citizens by entering their national identity number (Norwegian: "personnummer"). For further information, please contact: CEO Karl-Johan Bakken, tel. +47 901 05 697 CFO Olav Haugland, tel. +47 915 41 809 Farstad Shipping’s fleet currently consists of 56 vessels (27 AHTS, 22 PSV and 7 SUBSEA). The Company’s operations are managed from Aalesund, Melbourne, Perth, Singapore, Macaé and Rio de Janeiro with a total of 1,500 employees engaged onshore and offshore. The Company’s strategy is to be a leading quality provider of large, modern offshore service vessels to the oil industry. www.farstad.com  This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. * * * * * Important information: The release is not for publication or distribution, in whole or in part directly or indirectly, in or into Australia, Hong Kong, Canada, Japan, Switzerland or the United States (including its territories and possessions, any state of the United States and the District of Columbia). This release is an announcement issued pursuant to legal information obligations, and is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. It is issued for information purposes only, and does not constitute or form part of any offer or solicitation to purchase or subscribe for securities, in the United States or in any other jurisdiction. The securities mentioned herein have not been, and will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act") or under the securities laws of any state of the United States and accordingly, the securities may be offered or sold in the United States pursuant only to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and any applicable state securities laws. The Company does not intend to register any portion of the offering of the securities in the United States or to conduct a public offering of the securities in the United States. The securities referred to herein have not been and will not be registered under the applicable securities laws of Australia, Canada, Hong Kong, Japan or Switzerland and may not be offered, sold, taken up, exercised, resold, delivered or transferred, directly or indirectly, in or into Australia, Canada, Hong Kong, Japan or Switzerland. Copies of this announcement are not being made and may not be distributed or sent into Australia, Canada, Hong Kong, Japan, Switzerland or the United States. The subscription or purchase of shares in the Company is subject to specific legal or regulatory restrictions in certain jurisdictions. Neither the Company nor the Managers assumes any responsibility in the event there is a violation by any person of such restrictions. The distribution of this release may in certain jurisdictions be restricted by law. Persons into whose possession this release comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute violation of the securities laws of any such jurisdiction. The Managers are acting for the Company and no one else in connection with the Subsequent Offering and will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients or for providing advice in relation to any other matter referred to in this release. Forward-looking statements: This release and any materials distributed in connection with this release may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the Company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Codere selects Evolution as exclusive Live Casino provider for Mexico

The deal marks Evolution’s entry into the Mexican market, where Codere is already the largest operator of gaming halls. Since February 1, Codere – Real Madrid´s Official Sports Bookmaker – has enriched its gaming offer in Mexico with online gaming through the website www.codere.mx. The latest agreement will allow Codere to stream Evolution’s full portfolio of award-winning Live Casino games to online players on desktop, tablet and smartphone. This will include standard and VIP tables for Evolution Live Roulette, Blackjack, Baccarat and Baccarat Squeeze games, numerous Poker variants (including the new Live Caribbean Stud Poker with Progressive Jackpot) and Evolution’s new Dream Catcher Lucky Wheel. Amongst the Poker variants are titles exclusive to Evolution, such as Live Three Card Poker and Ultimate Texas Hold’em. Felipe Ludena Munoz, Corporate CIO at Codere, said: “Evolution´s extensive experience in Live Casino market in Europe makes us feel confident that Codere will be extremely well equipped to launch best-in-class online Live Casino in Mexico and maximise immediate and future online Live Casino opportunities in this market.” Gionata La Torre, Evolution’s Regional Director, added: “We are of course proud and delighted to be working with Codere, a major global brand, for our first entry into this important new market. We very much look forward to introducing the richest, most exciting line-up of world-class Live Casino games to Codere players in Mexico.”

Exercise of employee share options and release of employee restricted share units

1. Participants in the Company's share option program have on March 20th 2017 exercised 348,686 options and 335,205 RSU's. On the same date Opera Software purchased 530,618 own shares at a price of NOK 38.0355 per share to settle its obligation to deliver the shares. The price was equal to the volume weighted average price of the day. The shares were purchased in accordance with the proxy given by the Company's Annual General Meeting on 28 June 2016. 2. Options exercised and restricted share unites released by primary insiders March 20th 2017:   Baard Farmen Andresen has exercised 40,000 options in the Company, corresponding to 40 000 shares at the strike price of NOK 15.43.   Lars Boilesen has received 34,612 shares.   Thomas Bullen has received 1,000 shares.   Brian Kesterson has received 3,302 shares.   Will Kassoy has received 4,304 shares.     3. Transfer of rights and sale of shares On March 20th, 2017, the primary insiders mentioned below transferred their rights to receive shares resulting from the exercise of options to a third party.   Baard Farmen Andresen has transferred 40,000 rights.  When the participants receive the shares they will be subject to pay salary tax on the total value of the shares received. In order to cover the taxes the employees must at minimum sell a predetermined rate of the shares set by Opera. On March 20th, 2017 the primary insiders mentioned below ordered for the receivedshares to be immediately sold by a third party.  Lars Boilesen has sold 18,768 shares to cover taxes.   Thomas Bullen has sold 446 shares to cover taxes. Brian Kesterson has sold 3,302 shares.   Will Kassoy has sold 1,630 shares to cover taxes.   The sales amount will be finally determined on the basis of the price subsequently obtained by the third party when selling the shares in the market. The payment has been determined based on a selling price of NOK 38.0355 per share.  4. New Holding, prior to contingent options grants and cancelation of RSU’s at Opera EGM 4th April 2017.   After completion of the abovementioned transactions, Baard Farmen Andresen holds 20,000 unexercised options in the Company. As of today the primary insider holds 2 633 shares in the Company. After completion of the abovementioned transactions, Lars Boilesen holds 84,600 RSUs in the Company. As of today the primary insider holds 179 972 shares in the Company. After completion of the abovementioned transactions, Thomas Bullen holds 1,000 RSUs in the Company. As of today the primary insider holds 1 664 shares in the Company.  After completion of the abovementioned transactions, Brian Kesterson holds 50,000 RSUs in the Company. As of today the primary insider holds 621 shares in the Company.   After completion of the abovementioned transactions, Will Kassoy holds 329,167 RSUs in the Company. As of today the primary insider holds 191 162 shares in the Company.   For further information, please contact:  Petter Lade, CFO Phone: +47 91143878 E-mail: petterl@opera.com About Opera: Opera holds shares in several different businesses, including AdColony which helps publishers monetize their content through advertising and advertisers reach the audiences that build value for their businesses, capitalizing on a global consumer audience reach that exceeds 1 billion; Opera Apps and Games (Bemobi); "Performance & Privacy" (Skyfire and Surfeasy); and Opera TV.

The rights issue of convertible bonds in Arise has been completed

The final result in the rights issue of convertible bonds in Arise AB (publ) (“Arise” or “the Company”), for which the subscription period ended on 16 March 2017, shows that 8,004,697 convertible bonds, corresponding to approximately 72.0 per cent of the convertible bonds offered, were subscribed for by the exercise of subscription rights. In addition, 1,729,630 convertible bonds, corresponding to approximately 15.5 per cent of the convertible bonds offered have been subscribed for without subscription rights. The remaining 1,390,298 convertible bonds, corresponding to approximately 12.5 per cent were allotted to the guarantors in relation to their total undertaking, in accordance with the underwriting agreements entered into with the Company. Through the rights issue of convertible bonds, the Company receives proceeds amounting to approximately MSEK 245 before transaction related costs.If the convertible bonds are fully converted into shares, and given that all convertible bonds are converted during the last day for conversion, the share capital will increase with SEK 889,970.00 through the issuance of 11,124,625 shares.Allotment of convertible bonds that were subscribed for without subscription rights has been made in accordance with the principles outlined in the prospectus, which was published on 22 February 2017. Notification regarding the allotment of convertible bonds that have been subscribed for without subscription rights will be sent to those who have been allotted convertible bonds on or about 21 March 2017. Notification regarding the allotment of convertible bonds will only be distributed to those who have been allotted convertible bonds.Convertible bonds subscribed for with subscription rights are expected to be registered by the Swedish Companies Registration Office (Sw. Bolagsverket) on or about 23 March 2017. Convertible bonds subscribed for without subscription rights are expected to be registered by the Swedish Companies Registration Office on or about 29 March 2017. The last day of trading in the interim convertible bonds (“BTU”) is expected to be on 27 March 2017. Trading of the convertible bonds is expected to begin on Nasdaq Stockholm on or about 31 March 2017.Advisors Setterwalls Advokatbyrå is acting as legal advisor and Swedbank AB (publ) is financial advisor to Arise in connection with the convertible bond issue.For further information, please contact:Daniel Johansson, CEO of Arise, +46 (0)702 24 41 33.This information is information that Arise AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on 21 March 2017.About AriseArise is one of Sweden´s leading wind power companies, with the business concept to develop, build and manage onshore wind farms for its own account and on behalf of investors. The company is listed on NASDAQ Stockholm.Arise AB (publ), P.O. Box 808, SE-301 18 Halmstad, Sweden, telephone +46 (0)35 20 20 900, corporate id .no. 556274-6726E-mail info@arise.se, www.arise.seImportant information This announcement is not and does not form a part of any offer for sale of securities.Copies of this announcement are not being made and may not be distributed or sent into the United States, Canada, Japan, Hong Kong, Singapore, South Africa, New Zealand, Australia or any other jurisdiction in which such distribution would be unlawful or would require registration or other measures. The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and accordingly may not be offered or sold in the United States absent registration or an exemption from the registration requirements of the Securities Act and in accordance with applicable U.S. state securities laws. The Company does not intend to register any offering in the United States or to conduct a public offering of securities in the United States.Any offering of securities referred to in this announcement will only be made by means of the prospectus announced herewith. This announcement is not a prospectus for the purposes of Directive 2003/71/EC (together with any applicable implementing measures in any Member State, the “Prospectus Directive”). Investors should not invest in any securities referred to in this announcement except on the basis of information contained in the aforementioned prospectus.In any EEA Member State other than Sweden that has implemented the Prospectus Directive, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Directive, i.e., only to investors who can receive the offer without an approved prospectus in such EEA Member State.This communication is only being distributed to and is only directed at persons in the United Kingdom that are (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”) or (ii) high net worth entities, and other persons to whom this announcement may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “Relevant Persons”). This communication must not be acted on or relied on by persons who are not Relevant Persons.Any investment or investment activity to which this communication relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. Persons distributing this communication must satisfy themselves that it is lawful to do so.Matters discussed in this announcement may constitute forward-looking statements. Such statements are statements that are not historical facts and may be identified by words such as “regard”, “estimate”, “expect”, “anticipate”, “assume”, “predict”, “intend”, “may”, "continue", “should” and similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond its control. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The information, opinions and forward-looking statements contained in this announcement speak only as at its date, and are subject to change without notice.

NattoPharma Research Network Receives 4M€ Research Grant

OSLO, NORWAY and METUCHEN, NJ (March 21, 2017) – NattoPharma’s International Research Network, coordinated by the Cardiovascular Research Institute at Maastricht University (CARIM), has been awarded a second prestigious grant funded by the European Union within the Horizon 2020 Marie Skłodowska-Curie research and innovation program. Beneficiary partners of the network are three highly ranked research university departments in Europe (CARIM/MUMC+ Maastricht; Universitätsklinikum Aachen and Karolinska Institutet Stockholm. The 4M€ grant, INTRICARE (International Network for Training on Risks of vascular intimal Calcification And roads to Regression of cardiovascular disease), is coordinated by University of Maastricht CARIM, MUMC+, and will train 15 Early Stage Researchers (ESRs) focusing on vascular smooth muscle cell mediated microcalcification and the effect of vitamin K to hold or regress this process. “INTRICARE is a European joint doctorate (EJD) program shaped to address the urgent, unmet medical needs concerning vulnerable plaques,” says lead researcher Leon Schurgers at CARIM, Maastricht University, and the main contact between NattoPharma and the University. “It is guided by the academic and industrial demand for a new generation of entrepreneurial scientists, who have the skills, expertise and know-how to expedite our understanding of early atherosclerosis and translation thereof into concrete clinical interventions for prevention and therapy.” INTRICARE is an interdisciplinary and international consortium involving four leading academic institutions (CARIM/MUMC+ Maastricht; Universitätsklinikum Aachen; Karolinska Institutet Stockholm and King’s College London) and 9 SMEs (small- and medium-sized enterprises), including NattoPharma. The grant will fund 15 ESRs, who will engage in network-wide training events, public engagement activities, and international collaboration through secondments, at industrial or academic partner institutions within the EU. Six ESR’s will be hosted by CARIM, supervised by Leon Schurgers, Tilman Hackeng, Rory Koenen, Eline Kooi, Erik Biessen, and Thomas Unger. The INTRICARE network will be coordinated by Leon Schurgers, Tilman Hackeng, and Thomas Unger. “Organized around three pillars – initiation of atherogenesis, vascular remodelling associated microcalcification, and imaging of microcalcification and vulnerable plaque formation – the consortium will join forces to address the aforementioned needs through training and research,” Dr. Schurgers continues. Since 2004, NattoPharma has worked closely with the Maastricht University in documenting benefits of menaquinone-7, the company’s exclusive vitamin K2 branded as MenaQ7®. This grant will provide training in innovative therapeutic strategies that include MenaQ7, identifying selective targets for microvascular calcification, and its consequences for plaque stability, and provide subsequent strategies for prevention or amelioration of vulnerable plaque formation.   “Horizon 2020 grants are the European equivalent to a National Institutes of Health (NIH) grant here in the United States,” says NattoPharma Chief Medical Officer Hogne Vik, adding that NattoPharma’s first priority has always been the documentation of MenaQ7’s biological effects on bone and vasculature.” “The assignment of this grant is an honor that further validates the importance of the work we have been doing with Maastricht University, and shines a light on the impact vitamin K2 can have on improving global health. We could not be more thrilled to have a third grant awarded to our partner for further study of MenaQ7.” # # # About MenaQ7® MenaQ7® is the best documented, commercially available vitamin K2 as menaquinone-7 (MK-7) with guaranteed actives and stability, clinical substantiation, and international patents granted and pending. MenaQ7® is available in two varieties: MK-7 Crystals and MK-7 PURE. For more information on the health benefits of MenaQ7, visit menaq7.com. About NattoPharma NattoPharma ASA, based in Norway, is the world’s leader in vitamin K2 research and development. NattoPharma is the exclusive international supplier of MenaQ7® Vitamin K2 as MK-7, and has a multi-year research and development program to substantiate and discover the health benefits of vitamin K2 for applications in the marketplace for functional food and dietary supplements. With a global presence, the company established its North American subsidiary, NattoPahrma USA, Inc., in Metuchen, NJ. For more information, visit nattopharma.com. For more information, please contact: Hogne Vik, NattoPharma CMO Cell phone: +47 97 53 53 26 E-mail: hogne.vik@nattopharma.com Kate Quackenbush, Director of Communications NattoPharma USA, Inc. Phone: 609-643-0749 E-mail: kate.quackenbush@nattopharma.com

Additional patent protection for Ygalo granted in Europe until 2032

Stockholm - March 21, 2017 - Oncopeptides AB (Nasdaq Stockholm; ONCO) announced today that the European Patent Office (EPO) recently issued a notice that they intend to grant an additional European patent to Oncoeptides AB.The patent (EP2701720) covers inter alia the lyophilized formulation of Ygalo that is intended to be launched. The patent can be validated in 38 European countries. The patents will expire in April 2032."We are pleased to have received this patent notice. It is in line with expectation but has now also been confirmed. It clearly increases Ygalo’s future commercial value over time, assuming our clinical development programs are successful. It also increases the likelihood of getting a similar patent protection in the United States," said Jakob Lindberg, CEO Oncopeptides.About OncopeptidesOncopeptides is a research and development stage pharmaceutical company developing drugs for treatment of cancer. Since the founding of the Company in 2000, the Company has focused primarily on the development of the product candidate Ygalo, an innovative peptidase-potentiated alkylator intended for effective and focused treatment of blood-based cancer diseases, and in particular multiple myeloma. Ygalo is intended to demonstrate better results from treatment compared to established alternative drugs in the treatment of patients with multiple myeloma. Ygalo could potentially provide treating physicians with a new treatment option for patients suffering from this severe cancer disease. Visit www.oncopeptides.se for more information.For further information, please contact:Jakob Lindberg, CEO at OncopeptidesE-mail: jakob.lindberg@oncopeptides.seRein Piir, Head of Investor Relations at OncopeptidesE-mail: rein.piir@oncopeptides.se  This information is such that Oncopeptides is required to publish under the Swedish Financial Instruments Trading Act. The information was released for public disclosure, through the agency of the contact person above, on March 21, 2017 at 08.45 a.m. (CET).

Hemfosa’s Board proposes warrant programme for employees

The Board of Directors of Hemfosa Fastigheter AB (publ) (”Hemfosa”) has resolved to propose that the Annual General Meeting resolves on a warrant programme for employees within the Hemfosa Group. The Board’s proposal involves in brief that the Annual General Meeting shall resolve on a directed issue of a maximum of 1,450,000 warrants. The warrants shall be transferred to the employees within the Group divided in different categories at a price (warrant premium) that will be determined based on an estimated market value of the warrants. The company will by means of a cash bonus subsidize up to 100 per cent of the participants premium. The bonus consists of two payments, each of 50 per cent, during the term of the warrant program, one after two years and one after four years. The total cost for the subsidy, based on assumptions of the value of the warrants as set out above, is calculated to amount to not more than SEK 6.4 million including social security contributions, for the entire term of the warrant program of five years.  Each warrant shall entitle the holder to subscribe for one ordinary share in Hemfosa during the period from 1 May 2022 up to and including 31 May 2022 and from 1 August 2022 up to and including 31 August 2022. The subscription price for each share shall be equal to 115 per cent of the volume weighted average price according to Nasdaq Stockholm’s official price list for the ordinary share during the period 2 May 2017 up to and including 15 May 2017. The proposed issue of warrants entails a total dilution of a maximum of approximately 0.85 per cent of the total number of shares and 0.90 per cent of the total number of votes in the company after full subscription of all warrants. The reasons for the deviation from the shareholders’ preferential rights are to, through the warrant programme, establish a reward system that is competitive within all markets that the company operates within, that can function as a guideline for the company’s management in the work with the company’s strategy and that, in addition to function as focus-enhancing for the company’s employees, also provides the company’s employees with increased opportunity to participate in the successes of the company. The Board’s proposed warrant programme will be presented in the notice to the Annual General Meeting which will be published today, on 21 March 2017, and complete terms and conditions of the warrant programme will at the same time be available at the company’s website. Hemfosa’s Annual General Meeting will take place at 15.00 on 24 April 2017 at Hotel Rival, Mariatorget 3 in Stockholm

Don’t Overwash – new project drives sustainable care habits

Today, 90% of all clothing is discarded far earlier than needed, and as much as 70% of these are due to faded colors, shrinkage and misshaping. This could be prevented with better care habits. “Aftercare of clothes has a great impact on both the longevity of clothes and the environment. However, our care habits have not changed in a very long time, even though we now have modern technologies that can prolong the life of our clothes and be more gentle to the environment, if used correctly,” said Henrik Sundström, Vice President Sustainability Affairs at Electrolux. “To change this, we initiated the Care Label Project and are launching the new care label ‘Don’t Overwash.” In an international study conducted by AEG to map care habits in Europe, more than half of consumers state that they rely on care labels to feel confident when doing their laundry. However, a third find them confusing. In fact, care labels are only suggestions for how to do laundry, and it is established within the fashion industry to understate a fabric’s durability to avoid upsetting customers who accidently ruin their clothes due to the care label’s suggestions. ‘Don’t Overwash’ updates old care habits in three main categories; Dry Clean Only, Lower Temperatures and Wash Less. In addition to the new care label, The Care Label Project has created a Modern Care Guide, available on AEG’s website, with up-to-date tips on how to lovingly care for your clothes. Together, the care label and care guide set out to educate consumers and the industry on how to care for their clothes in a modern way that is less damaging for both clothes and environment. To test the new care label ‘Don’t Overwash’ and the Modern Care Guide, AEG teamed up with 14 up-and-coming designers from across Europe. They are all trying out AEG’s products and updated care habits, in order to themselves test and prove that modern technology can care for the most delicate fabrics in a satisfactory way. Other partners in the project are the Woolmark Company, Fashion Revolution, Not Just A Label (NJAL), adidas, Houdini and Electrolux. Sustainability is at the core of the Electrolux business strategy, and this campaign supports the company’s sustainability framework, For the Better .

Notice to attend the Annual General Meeting 2017 in Hemfosa Fastigheter AB

The shareholders of Hemfosa Fastigheter AB (publ) ("Hemfosa") are hereby invited to the Annual General Meeting on Tuesday 25 April 2017 at 3.00 p.m. CET at Hotel Rival, Mariatorget 3, in Stockholm, Sweden. Entry to the Annual General Meeting will commence at 2.00 p.m. CET. NOTIFICATION ETC. Shareholders who wish to attend the Annual General Meeting shall                    be entered in the share register maintained by Euroclear Sweden AB on Wednesday 19 April 2017, shall                    give notice of their attendance no later than on Wednesday 19 April 2017. Notification shall be submitted in writing to Hemfosa Fastigheter AB (publ), c/o Euroclear Sweden AB, "Annual General Meeting 2017", Box 191, 103 98 Stockholm, Sweden, or by telephone to +46 (0)8-402 92 96. Notification can also be made via Hemfosa’s website, www.hemfosa.se. The notification shall state the name, personal identification number or company registration number, address, telephone number and accompanying advisors, if any (not more than two). Shareholders whose shares are registered in the name of a nominee must temporarily re-register the shares in their own name in order to be entitled to attend and vote at the Annual General Meeting. Such re-registration must be effected with Euroclear Sweden AB on Wednesday 19 April 2017, which means that the shareholder must inform its nominee well before this date. Shareholders attending by proxy or a representative should send powers of attorney in original, certificates of incorporation and any other documents of authorisation to the company at the address above well before the Annual General Meeting. A template proxy form is available on the company’s website, www.hemfosa.se. Shareholders cannot vote or in other ways attend the Annual General Meeting by remote access. PROPOSED AGENDA 1. Opening of the meeting 2. Election of Chairman of the meeting 3. Preparation and approval of the voting register 4. Election of one or two persons to check and verify the minutes 5. Determination of whether the meeting has been duly convened 6. Approval of the agenda 7. Presentation of the annual report and the auditor’s report and the consolidated financial statements and the auditor’s report for the group 8. Report by the Chairman of the Board on the work of the Board 9. Presentation by the CEO10. Resolutions regarding a)        adoption of the income statement and the balance sheet and the consolidated income statement and the consolidated balance sheet, b)        disposition of the company’s result in accordance with the adopted balance sheet, and c)         whether the Board members and the CEO should be discharged from liability 1. Determination of remuneration to be paid to the Board members and the auditor 2. Election of Board members and auditor 3. Resolution regarding approval of new issue of shares in the subsidiary Hemfosa Samfunnsbygg AS 4. Resolution regarding authorisation for the Board of Directors to resolve upon new issue of ordinary shares 5. Resolution regarding authorisation for the Board of Directors to resolve upon acquisitions and transfers of ordinary shares in the company 6. Resolution regarding guidelines for remuneration to the senior executives 7. Resolution regarding warrant program including issue and transfer of warrants 8. Closing of the meeting PROPOSED RESOLUTIONS Item 2 – Election of Chairman of the meeting The nomination committee proposes that Wilhelm Lüning, member of the Swedish Bar Association, is elected Chairman of the Annual General Meeting. Item 10 b – Resolution regarding disposition of the company’s result in accordance with the adopted balance sheet The Board of Directors proposes that the meeting resolves that, until the next Annual General Meeting, a dividend to the shareholders of ordinary shares shall be paid in a total amount of SEK 4.40 per ordinary share, with quarterly payments of SEK 1.10 per ordinary share. Proposed record days for the quarterly dividends on the ordinary shares are 27 April 2017, 10 July 2017, 10 October 2017 and 10 January 2018. In the event that such day is not a banking day, the record day shall be the immediate preceding banking day. The dividend payments on the ordinary shares are estimated to be distributed by Euroclear Sweden AB on the third banking day after each record day. The Board of Directors further proposes that the meeting resolves that, until the next Annual General Meeting, a dividend to the shareholders of preference shares shall be paid in a total amount of SEK 10.00 per preference share, with quarterly payments of SEK 2.50 per preference share. Proposed record days for the quarterly dividends for the preference shares are 10 July 2017, 10 October 2017, 10 January 2018 and 10 April 2018. In the event that such day is not a banking day, the record day shall be the immediately preceding banking day. The dividend payments on the preference shares are estimated to be distributed by Euroclear Sweden AB on the third banking day after each record day. In aggregate, the proposed dividend as set out above amounts to SEK 804,004,286. The Board of Directors has furthermore proposed that the Annual General Meeting authorises the Board of Directors to resolve upon new issues of ordinary shares (item 14 on the agenda). The Board of Directors proposes that the new ordinary shares that may be issued pursuant to the authorisation shall entitle to dividend as set out above as of the day on which they are entered in the share register maintained by Euroclear Sweden AB. At a maximum use of the authorisation, the dividend for the new ordinary shares may amount to SEK 69,400,430. The Board of Directors proposes that the remaining profits are carried forward. Item 11 – Determination of remuneration to be paid to the Board members and the auditor The nomination committee proposes that an annual remuneration of SEK 450,000 (previously SEK 400,000) shall be paid to the Chairman of the Board of Directors and that SEK 200,000 (previously SEK 180,000) shall be paid to each of the other Board members elected by the Annual General Meeting who are not employed by the company. The nomination committee has further proposed that an annual remuneration of SEK 60,000 (unchanged) shall be paid to the Chairman of the audit committee and SEK 35,000 (unchanged) to each of the other members of the audit committee. No remuneration will be paid for work in the remuneration committee. Provided that it is cost neutral for the company, remuneration may be invoiced by a Board member through a wholly-owned company. The nomination committee proposes that remuneration to the company’s auditor shall be paid in accordance with approved invoices. Item 12 – Election of Board members and auditor The nomination committee proposes that the Board of Directors shall consist of seven ordinary members and that Bengt Kjell, Anneli Lindblom, Caroline Sundewall, Ulrika Valassi, Per-Ingemar Persson and Jens Engwall are re-elected as Board members for the period until the end of the next Annual General Meeting, and that no deputy directors are elected. The nomination committee proposes that Gunilla Högbom shall be elected as a new member of the Board. The nomination committee further proposes that Bengt Kjell is re-elected as Chairman of the Board. A report on the nomination committee’s proposals and further information regarding the proposed Board members is available on the company’s website, www.hemfosa.se. The nomination committee further proposes that the registered accounting firm KPMG AB is re-elected as auditor until the end of the next Annual General Meeting. KPMG AB will appoint Björn Flink to be auditor in charge. Item 13 - Resolution regarding approval of new issue of shares in the subsidiary Hemfosa Samfunnsbygg AS The Board of Directors proposes that the Annual General Meeting approves the resolution previously adopted by the general meeting of the subsidiary Hemfosa Samfunnsbygg AS (“Samfunnsbygg”) on 4 July 2016 regarding a new issue of shares in Samfunnsbygg. The background to the proposed resolution is set out below. Hemfosa has since 2015 conducted business in Norway. Simon Venemyr Ottersland, who is responsible for the Norwegian business, acts as consultant through his wholly owned company Immob Holding AS ("Immob"). The business in Norway is conducted through Samfunnsbygg which nowadays is a subsidiary of Hemfosa. Simon Venemyr Ottersland is the CEO (No. daglig leder) of Samfunnsbygg. In connection with Hemfosa establishing a presence in Norway, Hemfosa acquired an equity interest in Samfunnsbygg, which, previously, had been wholly owned by Immob. After the acquisition, Hemfosa was owner to 97.23 per cent of the shares and the votes in Samfunnsbygg and Immob owned 2.77 per cent of the shares and the votes. To provide incentive and a shared risk-taking during the building up of the business in Norway, Immob, has had the right and obligation, under certain circumstances, to subscribe for shares in Samfunnsbygg, up to a maximum of five percent of the total number of shares in Samfunnsbygg. Such new share issues shall be made at market value in connection with Samfunnsbygg’s acquisitions of real estate in Norway. The general meeting of Samfunnsbygg resolved on 4 July 2016 to issue shares with deviation from the shareholders’ preferential rights. The new share issue resulted in the number of shares in Samfunnsbygg being increased with 1,704,377 shares. Hemfosa subscribed for 1,619,159 shares and Immob subscribed for 85,218 shares. The subscription price per share was NOK 214. Immob increased its relative shareholding in Samfunnsbygg from 2.77 per cent to 4.18 per cent through the new share issue. The new share issue was carried out at an estimated market value and there was no value transfer to Immob. Since Simon Venemyr Ottersland was the CEO of Samfunnsbygg at the time of the resolution to issue new shares, the share issue to Immob falls within the scope of Chapter 16 of the Swedish Companies Act, which means that the resolution requires approval also by the Annual General Meeting of Hemfosa. Item 14 – Resolution regarding authorisation for the Board to resolve upon new issue of ordinary shares The Board of Directors and management see continued good potential to carry out acquisitions of real property in order to increase company growth and improve results and cash flow, and thereby attend to the interests of the shareholders. The Board of Directors therefore proposes that the Annual General Meeting resolves to authorise the Board of Directors to, on one or more occasions for the period until the end of the next Annual General Meeting, with or without deviation from the shareholders’ pre-emption right, resolve upon a new issue of ordinary shares to the extent that such new issue can be made without amending the articles of association. The total number of ordinary shares that may be issued pursuant to the authorisation may not exceed ten per cent of the total ordinary shares in Hemfosa, at the time of exercising the authorisation. Such new ordinary shares shall be issued at a subscription price corresponding to market terms and payment can be made, except for payment in cash, by assets contributed in kind or by set-off. The purpose of the authorisation, and the reason for any deviation from the shareholders’ pre-emption right, is that the Board of Directors shall be able to resolve on new issues in order to finance acquisitions of real property or real property companies, or part of real property or real property companies, or in order to finance investments in new or existing real property. The Board of Directors proposes that the CEO, or any person appointed by the CEO, shall be authorised to make minor adjustments of the resolution mentioned above, as may be required in connection with the registration of the decision with the Swedish Companies Registration Office. Item 15 – Resolution regarding authorisation for the Board to resolve upon acquisitions and transfers of ordinary shares in the company The Board of Directors proposes that the Annual General Meeting resolves to authorise the Board to, at one or more occasions for the period until the end of the next Annual General Meeting, acquire ordinary shares in the company so that, as a maximum, the company’s holding following the acquisition does not exceed 10 per cent of all the shares in Hemfosa at any time. Acquisitions may only be conducted at Nasdaq Stockholm and at a price that is within the registered range for the share price prevailing at any time, that is, the range between the highest ask price and the lowest bid price. In the event that acquisitions are effected by a stock broker as assigned by the company, the price for the ordinary shares may, however, correspond to the volume weighted average price during the time period within which the ordinary shares were acquired, even if the volume weighted average price on the day of delivery to Hemfosa falls outside the price range. Payment for the ordinary shares shall be made in cash. The Board of Directors further proposes that the Annual General Meeting resolves to authorise the Board to, at one or more occasions for the period until the end of the next Annual General Meeting, resolve upon transfers of the company’s ordinary shares. The number of ordinary shares transferred may not exceed the total number of shares held by the company at any time. Transfers may be conducted on or outside Nasdaq Stockholm, including a right to resolve upon deviations from the shareholders’ pre-emption right. Transfers of ordinary shares on Nasdaq Stockholm shall be conducted at a price within the registered price range. Transfers of ordinary shares outside Nasdaq Stockholm shall be conducted at a price in cash or value in property that corresponds to the, at the time of the transfer, current market share price of the ordinary shares in Hemfosa that are transferred, with such deviation that the Board of Directors considers appropriate in each case. The purpose of the authorizations is to provide the Board of Directors with greater flexibility to adapt the company’s capital structure to the capital needs from time to time as well as to enable the financing of acquisitions of real property or real property companies, or part of real property or real property companies in a cost efficient way through payment with the company’s ordinary shares. Item 16 – Resolution regarding guidelines for remuneration to the senior executives The Board of Directors proposes that the Annual General Meeting resolves on the following guidelines for remuneration to the company’s senior executives. Hemfosa shall apply the remuneration levels and employment terms necessary in order to attract and retain a highly competent management with capacity to achieve set goals. The forms of remuneration shall motivate the senior executives to do their utmost to secure the shareholders’ interests. Accordingly, the remuneration structure shall be in line with market terms and be competitive. It shall also be simple, long-term and measurable. The remuneration to senior executives may comprise of a fixed and a variable part. The fixed salary for senior executives is to be adapted to market conditions and based on competence, responsibility and performance. A variable part shall reward results clearly linked to targets and improvements in simple and transparent structures and shall be maximised. Any outcome must relate to the fulfilment of pre-determined goals with respect to results, cash flow, growth, value and individually measurable goals. Variable remuneration to each senior executive may not exceed four months’ salary and shall not entitle to pension benefits. The variable salary for all senior executives in the group, taken as a whole, may not exceed SEK three million. Regarding the right and possibility to receive variable remuneration, the group CEO and CFO are excluded during 2017. Senior executives’ non-monetary benefits shall facilitate the work of the senior executives and correspond to what may be deemed reasonable in relation to standard practices on the market in which each senior executive is active. Senior executives may be offered incentive schemes which shall primarily be share based or related to the share price. Any incentive scheme must ensure long-term commitment to the company’s development and be implemented on market terms. Share based incentive schemes and incentive schemes related to the share price shall be resolved by the general meeting of shareholders. The company shall be able to pay remuneration in cash linked to senior executives’ acquisitions of shares or share-related instruments. Such remuneration in cash shall not generally exceed 15 per cent of the fixed salary. The terms for pension benefits for senior executives will be based on defined contribution pension plans and comply with or correspond to general pension plans, the ITP1 plan in Sweden. Salary during the notice period upon termination and severance pay for a senior executive is not to exceed a total of 18 months’ salary, if the company terminates the employment and six months if a senior executive resigns. In this context, senior executives are defined as the CEO, CFO and other members of the group executive management. The Board of Directors shall be entitled to deviate from the guidelines for remuneration to senior executives set out above if there are special reasons in an individual case. In such a case, the Board of Directors shall give an account for the reason for deviation from the guidelines for remuneration to senior executives at the next Annual General Meeting. Item 17 – Resolution regarding warrant program including issue and transfer of warrants 1. Issue of warrants 1.1               The board proposes that the general meeting resolves to carry out a directed issuance in respect of not more than 1 450 000 warrants, entailing an increase in the share capital of not more than SEK 725 000 if the issuance is fully taken up. The resolution shall otherwise be governed by the following terms and conditions. 1.2               The right to subscribe for the share warrants shall, with deviation from the shareholders’ preferential right, be vested in the company’s wholly owned subsidiary Bråtabergen Fastighets AB, 556811-5298 (the “Subsidiary”), with the right and obligation for the Subsidiary to transfer the share warrants to employees pursuant to Section 2 below. Over-subscription is not possible. The warrants shall be issued at no consideration to the Subsidiary. 1.3               The reason for not applying the shareholders’ pre-emption rights is to introduce an incentive program and thereby a remuneration element which is competitive within each market the company operates, to provide alignment for the management team with company strategy, to create focus amongst employees on delivering exceptional performance which contributes to value creation for shareholders and to give employees the opportunity to take part in the company’s success. 1.4               Subscription must be completed no later than three weeks after the resolution on issue of warrants. The board shall be entitled to extend the subscription period. 1.5               Each warrant entitles a right to subscribe for one common share in the company. The warrants may be exercised to subscribe for new common shares, in accordance with the terms and conditions of the warrants, during the following periods: (i)                 from 1 May 2022 up to and including 31 May 2022; and (ii)                from 1 August 2022 up to and including 31 August 2022. 1.6               The new shares which may be issued due to subscription are not subject to any restrictive provisions. 1.7               The subscription price (strike price) shall correspond to 115 per cent of the volume weighted average rate of the common share according to the official list of Nasdaq Stockholm during the period between 2 May 2017 up until and including 15 May 2017. 1.8               Shares which are newly issued following subscription shall carry an entitlement to participate in dividends for the first time on the next record date for dividends which occurs after subscription is effected. 1.9               The board of the company may by means of a board resolution and with the consent from the board of directors in the Subsidiary cancel the warrants held by the Subsidiary’s and which are not transferred in accordance with Section 2. Cancellation shall be registered with the Swedish Companies Registration Office. 1.10                The board of directors or a person appointed by the board of directors is authorized to make such minor adjustments to the general meeting’s resolution which may prove necessary in order to register the warrants with the Swedish Companies Registration Office. 1.11           Other terms and conditions according to the full text warrant terms. 1. Approval of transfer of warrants 2.1               The board proposes that the general meeting approves of the Subsidiary’s transfer of warrants on the following conditions. 2.2               The right to purchase warrants from the Subsidiary shall vest in the following categories of employees: +----------------+----------------+-------------------+----------------+|Category |Minimum   number|Guaranteed   number|Maximum   number|| |of |of warrants/person |of || |warrants/person | |warrants/person |+----------------+----------------+-------------------+----------------+|A. Managing |50   000 |100   000 |150   000 ||director (not | | | ||more | | | ||than 1 person) | | | |+----------------+----------------+-------------------+----------------+|B. Management |20 000 |50 000 |75 000 ||(not more than |(Category:  200 |(Category: 500 000)|(Category:750 ||10 |000) | |000) ||persons) | | | |+----------------+----------------+-------------------+----------------+|C. Key employees|10 000 |25 000 |40 000 ||and regional |(Category: 140 |(Category: 350 000)|(Category:560 ||management (not |000) | |000) ||more   than 14 | | | ||persons) | | | |+----------------+----------------+-------------------+----------------+|D. Other |3 000 |10 000 |15 000 ||employees (not |(Category: 150 |(Category:500 000) |(Category:750 ||more than |000) | |000) ||50 persons) | | | |+----------------+----------------+-------------------+----------------+ 2.3               The right to purchase warrants from the Subsidiary shall only vest in employees who have not terminated their employment or whose employment have not been terminated at the end of the application period. 2.4               Warrants may also be offered to future employees. For such acquisitions, the conditions shall be the same or equivalent to what is stated in this resolution. This means that acquisitions shall be made to the market value at the time of the acquisition. The board of the company shall be entitled to set a corresponding application period for new employees whose acquisitions are made after the expiration of the initial application period. 2.5               Allotment is conditional upon it being legally possible to purchase the warrants, and that such transfers can be done using reasonable administrative and financial resources according to the assessment of the board. Furthermore, the board of the company shall be entitled to, with regard to certain participants, alter the program in to a cash based program or a program based on synthetic warrants, should this according to the board be motivated due to for instance tax and/or legal reasons. Application and allotment 2.6               Application for acquisition of warrants shall be made during the period from 16 May 2017 up until and including 23 May 2017. The board of the company shall however be entitled to extend the application period for acquisitions and to set a corresponding application period for new employees whose acquisitions are made after the expiration of the initial application period. 2.7               Should warrants remain with the Subsidiary after all applications have been satisfied up to the guaranteed level as set out in Section 2.2 above, the remaining warrants shall be available for allotment to participants regardless of category. Such distribution shall however at the most result in the maximum number of warrants per person within certain category amounting to the maximum number of warrants set out in the table under Section 2.2 above. Should not all participants who wish to subscribe for the maximum number of warrants set out in the table under Section 2.2 above be able to do so, the remaining warrants shall be allotted to these participants pro rata in relation to the number of warrants subscribed for, however not more than the maximum number of warrants as set out in the table under Section 2.2. The board of the company shall determine the final allotment.     Price and payment etc. 2.8               The warrants shall be transferred on market terms at a price (premium) established on the basis of a market value of the warrants calculated by an independent valuation institute using the Black & Scholes valuation model. A new market value shall be established in an equivalent way for acquisitions made by new employees after the expiration of the initial application period. The value has preliminary been calculated to be SEK 3.34 per warrant based on a share price of SEK 79.00 and a subscription price per share of SEK 90.90. 2.9               Payment for the allocated warrants shall be made in cash no later than five days following notification of the allotment. The board shall establish a corresponding date of payment for acquisitions made by new employees. 2.10           The company will by means of a cash bonus subsidize up to 100 per cent of the participants premium. The bonus consists of two payments, each of 50 per cent, during the term of the warrant program, one after two years and one after four years. The total cost for the subsidy, based on assumptions of the value of the warrants as set out above, is calculated to amount to not more than SEK 6.4 million including social security contributions, for the entire term of the warrant program of five years. Accrued payroll taxes due to the bonus shall be paid by the participants. 2.11           In order to be eligible for the bonus the participant shall, at the time of the payment of the bonus, remain an employee of the company and not having transferred his or her warrants. Furthermore, only the participants premium as regards warrants up to the guaranteed level as set out in Section 2.2 is subsidized. 2.12           The warrants shall be subject to market terms and conditions. 2.13           Pre-emption and termination of employment The warrants shall be subject to an obligation for participants who wish to transfer or otherwise dispose of his or her warrants to a third party, to first offer the warrants to the company. Furthermore, the warrants shall be subject to a right for the company to repurchase the warrants should a participant’s employment with or assignments for the company be terminated within two years after the day of the resolution on final allotment. Should a participant’s employment with the company be terminated later than two years after the day of the resolution on final allotment, the participant shall be entitled to keep the warrants he or she has acquired, irrespective of the reason for termination. However, the termination of a participant’s employment can result in the right to subsidization as regards the premium being limited in accordance with Section 2.11 above. 1. Further information on the warrant program 3.1               Dilution Upon full exercise of all warrants, 1 450 000 new shares can be issued, which corresponds to a dilution of approximately 0.85 per cent of the total number of shares and 0.90 per cent of the total number of votes in the company, however, subject to the adjustment which may occur as a result of the terms and conditions of the warrants. 3.2               Impact of financial ratios and costs for the company etc. The warrant program is expected to have a marginal impact on the company’s financial ratios. The costs before taxes for the company associated with the warrant program, including the directed issuance, the subsequent transfer of warrants and the subsidy, includes administrative costs and costs relating to social security contributions. The total cost of the warrant program, assuming full participation, is expected to amount to approximately SEK 6.4 million during a period of five years. 3.3               Preparation of the matter The principles of the warrant program have been prepared by the board of the company. The proposal has been prepared with the assistance of external advisors and after consultation with shareholders. The board has thereafter decided to submit this proposal to the Annual General Meeting. Except for the officials who prepared the matter pursuant to instructions from the board, no employee that may be included in the program has taken part in the preparation thereof. 3.4               Other share related incentive programs etc. Except from the current proposal to the general meeting as regards the issue of warrants series 2017:1, the company has no outstanding share related incentive programs. 3.5               Instruction to the board of directors The board proposes that the general meeting instructs the company’s board of directors to execute the resolution in accordance with Section 1 above and to ensure that the Subsidiary’s board of directors carries out the transfer of the warrants in accordance with Section 2 above. MISCELLANEOUS Shares and votes As of the date of this notice, there is a total number of 168,728,248 shares in Hemfosa, of which 157,728,249 are ordinary shares carrying one vote per share and 10,999,999 are preference shares, carrying one-tenth of a vote per share, corresponding to a total number of 158,828,249 votes in the company. The company does not hold any own shares. Majority requirements The resolutions under items 13 and 17 are valid only if supported by shareholders holding not less than nine-tenths of the votes casted and the shares represented at the Annual General Meeting. The resolutions under items 14 and 15 are valid only if supported by shareholders holding not less than two-thirds of the votes casted and the shares represented at the Annual General Meeting. Shareholders’ right to request information The Board of Directors and the CEO shall, if any shareholder so requests and the Board of Directors believes that it can be done without material harm to the company, provide information regarding circumstances that may affect the assessment of an item on the agenda, circumstances that can affect the assessment of the company’s or its subsidiaries’ financial situation and the company’s relation to other companies within the group and the consolidated accounts. Documentation The annual report, audit report and the auditor’s report regarding whether the previously adopted guidelines for remuneration to the senior executives have been complied with, the complete proposals for resolutions such as complete warrant terms and conditions (item 17) and the reasoned statement of the Board of Directors pursuant to Chapter 18 Section 4 and Chapter 19 Section 22 of the Swedish Companies Act (2005:551) (items 10 b and 14) will be available at the company’s premises at the address Hästholmsvägen 28 in Nacka, Sweden, and at the company’s website, www.hemfosa.se, no later than on Tuesday 4 April 2017 and will be sent to those shareholders who so request and state their address. All of the above mentioned documents will be presented at the Annual General Meeting. _________________ Nacka, March 2017HEMFOSA FASTIGHETER AB (PUBL)Board of Directors Other information Schedule for the Annual General Meeting: 2.00 p.m. CET - The doors open for shareholders. 3.00 p.m. CET – The Annual General Meeting commences. _________________

ÅF to be in-house consulting partner for the new tunnel construction between Denmark and Germany

A comprehensive international team of consultants comprising of ÅF in Denmark, Norway, Sweden, Atkins Danmark and the German consultancy company Obermeyer Planen + Beraten GmbH will be in-house consultants to Femern A/S’ Technical Division for the coming years. During the framework agreement ÅF and sub-consultants will provide specialists and resource personnel to Femern A/S’s Technical Division which is responsible for projecting and establishing the tunnel, technical installations and land installations.   The connection will be an 18 km immersed tunnel between Rødby in Denmark and Puttgarden in Germany, and it will be the world’s longest immersed tunnel with combined road and railroad. The tunnel will shorten the trip between Copenhagen and Hamburg by 160 km.  “We are very proud to contribute to making history when Scandinavia is more firmly linked together with the European continent. The Fehmarnbelt tunnel will create great opportunities, not least when it comes to jobs and trading possibilities between the countries. Our strong team from Denmark, Sweden, Norway and Germany has the required core competence, and we are looking forward to getting started,” says Mats Påhlsson, President ÅF Infrastructure Division. The international team poses a skilled team of consultants and gives Femern A/S the opportunity to call upon various highly specialised experts from the partner’s network of consultants. “The parties we have chosen have a very attractive offer, and we look forward to working with them,” says Henrik Christensen, Technical Director at Femern A/S.  The framework agreement has an estimated value of EUR 35 million.

Successful private placement in Keliber

Keliber has successfully concluded a private placement with gross proceeds of EUR 5.0 million. The share issue was subscribed by four Finnish investors; i.a. the investment companies Osuuskunta PPO and Jussi Capital Oy. In total, 125,000 new shares have been allocated to the investors in the private placement. Following the private placement Keliber has around 954.000 shares.The proceeds from the private placement will be used for the ongoing definitive feasibility study (“DFS”), the environmental permitting process related to the future operations, product marketing and commercial arrangements, and other activities in connection with the lithium project. The DFS is scheduled for completion in Q3 2017.Subsequent of the private placement, Keliber will carry out a repair issue of up to 125,000 shares on the same terms and conditions as for the private placement and with subscription rights for the shareholders prior to the private placement. The subscription period for the repair issue will end 6 April 2017.The abovementioned share issues were authorised by the general meeting in Keliber on 16 March 2017. The general meeting also resolved to carry out incentive issues for members of the management and the board. In total, 9.720 shares may be issued in connection with incentive schemes in 2017.For further information please contact CFO Lars K. Grøndahl, telephone +47 901 60 91.Oslo, 21 March 2017Nordic Mining ASANordic Mining ASA (www.nordicmining.com)Nordic Mining ASA (“Nordic Mining” or “the Company”) is a resource company with focus on high-end industrial minerals and metals in Norway and internationally. The Company’s project portfolio is of high international standard and holds a significant economic potential. The Company’s assets are in the Nordic region.Through the subsidiary Nordic Rutile AS Nordic Mining is undertaking a large-scale project development at Engebøfjellet in Sogn and Fjordane where the Company has rights and permits to a substantial eclogite deposit with rutile and garnet. Permits for the project have been granted by the Norwegian government. Nordic Mining has rights for exploration and production of high-purity quartz in Kvinnherad in Hordaland and develops the project through its subsidiary Nordic Quartz AS. Nordic Mining’s associated company Keliber Oy in Finland plans to start mining of lithium bearing spodumene and production of lithium carbonate. Nordic Mining holds exploration rights on the Øksfjord Peninsula in Troms and Finnmark, where the Company has discovered a prospective area of sulphide mineralisation. Through the subsidiary Nordic Ocean Resources AS, Nordic Mining is exploring opportunities related to seabed mineral resources.Nordic Mining is listed on Oslo Axess with ticker symbol “NOM”.

Annual General Meeting of Sandvik Aktiebolag

The shareholders in Sandvik Aktiebolag are convened to the Annual General Meeting to be held on Thursday, 27 April 2017 at 5:00 p.m. at the Göransson Arena, Sätragatan 21, Sandviken, Sweden. RIGHT TO PARTICIPATE AND Notice Shareholders who wish to participate in the Meeting must be recorded in the share register maintained by Euroclear Sweden AB on Friday, 21 April 2017 and notify the company of their participation in the Meeting not later than Friday, 21 April 2017. Notice of participation in the Meeting shall be made on the Company’s website home.sandvik , by telephone +46 (0) 26-26 09 40 weekdays 9:00 a.m.–4:00 p.m. or by letter to Computershare AB, “Sandvik’s AGM”, Box 610, SE-182 16 Danderyd, Sweden. Shareholders whose shares are registered in the name of a nominee must temporarily have re-registered the shares in their own name at Euroclear Sweden AB on Friday, 21 April 2017 to be entitled to participate in the Meeting. Please note that this procedure also applies with respect to shares held on a bank’s shareholder deposit account and certain investment savings accounts. When giving notice, please state name, personal or corporate registration number, address and telephone number and the number of assistants, if any. If participation is by proxy, the proxy should be submitted to the address stated above in advance of the Meeting. Proxy forms are available on the Company’s website home.sandvik. Agenda 1. Opening of the Meeting. 2. Election of Chairman of the Meeting. 3. Preparation and approval of the voting list. 4. Election of one or two persons to verify the minutes. 5. Approval of the agenda. 6. Examination of whether the Meeting has been duly convened. 7. Presentation of the Annual Report, Auditor’s Report and the Group Accounts and Auditor’s Report for the Group. 8. Speech by the President. 9. Resolution in respect of adoption of the Profit and Loss Account, Balance Sheet, Consolidated Profit and Loss Account and Consolidated Balance Sheet.10. Resolution in respect of discharge from liability of the Board members and the President for the period to which the accounts relate.11. Resolution in respect of allocation of the Company’s result in accordance with the adopted Balance Sheet and resolution on record day.12. Determination of the number of Board members, Deputy Board members and Auditors.13. Determination of fees to the Board of Directors and Auditor.14. Election of Board members:14.1  Marika Fredriksson14.2  Jennifer Allerton14.3  Claes Boustedt14.4  Johan Karlström14.5  Johan Molin14.6  Björn Rosengren14.7  Helena Stjernholm14.8  Lars Westerberg15. Election of Chairman of the Board.16. Election of Auditor.17. Resolution on guidelines for the remuneration of senior executives.18. Resolution on a long-term incentive program (LTI 2017).19. Closing of the Meeting. PROPOSALS FOR RESOLUTIONS Item 11 – Dividend and record day The Board of Directors proposes that the Annual General Meeting resolve on a dividend of SEK 2.75 per share. Tuesday, 2 May 2017 is proposed as the record day. If the Meeting approves these proposals, it is estimated that the dividend be paid by Euroclear Sweden AB on Friday, 5 May 2017. The Nomination Committee's proposals The Nomination Committee consists of its Chairman Fredrik Lundberg (AB Industrivärden), Kaj Thorén (Alecta), Pär Boman (Handelsbanken Pension), Marianne Nilsson (Swedbank Robur Funds) and Johan Molin (Sandvik’s Chairman of the Board). The Nomination Committee proposes that the Annual General Meeting resolve on the following:  Item 2 –             Attorney Sven Unger as Chairman of the Meeting. Item 12 –           Eight Board members with no deputies and a registered public accounting firm as Auditor. Item 13 –           Fees to the Board of Directors: · Chairman of the Board of Directors: SEK 2,200,000 (2,000,000) · Other Board members not employed by the Company: SEK 630,000 (600,000) each · Chairman of the Audit Committee: SEK 275,000 (225,000) · Other members of the Audit Committee: SEK 150,000 (150,000) each · Chairman of the Remuneration Committee: SEK 125,000 (125,000) · Other members of the Remuneration Committee: SEK 100,000  (100,000) each Fees to the Auditor shall be paid in accordance with approved invoices. Item 14 –           Election of the following persons as Board members: 14.1       Marika Fredriksson (new)14.2       Jennifer Allerton (re-election)14.3       Claes Boustedt (re-election)14.4       Johan Karlström (re-election)14.5       Johan Molin (re-election)14.6       Björn Rosengren (re-election)14.7       Helena Stjernholm (re-election)14.8       Lars Westerberg (re-election)  Jürgen M Geissinger has informed that he is not available for re-election. Marika Fredriksson, born 1963, Master of Business Administration, is CFO & Group Executive Vice President of Vestas Wind Systems A/S since 2013. She was previously CFO of Gambro AB, CFO of Autoliv Inc. and has held several senior positions within the Volvo Group. She is a Board member in ÅF AB and SSAB AB. Item 15 –           Re-election of Johan Molin as Chairman of the Board of Directors. Item 16 –           Pursuant to the recommendation of the Audit Committee, re-election of KPMG AB as Auditor for the period until the end of the 2018 Annual General Meeting. Item 17 – Proposal by the Board of Directors for a resolution on guidelines for the remuneration of senior executives The Board of Directors proposes that the Annual General Meeting resolve to adopt the following guidelines for the remuneration of senior executives for the period extending until the 2018 Annual General Meeting, which guidelines correspond essentially to those adopted by the 2016 Annual General Meeting. The remuneration of the Group Executive Management is to comprise fixed salary, variable salary, pension and other benefits. The total remuneration package should be based on market terms, be competitive and reflect the individual’s performance and responsibilities as well as the Group’s earnings trend. The variable salary may comprise short-term incentives in cash and long-term incentives in cash, shares and /or share-based instruments in Sandvik AB. Variable salary in cash is conditional upon the fulfillment of defined and measurable goals and should be maximized in relation to the fixed salary. Long-term incentives in the form of shares and /or share-based instruments in Sandvik AB may be provided through participation in long-term incentive programs approved by the General Meeting. Terms and conditions for variable salary should be designed so that the Board of Directors, if exceptional economic circumstances prevail, has the option of limiting or refraining from payment of variable salary if such a measure is considered reasonable. In specific cases, agreements may be reached regarding one-off remuneration amounts provided that such remuneration does not exceed an amount corresponding to the individual’s annual fixed salary and maximum variable salary in cash, and is not paid more than once per year and individual. Pension benefits should be defined contribution. Normally, severance pay is paid when employment is terminated by Sandvik. Members of the Group Executive Management generally have a period of notice of not more than 12 months, in combination with severance pay corresponding to 6–12 months fixed salary. An alternative solution may be applied to the President comprising a period of notice of 24 months and no severance pay. No severance pay will be paid when employment is terminated by the employee. The Board of Directors is to have the right to depart from the guidelines resolved on by the Annual General Meeting if, in an individual case, there are special reasons for this. The sphere of senior executives encompassed by the guidelines comprises the President and other members of the Group Executive Management. For information concerning the current remuneration of senior executives, including ongoing long-term incentive programs, refer to note 3.5 in the Company’s 2016 Annual Report and the company’s website. Item 18 – Proposal by the Board of Directors for a resolution on a long-term incentive program (LTI 2017) Background Since 2014 Sandvik’s Annual General Meeting has annually resolved on long-term incentive programs for senior executives and key employees, in the form of performance share programs requiring investment by all participants. The Board of Directors considers that these programs fulfill their purpose of aligning the interests of the participants and the shareholders, strengthening the Sandvik Group’s ability to attract, retain and motivate qualified employees and strengthening Sandvik’s focus and objective to meet its long-term business goals. Accordingly, the Board of Directors proposes that the Annual General Meeting resolve on a long-term incentive program for senior executives and key employees for 2017 (“LTI 2017”), on substantially the same terms and conditions as the previous three long-term incentive programs. General LTI 2017 encompasses approximately 350 senior executives and key employees in the Sandvik Group, divided into four categories. The maximum number of Sandvik shares that can be allocated pursuant to LTI 2017 is 3,500,000 shares, which corresponds to approximately 0.28 percent of the number of outstanding shares in Sandvik. In order to participate in LTI 2017 the employee is required to invest in Sandvik shares at market price no later than 12 June 2017 (“Investment Shares”). In the event that the employee is not able to invest before this date due to being entered in an insider list (logbook) kept by Sandvik, the Board shall be entitled to postpone the date of investment for such employee. The employee may within the scope of LTI 2017 invest up to an amount corresponding to 10 percent of the employee’s fixed annual salary before tax at the time of the investment. Provided such acquisition of Investment Shares is made, participants of LTI 2017 will be entitled to allotment of Sandvik shares, free of charge, after a period of three years on the terms and conditions set forth below. Matching Shares Each acquired Investment Share entitles participants, in all four categories, to be allotted one Sandvik share (“Matching Share”). Performance Shares Each acquired Investment Share entitles participants to be allotted, in addition to Matching Shares, further Sandvik shares provided certain performance targets are met (“Performance Shares”). The maximum number of Performance Shares that may be allotted for each acquired Investment Share is: -          7 for the President,-          6 for each additional member of the Group Executive Management (currently 7 persons),-          5 for each senior manager (approximately 60 persons), and-          4 for each key contributor (approximately 283 persons). Each member of the Group Executive Management shall nominate the persons that are to be offered participation in LTI 2017 and that are to be classified as senior manager and key contributor, respectively, based on position, qualification and individual performance. All nominations are to be approved by the President. The number of Performance Shares that will finally be allotted to the participant for each acquired Investment Share is dependent on the development of the Sandvik Group adjusted Earnings Per Share (“EPS”) during the financial year 2017, compared to adjusted EPS for the financial year 2016. The Board of Directors establishes the levels regarding adjusted EPS that must be attained for allotment of a certain number of Performance Shares. In order for any Performance Shares to be allotted adjusted EPS growth for the financial year 2017 must exceed 5 percent in relation to adjusted EPS for the financial year 2016. The established levels and the extent to which they are attained will be disclosed in the 2017 Annual Report. Prerequisites for allotment The allotment of Matching and Performance Shares, respectively, requires continuous employment and that all Investment Shares be held during a period of three years from the acquisition of the Investment Shares (“Vesting Period”). The Chairman of the Board of Directors may in special cases grant exemptions from the requirement to hold the Investment Shares during the whole Vesting Period. The right to be allotted Matching Shares presupposes that the 2018 Annual General Meeting decides on dividends for the financial year 2017. Whether or not dividends are decided on does not impact a participant’s right to be allotted Performance Shares. If the prerequisites for allotment set forth for LTI 2017 are met, allotment of Matching and Performance Shares, respectively, will take place during 2020, and no later than 30 June 2020. The allotment will take place free of charge, subject to tax. Adjustment of the number of Performance Shares and/or Matching Shares etc. Before the allotment of Performance Shares takes place, the Board of Directors shall consider whether the number of Performance Shares is reasonable taking into account the financial results and position of Sandvik, the impact of larger acquisitions, divestments and other significant capital transactions, stock market conditions and other circumstances. If the Board of Directors deems that this is not the case, the Board of Directors shall reduce the number of Performance Shares to the lower number the Board of Directors finds appropriate or decide that no allotment should take place. In the event of a bonus issue, split, rights issue and/or other similar events in Sandvik, the Board of Directors shall be entitled to decide on the recalculation of the terms of LTI 2017. The Board of Directors may decide on the implementation of an alternative cash based incentive solution for participants in countries where the acquisition of Investment Shares or allotment of Matching and Performance Shares, respectively, is not appropriate, or if such solution is otherwise considered appropriate. Such alternative incentive solution shall to the extent practically possible be designed to correspond to the terms of LTI 2017. The Board of Directors, or a committee appointed by the Board of Directors for this purpose, shall be responsible for the detailed design and administration of LTI 2017 based on the main terms set forth herein. The right to be allotted Matching and Performance Shares, respectively, cannot be transferred and does not give the participant a right to compensation for dividend distributed during the Vesting Period with respect to the underlying shares. Costs of LTI 2017 and hedging arrangements The total cost of LTI 2017 is estimated up to SEK 318 million, at maximum allotment of Matching and Performance Shares. The costs will be allocated over the years 2017–2019. The costs have been calculated as the sum of personnel costs, including social security costs, and administration costs of SEK 3 million for the program. The personnel costs (excluding social security costs) have been calculated based on the value, at the start of the program, of the Matching and Performance Shares that may be allotted at maximum performance, less the present value of the expected dividend during the Vesting Period. The calculation of the costs is based on maximum performance and on a price per share of SEK 100. Sandvik intends to secure its commitment to deliver up to 3,500,000 Sandvik shares under LTI 2017 through a share swap agreement with a third party. The interest cost for such a share swap is estimated at approximately SEK 4 million per year based on the current interest levels and a share price of SEK 100. Against this cost, however, stands the value of possible dividends. Preparation of the proposal The proposal has been prepared by the Board’s Remuneration Committee and has been discussed and resolved on by the Board of Directors. The President has not taken part in the Board of Directors’ discussion and resolution with respect to the proposal. Majority requirement The resolution regarding LTI 2017 requires a majority of more than half of the votes cast at the Meeting. Other For a description of other long-term incentive programs within Sandvik reference is made to note 3.5 in Sandvik’s 2016 Annual Report and to the Company’s website. INFORMATION AT THE ANNUAL GENERAL MEETING The Board of Directors and the President shall, if any shareholder so requests and the Board of Directors believes that it can be done without material harm to the Company, provide information regarding circumstances that may affect the assessment of an item on the agenda, and circumstances that can affect the assessment of the Company’s or its subsidiaries’ financial situation, or the Company’s relation to other group companies. DOCUMENTATION The Nomination Committee’s proposals under items 2 and 12–16 and the Board of Directors’ proposals under items 17 and 18 are included in their entirety in this notice. The Nomination Committee’s statement and the presentation of the proposed Board members are available on the Company’s website home.sandvik. Accounting documents, the Auditor’s Report and the Auditor’s statement regarding the application of the guidelines for remuneration are available at Sandvik AB, Kungsbron 1, section G, floor 6, Stockholm, as well as on the Company’s website home.sandvik . Copies of the documents will be sent without charge to those shareholders who so request and provide their address to the Company. SHARES AND VOTES The total number of shares and votes in the Company is 1,254,385,923. PROGRAM Registration for the Meeting will commence at 3:00 p.m. There will be musical entertainment and a light meal served as from 3:00 p.m. A program with focus on how we secure the best talents for Sandvik will begin at 4:00 p.m. and the award of the Wilhelm Haglund medal will take place at approx. 4:30 p.m. Stockholm, March 2017 SANDVIK AKTIEBOLAG (PUBL) The Board of Directors 

Notice of Annual General Meeting of Vitrolife AB (publ)

Shareholders wishing to participate at the Annual General Meeting shall notify the company by mail to Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg, Sweden, Att: Anita Ahlqvist, by phone +46 31 721 80 83, by fax +46 31 721 80 99 or by e-mail investors@vitrolife.com (aahlqvist@vitrolife.com). Full name/business name, preferably personal identification number/ company registration number (or the equivalent), address, telephone number, number of shares, details of any advisors and where appropriate details of a representative or proxy must be stated in the notification. A proxy form in Swedish for shareholders wishing to be represented by proxy will be found on www.vitrolife.com. Shareholders that have their shares registered in the name of a nominee must temporarily record their shares in the share register kept by Euroclear Sweden AB in their own names to be able to attend the General Meeting. Such registration must be carried out no later than Friday, April 21, 2017. The following proposals will be amongst those presented at the Annual General Meeting: ·  Dividend of SEK 2.60 per share and Tuesday, May 2, 2017, as the record date for the dividend. · The Election Committee proposes that the Board shall consist of six members. The Election Committee proposes re-election of Carsten Browall, Barbro Fridén, Tord Lendau, Pia Marions, Fredrik Mattsson and Jón Sigurdsson. It is proposed that Carsten Browall is elected as Chairman of the Board (re-election). Remuneration to the Board members is proposed to be SEK 1,615,000, of which SEK 500,000 to the Chairman of the Board, SEK 175,000 to each of the other members of the Board. SEK 60,000 to the Chairman of the Audit Committee, SEK 60,000 to the Chairman of the Remuneration Committee and SEK 30,000 to the other members of these committees. The proposal means no change compared to the previous year. ·  Authorization for the Board to resolve to issue new shares up until the next Annual General Meeting. ·  Authorization for the Board to make a decision on the acquisition of the company’s own shares during the period up until the next Annual General Meeting. Attachment: Full notice Gothenburg, March 21, 2017VITROLIFE AB (publ)The Board

YIT starts the construction of an apartment building in Lauttasaari, Helsinki, Finland

YIT starts the construction of an apartment building project in Lauttasaari, Helsinki, Finland. The project is Asunto Oy Helsingin Luhtahuitti with 54 apartments to be sold. The value of the project is approximately EUR 23 million and it will be completed in spring 2019. The project is recorded in the order backlog in the first quarter. This is the second project in the city block of four housing co-operatives developed by YIT. The first project called Koskikara will be completed in May 2017. Luhtahuitti offers unique living facilities nearby the sea. The size of the apartments varies from studios to five-room apartments, and almost every apartment has a glassed-in balcony. This project is located next to the school and Lauttasaari sports park with excellent transportation connections close to the future metro stations. Lauttis Shopping Centre, constructed by YIT, is also located close by with grocery shops, restaurants, coffee houses and several special stores. The Luhtahuitti apartments are currently at the pre-marketing stage. Read more about the project on YIT’s Homes website (in Finnish).  For further information, please contact: Hanna Jaakkola, Vice President, Investor Relations, YIT Corporation, tel. +358 40 5666 070, hanna.jaakkola@yit.fi  Harri Isoviita, Senior Vice President, Residential Construction, YIT Construction Ltd, tel. +358 40 553 3833, harri.isoviita@yit.fi YIT CORPORATION Hanna Jaakkola Vice President, Investor Relations Distribution: Nasdaq Helsinki, major media, www.yitgroup.com YIT creates better living environment by developing and constructing housing, business premises, infrastructure and entire areas. Our vision is to bring more life in sustainable cities. We want to focus on caring for customer, visionary urban development, passionate execution and inspiring leadership. Our growth engine is urban development involving partners. Our operating area covers Finland, Russia, the Baltic countries, the Czech Republic, Slovakia and Poland. In 2016, our revenue amounted to nearly EUR 1.8 billion, and we employ about 5,300 employees. Our share is listed on Nasdaq Helsinki. www.yitgroup.com

Annual General Meeting in Alfa Laval AB (publ)

Program for shareholders In connection with the meeting, there will be an opportunity to view the production of plate heat exchangers at the facility in Lund. The tour begins with a gathering at Sparbanken Skåne Arena, not later than 1.30 p.m. Buses will then transport the visitors to the production facility and afterwards back to the premises at which the meeting will be held. The number of visitors on the tour is limited, and a notification of participation in the tour shall be made in connection with the notification of participation in the Annual General Meeting. 1.30 p.m.       The buses depart from Sparbanken Skåne Arena to the Alfa Laval production facility in Lund3.00 p.m.       Coffee is served adjacent to the premises at which the meeting is held3.30 p.m.       Registration for the Annual General Meeting begins4.00 p.m.       The Annual General Meeting is opened Right to participate ·  A shareholder who wishes to participate in the meeting and have the right to vote shall be registered in the share register maintained by Euroclear Sweden AB on Thursday 20 April 2017, and ·  notify its participation to Alfa Laval AB – together with any advisors (though not more than two) – not later than on Thursday 20 April 2017, preferably before 12.00 noon. In addition, a shareholder whose shares are nominee-registered must temporarily have its shares registered in its own name in the share register maintained by Euroclear Sweden AB in order to be entitled to participate in the meeting. Such temporary ownership registration shall be executed by Thursday 20 April 2017. This means that the shareholder must notify the nominee in ample time prior to that date. Notification Notification to participate in the meeting can be made ·  by mail: Alfa Laval AB, Juridik, P.O. Box 73, SE-221 00 Lund, Sweden, ·  by e-mail: arsstamma.lund@alfalaval.com, ·  on the website: www.alfalaval.com/investors, or ·  by telephone +46 46 36 74 00 or +46 46 36 65 00. The notification shall include name, personal or corporate ID number, address and telephone number as well as information of any advisors (though not more than two). The notification shall also include any wish to participate in the tour of the production facility. A proxy for a shareholder shall, at the Annual General Meeting at the latest, present the original copy of a dated proxy form in writing. The proxy form may at the time of the meeting not be older than one year, if not the limitation stated in the proxy is longer (not more than five years). A proxy form can be obtained from Alfa Laval AB, Juridik, P.O. Box 73, SE-221 00 Lund, Sweden and is also available at the Company’s website, www.alfalaval.com/investors/corporate-governance/annual-general-meetings. In addition, a proxy or a representative of a legal entity shall submit a certificate of registration no later than at the Annual General Meeting. To facilitate the registration, the proxy form and, if applicable, the certificate of registration shall be sent (although not electronically) to Alfa Laval AB in connection with the notification. Alfa Laval AB will, on 21 April 2017 at the earliest, dispatch an entrance card to be produced at the registration as a confirmation of the notification. Proposed agenda 1. Opening of the meeting. 2. Election of a Chairman for the meeting. 3. Preparation and approval of the voting register. 4. Approval of the agenda for the meeting. 5. Election of one or two persons to attest the minutes. 6. Determination whether the meeting has been duly convened. 7. Statement by the Managing Director. 8. Report on the work of the Board of Directors and the Committees of the Board of Directors. 9. Presentation of the annual report and the Auditor’s report, as well as the consolidated annual report and the Auditor’s report for the group, and the Auditor’s report regarding compliance with the guidelines for compensation to senior management adopted at the 2016 Annual General Meeting.10. Resolution on(a)   the adoption of the income statement and the balance sheet as well as the consolidated income statement and the consolidated balance sheet;(b)   allocation of the Company’s profit according to the adopted balance sheet, and record date for distribution of profits; and(c)   discharge from liability for members of the Board of Directors and the Managing Director.11. Report on the work of the Nomination Committee.12. Determination of the number of members of the Board of Directors and deputy members of the Board of Directors to be elected by the meeting as well as the number of Auditors and deputy Auditors.13. Determination of the compensation to the Board of Directors and the Auditors.14. Election of Chairman of the Board of Directors, other members of the Board of Directors and deputy members of the Board of Directors, Auditors and deputy Auditors.15. Resolution on guidelines for compensation to senior management.16. Closing of the meeting. Proposed resolutions Item 2 The Nomination Committee proposes that the Chairman of the Board of Directors, Anders Narvinger, is appointed Chairman of the 2017 Annual General Meeting. Item 10 (b) The Board of Directors proposes a distribution of profits in an amount of SEK 4.25 per share for 2016. Friday 28 April 2017 is proposed as record date for the right to receive dividend. If the meeting resolves in accordance with this proposal, Euroclear Sweden AB is expected to pay the dividend on Thursday 4 May 2017. Item 12 -14 The Nomination Committee proposes as follows: Item 12: The number of members of the Board of Directors to be elected by the meeting is proposed to be eight with no deputies. Both the number of Auditors and the number of deputy Auditors are proposed to be two. Item 13: The compensation to the Board of Directors is proposed to be a total of SEK 5,250,000 (SEK 5,105,000) to be distributed among the members of the Board of Directors who are elected by the meeting and not employed by the Company as follows: ·  Chairman of the Board of Directors                               SEK 1,575,000 (SEK 1,500,000) ·  Other members of the Board of Directors                      SEK 525,000 (SEK 515,000) In addition to the proposed compensations to members of the Board of Directors, it is also proposed that the compensations mentioned below shall be distributed to the members who are Chairman or member of the Committees mentioned below. The proposed compensations are as follows: +--------------------------------+---------------+|Extra amount for the Chairman of|SEK 175,000 ||the Audit   Committee |(SEK 150,000) || |  |+--------------------------------+---------------+|Extra amount for the other |SEK 125,000 ||members of the Audit   Committee|(SEK 100,000)  |+--------------------------------+---------------+|Extra amount for the Chairman of|SEK 50,000 ||the Remuneration Committee |(SEK 50,000)  |+--------------------------------+---------------+|Extra amount for the other |SEK 50,000 ||members of the   Remuneration |(SEK 50,000) ||Committee | |+--------------------------------+---------------+   Bracketed figures refer to compensation for 2016. Compensation to the Auditors is proposed to be paid as per approved invoice. Item 14: Members of the Board of Directors Arne Frank, Ulla Litzén, Anders Narvinger, Finn Rausing, Jörn Rausing, Ulf Wiinberg and Margareth Øvrum are proposed to be re-elected for the time up to the end of the 2018 Annual General Meeting. Anna Ohlsson-Lejon is proposed to be elected as new member of the Board of Directors. Gunilla Berg has declared that she declines re-election. Anna Ohlsson-Lejon is 48 years old and has a B.Sc. in Business Administration and Economics from the University of Linköping. Anna Ohlsson-Lejon is since 2016 member of Electrolux AB's Group Management. She has been employed in Electrolux since 2001 and she is the company's CFO since 2016. She has previously held a number of senior positions in the company, such as CFO of Major Appliances EMEA, Head of Electrolux Corporate Control & Services, Electrolux Group Treasurer and Head of Internal Audit.  The Nomination Committee proposes that Anders Narvinger shall be appointed Chairman of the Board of Directors. Should Anders Narvinger’s assignment as Chairman of the Board of Directors end prematurely, the Board of Directors shall appoint a new Chairman. Information on all members proposed to the Board of Directors and the Nomination Committee’s reasoned statement is available at Alfa Laval AB’s website, www.alfalaval.com and will also be available at the meeting. The Nomination Committee proposes, in accordance with the remuneration committee’s recommendation, that the authorized public accountants Håkan Olsson Reising and Joakim Thilstedt are re-elected as the Company’s Auditors for the forthcoming year, thus for the time up to the end of the 2018 Annual General Meeting. The Nomination Committee also proposes, in accordance with the remuneration committee’s recommendation, that the authorized public accountants David Olow and Duane Swanson are re-elected as the Company’s deputy Auditors for the forthcoming year, thus for the time up to the end of the 2018 Annual General Meeting.   Item 15 The Board of Directors proposes that the meeting adopts a resolution on the following guidelines for compensation to senior management: 1. Scope The term senior management refers to the Managing Director and the group management. These guidelines apply to employment contracts for members of the senior management entered into following the adoption of these guidelines by the meeting, and to amendments to existing employment contracts for senior management made thereafter. The Board of Directors has the right to deviate from the guidelines if there are special circumstances for such deviation in an individual case. Special circumstances may, e.g., be that it must be possible to offer to members of the senior management who reside outside Sweden terms which are competitive in their country of residence. 2. The main principle and how compensation matters are prepared The main principle for the guidelines is that Alfa Laval AB shall offer compensation on market terms so that the Company can attract and retain a competent senior management. The Board of Directors has established a Committee within the Board, with the tasks of preparing the guidelines for compensation for the senior management, which shall be resolved upon by the Annual General Meeting, as well as to propose to the Board of Directors remuneration and employment provisions for the Managing Director. The Board of Directors shall resolve on matters regarding remuneration and employment provisions for the Managing Director following preparation by the Remuneration Committee. The Committee shall resolve on matters regarding remuneration and employment provisions for senior management which reports directly to the Managing Director. The Committee shall continuously report to the Board of Directors. 3. Fixed compensation The fixed salaries shall be revised annually and shall be based upon the competence and areas of responsibility of each individual. 4. Variable compensation The variable compensation comprises (i) an individual annual variable compensation, and may also, as a supplement, include (ii) a long-term incentive program. (i)               The individual annual variable compensation may be between 30 and 60 percent of the fixed compensation, depending on position. The outcome depends on the degree of fulfilment of, in particular, financial targets, and to a more limited extent also on qualitative targets. (ii)              The long-term incentive program directed to not more than 85 of the Company’s top executives, including the senior management, is intended to be a supplement to the individual annual variable compensation. It is the Board of Directors’ proposal to implement a long-term incentive program also in 2017, on terms similar to those of the current programs. The long-term incentive program for 2017 is, just as the long-term incentive programs for 2014, 2015 and 2016, a cash-based program connected to the Company’s earnings per share, taking possible acquisitions of the Company's own shares into account. The long-term incentive program for 2017 will run for three years. The proposed program may generate up to a maximum of 75 percent in total of the participants’ individual annual variable compensation over a period of three years. Payment to the participants of the program will be made after three years, provided, however, that they are still employees at that time. The Board of Directors may consider to propose the General Meeting a share or share price-related program for the senior management. 5. Pension benefits A detailed description of current pension schemes for the senior management is available in note 6 of the Annual Report for 2016. Early retirement is offered selectively and only after a special decision by the Remuneration Committee. As from 2006, a premium based early retirement scheme with a premium of 15 percent of the pensionable income is offered. For old-age pension, in addition to the ITP benefits, a premium based scheme, with a premium of 30 percent of the pensionable income above 30 basic amounts is being offered since 2006. Members of the senior management also have a special family pension which fills the gap between the old-age pension and the family pension according to the ITP plan. In addition, they have the opportunity to allocate salary and bonus to a temporary old-age and family pension. 6. Non-monetary benefits Members of the senior management have the right to normal non-monetary benefits, such as company car and healthcare benefits. In certain cases, Alfa Laval AB can also arrange for a residence supplied by the Company. 7. Dismissal and severance pay Should Alfa Laval AB dismiss a member of the senior management, the compensation during the notice period and the severance pay may be an amount corresponding to a maximum of two yearly salaries. Available documents The annual report, the Auditors’ report, the Board of Directors’ reasoned statement regarding the proposed distribution of profits under item 10 (b), the Auditors’ report regarding compliance with the guidelines for compensation to senior management adopted at the Annual General Meeting held in 2016 and complete proposals for all other resolutions as set out above will be held available for the shareholders at Alfa Laval AB on Wednesday 5 April 2017 at the latest. Copies of the documents will be sent to shareholders who so request and state their postal address. The documents will also be held available on the Company’s website, www.alfalaval.com/investors/corporate-governance/annual-general-meetings no later than on the above-mentioned date. The proposals from the Nomination Committee and their reasoned statement will also be held available on the same web address. Number of shares and votes in the Company At the date of this notice, the total number of shares and votes in the Company is 419,456,315. All shares are of the same class. The Company itself holds no shares in the Company. Information at the Annual General Meeting The Board of Directors and the Managing Director shall, if any shareholder so requests, and if the Board of Directors considers that this can be done without significant harm for the Company, give information on circumstances that can affect the assessment of an item on the agenda, circumstances that can affect the assessment of the financial situation of the Company or its subsidiaries and the Company’s relationship with another group company. __________________________ Lund, March 2017 ALFA LAVAL AB (publ) The Board of Directors

Holmen strengthens wood products business

Today, Holmen has signed an agreement to acquire Linghem Sawmill from its present owner, Rörvik Timber. The sawmill has a new saw line with capacity to produce 75 000 cubic metres per year. Logs more slender than those sawn at the Group’s Braviken Sawmill, 40 km from Linghem, are used as raw material. The purchase price is SEK 48 million. “The acquisition of Linghem Sawmill forms part of our strategy to make use of a greater proportion of the raw material in the area around our sawmills. It makes us an even better partner in relation to the forest owners,” says Johan Padel, head of Wood Products business area, and continues: “Linghem’s products supplement Holmen’s current business structure and reinforce the company’s market position in Sweden and the UK.”   A planing mill is also included in the sawmill, which employs 28 people. The takeover has been planned to take place on 28 April.   Ongoing measures are being taken at Holmen’s two existing sawmills to refine the business. At Braviken Sawmill, two types of wood are now being sawn, distribution has been streamlined and the degree of added value is being increased through the construction of a wood treatment plant. At Iggesund Sawmill, investments in the plant have increased capacity by 15 per cent over the past year. Furthermore, opportunities to establish production of solid wood wall modules (cross laminated timber) are being investigated as a result of the greater interest in wood construction.  For more information, please contact:Johan Padel, head of Wood Products business area, tel. +46 702 14 82 44Ingela Carlsson, Communications Director, Holmen, tel. +46 702 12 97 12 This information is information that Holmen AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on 21 March 2017 at 14.30 CET.

Planmeca announces new compact and lightweight intraoral scanner

The compact and extremely light Planmeca Emerald™ intraoral scanner makes intraoral imaging easy for the dentist and highly comfortable for the patient. The small size and seamless design of the scanner guarantee a great patient experience.“This revolutionary product makes chairside workflow effortless. The accuracy of the impressions meets the most demanding needs with a fully integrated colour scanning option,” commented Jukka Kanerva, Vice President of Planmeca’s Dental care units & CAD/CAM division.The lightweight structure and user-friendly form of the scanner ensure optimal ergonomics. With the active antifog feature of the scanner’s tip mirror, visibility is always clear. It is an easy and simple plug-and-play solution which makes it easy to share between operatories.Infection control of the scanner is impeccable due to the autoclavable tip and seamless design. The dental unit integration enables hands-free operation with the foot control. The scanner is compatible with Planmeca Romexis® and Planmeca PlanCAD® Easy software suites for constant access to real-time scanning data.“Small in size, light in weight, outstanding speed, and superior accuracy, also in full natural colours. I’m confident that with these features Planmeca Emerald will become one of the most precious tools in the world of intraoral scanning,” Mr. Kanerva concluded.Planmeca will be presenting Planmeca Emerald at IDS 2017. Deliveries estimated to start in Q3, 2017.

Green light to Oncology Venture for DRP focused clinical APO010 study in Multiple Myeloma

“I’m excited that APO010 is now approved for use in our DRP focused studies. APO010 is a new immuno-oncology product that kills tumor cells as our immune system, and is a first-in-class product which we believe can become a new treatment option in immuno-oncology says Adjunct Professor Peter Buhl Jensen, M.D., CEO of Oncology Venture. Our first study is against Multiple Myeloma and the aim is to demonstrate single agent efficacy. In due course the APO010 is expected to be used in combination with other active immune-oncology products. We aim to treat 15 Multiple Myeloma patients that have been screened for high likelihood of effect to APO010 as per our Drug Response Predictor - DRP™ - technology,” This DRP™ enables us to develop drugs in a highly focused way,“ Peter Buhl Jensen, further comments. About APO010APO010 is a multimeric form of FAS-ligand for immuno-cancer therapy with a unique mechanism of action. APO010 acts through the FAS-receptor leading to apoptosis of the malignant cells. APO010 is expected to act in synergy with other cancer immunology agents such as ipilimumab and PD-1/PD-L1 inhibitors. The drug candidate is complemented by a companion diagnostic technology (APO010 DRP™) for enrichment of the patient population. APO010 was tested in 25 patients with solid tumors in a phase 1 study. The drug was well tolerated. Pre-clinical studies have revealed that APO010 is highly efficient in Multiple Myeloma. Next step is a focused study on 15 patients with Multiple Myeloma that have been pre-screened for sensitivity using the APO010 DRP™ technology. About Multiple MyelomaMultiple Myeloma (bone marrow cancer) is a systemic malignancy in the blood, affecting plasma cells. The introduction of high-dose therapy with autologous stem cell support, and introduction of new therapies like the proteasome inhibitor bortezomib and IMIDs (thalidomide and lenalidomide) has improved the outcome. In spite of this, eventually all patients will experience progressive disease and continue into second and later lines of treatment. OV will approach this important clinical issue by introducing a novel systemic chemotherapeutic treatment together with a predictive biomarker test. Based on DRP™, APO010 will be developed for use in treatment of Multiple Myeloma. About the Drug Response Predictor (DRP™) screening toolThis method builds on the comparison between sensitive and resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology and clinical correlates in a systems biology network. For further information, please contact Peter Buhl Jensen, CEO                                      Ulla Hald Buhl  Telephone: +45 21 60 89 22                                              Telephone: +45 21 70 10 49 E-mail: pbj@oncologyventure.com                  E-mail: uhb@oncologyventure.com This information is information that Oncology Venture Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on March 21st 2017.  About Oncology Venture Sweden ABOncology Venture Sweden AB is engaged in the research and development of anti-cancer drugs via its wholly owned Danish subsidiary Oncology Venture ApS. Oncology Venture has a license to use Drug Response Prediction – DRP™ – in order to significantly increase the probability of success in clinical trials. DRP™ has proven its ability to provide a statistically significant prediction of clinical outcomes from drug treatment in cancer patients in 29 of the 37 clinical studies that were examined. The Company uses a model that alters the odds in comparison with traditional pharmaceutical development. Instead of treating all patients with a particular type of cancer, patients’ tumors genes are screened first and only those who are most likely to respond to the treatment will be treated. Via a more well-defined patient group, the risk and costs are reduced while the development process becomes more efficient.The current product portfolio: LiPlaCis® for Breast Cancer in collaboration with Cadila Pharmaceuticals, Irofulven developed from a fungus for prostate cancer and APO010 – an immuno-oncology product for Multiple Myeloma.Oncology Venture has spun out two companies in Special Purpose Vehicles: 2X Oncology Inc. a US based company focusing on Precision medicine for women’s cancers with a pipeline of three promising phase 2 product candidates and Danish OV-SPV 2 will test and potentially develop an oral phase 2 Tyrosine Kinase inhibitor.

Pomegranate publishes prospectus and announces price range for its offering of shares

Pomegranate Investment AB (publ) (“Pomegranate” or the “Company”), an investment company that has invested in the unique emerging market opportunity in Iran, today publishes a prospectus and announces the price range for its offering of shares (the “Offering”).  Pomegranate Investment AB (publ) was founded in Sweden in 2014 by a pioneering team with a long and successful track record of investing in high growth companies in emerging markets. Pomegranate has identified opportunities in Iran and invested early in future market leaders within consumer technology, e-commerce and offline sectors where first mover advantage has proven to be key, with a view to transfer knowhow and partner with Iranian entrepreneurs. Having gone in earlier than most in Iran, Pomegranate has a critical headstart and is, with its local partners, well positioned to continue expanding in Iran. Pomegranate has a strong position in Iran’s consumer internet sector with premium investments and leading positions in key markets, held directly and indirectly. In addition to the continued potential for value appreciation within the Iranian consumer internet sector, Pomegranate has identified investment opportunities in the Iranian offline retail sectors, particularly in retail fast-moving consumer goods and food retail. The Offering in brief ·  The Offering comprises up to 1,250,000 newly issued shares, corresponding to up to approximately 23.1 percent of the outstanding shares and votes after the Offering. ·  The final price in the Offering is expected to be set within the Offering Price Range of EUR 24 – 26 per Offer Share, corresponding to a pre-money valuation of the Company of EUR 100 million – 108 million. ·  The new share issue that is conducted as a part of the Offering is expected to render proceeds of up to EUR 30 million to the Company before transaction costs. ·  Pomegranate intends to use the net proceeds from the contemplated transaction primarily to finance a pipeline of two new landmark deals, among others: · Project Hard Discount Iran (“Project HDI”): Total investment of up to c. EUR 30 million payable between 2017-2020 · Fast-Moving Consumer Goods Joint Venture – “Project Safi”: Total investment of up to c. EUR 5-15 million · Basket of smaller deals: Total investment of EUR 4.5 – 8 million in 2017 ·  The Offering is being made to institutional investors in Sweden and internationally as well as the general public in Sweden. ·  Pomegranate has applied for listing of the Company’s shares on NGM Equity. As part of this process and in order to meet the listing requirements, Pomegranate intends to convert to IFRS accounting during 2017. A listing on NGM Equity may take place at the earliest after the announcement of the Company’s second quarterly report for 2017 provided that Pomegranate meets all the listing requirements and deems a listing to be appropriate, subject to approval from NGM and favourable market sentiment. Florian Hellmich, CEO, comments: “Since inception in 2014, Pomegranate has seen considerable positive development around its investments case. Following our latest capital raising one year ago, much has been achieved and many positive developments have taken place. New deals have been negotiated, holdings in existing companies have been strengthened and the team broadened with strong (tech) entrepreneurs and a CFO with significant emerging markets experience. I am particularly excited about the two investment term-sheets signed in December 2016, both of landmark quality. These transactions are intended to diversify our portfolio with investments that have similar expected returns as the online industry with potentially lower, albeit different, execution risk. This public offering will enable us to diversify our portfolio and yet again, we are partnering with very strong, successful entrepreneurs and companies to transfer know-how and create local jobs.” Preliminary timetable Application period for the general public in Sweden:                                                   22 – 29 March 2017 Application period for institutional investors in Sweden and internationally:                22 – 30 March 2017 Announcement of the final price in the Offering:                                                          On or about 31 March 2017 Payment date:                                                                                                              5 April 2017 Delivery of shares:                                                                                                       On or about 12 April 2017 Prospectus A prospectus with full terms and conditions is published today 21 March 2017, on the Company’s website www.pomegranateinvestment.com and on Pareto Securities’ website www.paretosec.com/corp/201703pomegranate  For further information, please contact Gustav Wetterling, CFO Tel: +46 8 545 015 50 Email: ir@pomegranateinvestment.com Advisors In connection with the Offering, Pareto Securities acts as Global Coordinator and Joint Bookrunner, Gazprombank acts as Joint Bookrunner, Vinge acts as legal adviser with regards to Swedish law and Freshfields Bruckhaus Deringer LLP acts as legal advisor with regards to sanctions compliance. IMPORTANT NOTICE The release, publication or distribution of this press release in certain jurisdictions may be restricted. This press release does not constitute an offer of, or an invitation to purchase or subscribe for, any securities of Pomegranate in any jurisdiction. Specifically, without limiting the foregoing, the Offer Shares have not been registered, and will not be registered, under the United States Securities Act of 1933, as amended (the “Securities Act”) or the securities legislation of any state or other jurisdiction in the United States, and may not be offered, sold or otherwise transferred, directly or indirectly, in or into the United States or to U.S. persons. The Offer Shares are being offered outside the United States in compliance with Regulation S under the Securities Act. This press release is not a prospectus for the purposes of Directive 2003/71/EC (such Directive, together with any applicable implementing measures under such Directive in the relevant home Member State, the “Prospectus Directive”). Pomegranate has not authorised any offer to the public of shares or rights in any Member State of the European Economic Area and no prospectus or other offering document has been or will be prepared in connection with the Private Placement. With respect to each Member State of the European Economic Area and which has implemented the Prospectus Directive (each, a “Relevant Member State”), no action has been undertaken to date to make an offer to the public of shares or rights requiring a publication of a prospectus in any Relevant Member State. This press release is being issued solely to and directed at persons having professional experience in matters relating to investments and on the basis that each person in the United Kingdom to whom it is issued is reasonably believed to be such a person as is described in Article 19 (Investment professionals) or Article 49 (High net worth companies, unincorporated associations etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 ("Exempt Persons" and each an "Exempt Person"), or is a person to whom this document may otherwise lawfully be distributed. In addition to the foregoing restrictions, in relation to persons who are in the United Kingdom, this press release is made and directed only at persons falling within the meaning of "qualified investors" as defined in Section 86 of the Financial Services and Markets Act 2000. Warning: The contents of this press release nor the referenced prospectus have not been reviewed by any regulatory authority in Hong Kong. You are advised to exercise caution in relation to the Offering. If you are in any doubt about any of the contents of the press release or the referenced prospectus, you should obtain independent professional advice. The Offer Shares may not be offered or sold in Hong Kong, by means of any document, other than (a) to “professional investors” as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) and any rules made under that Ordinance; or (b) in other circumstances which do not result in the prospectus being a “prospectus” as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32 of the Laws of Hong Kong) or which do not constitute an offer to the public within the meaning of that Ordinance; and no advertisement, invitation or document relating to the Offer Shares may be issued or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to the Offer Shares which are or are intended to be disposed of only to persons outside Hong Kong or only to “professional investors” as defined in the Securities and Futures Ordinance and any rules made under that Ordinance. In South Africa, this press release does not constitute an offer to the public as contemplated in section 96 of the Companies Act, No 71 of 2008 (as amended) (the "Companies Act"), nor does it call attention to or advertise an offer to the public. To the extent that this document contains any details about any offer to be made in South Africa (if at all), such offer will be directed only at persons who would fall within the categories of persons who are not regarded as members of the public in accordance with the Companies Act, namely: 1. (i) persons whose ordinary business, or part of whose ordinary business, is to deal in securities, whether as principals or agents; (ii) the Public Investment Corporation as defined in the Public Investment Corporation Act, No. 23 of 2004 (as amended); (iii) persons regulated by the Reserve Bank of South Africa; (iv) authorised financial services providers as defined in the Financial Advisory and Intermediary Services Act, No. 37 of 2002 (as amended); (v) financial institutions as defined in the Financial Services Board Act, No. 97 of 1990; (vi) a wholly owned subsidiary of the persons contemplated in (iii), (iv) and (v), acting as agent in the capacity of authorised portfolio manager for a pension fund registered in terms of the Pension Funds Act, No. 24 of 1956 or as a manager for a collective investment scheme registered in terms of the Collective Investment Schemes Control Act, No. 45 of 2002; (vii) any combination of the persons contemplated in (i) to (vi); or 2. persons who, were they to subscribe for securities, would subscribe for a minimum amount of R1,000,000 per single addressee acting as principal. This press release may contain "forward-looking statements”, which are statements related to future events. In this context, forward-looking statements often address Pomegranate’s expected future business and financial performance, and often contain words such as "expect”, "anticipate”, "intend”, "plan”, "believe”, "seek”, or "will”. Forward-looking statements by their nature address matters that are, to different degrees, uncertain and can be influenced by many factors, including the behavior of financial markets, fluctuations in interest and exchange rates, commodity and equity prices and the value of financial assets; the impact of regulation and regulatory, investigative and legal actions; strategic actions; and numerous other matters of national, regional and global scale, including those of a political, economic, business and competitive nature. These factors may cause Pomegranate’s actual future results to be materially different than those expressed in its forward-looking statements. Pomegranate does not undertake to update its forward-looking statements.

Finnair Announces Indicative Tender Offer Results

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Finnair Plc, Stock Exchange Release, 22 March 2017 at 9:00 Finnish time (EET). Finnair Plc (the “Company”) announces today the indicative results of the invitation to all holders of its outstanding EUR 150 million 5.000 per cent. notes due 29 August 2018 (ISIN: FI4000068598) (the “Notes”) to tender their Notes for purchase by the Company for cash (the “Tender Offer”). The offer period for the Tender Offer expired at 4:00 p.m. Finnish time (EET) on 21 March 2017 (the “Expiration Deadline”). At the Expiration Deadline, the aggregate principal amount of the Notes validly tendered by the noteholders for purchase was EUR 81,932,000. Pursuant to the terms of the Tender Offer, the Company has reserved the right, in its sole discretion, to decide on acceptance of the Notes for purchase, including not to accept any Notes for purchase. The acceptance by the Company of any Notes for purchase is subject to, without limitation, the successful pricing of the potential issue of new euro-denominated fixed rate notes (the “New Issue Condition”). As at this announcement, the New Issue Condition has not yet been fulfilled. If the Company chooses to accept the Notes for tender pursuant to the Tender Offer, tender instructions will be accepted in full without pro-ration. The Company expects to announce the final results of the Tender Offer, and whether the New Issue Condition has been fulfilled or not, as soon as feasible, and no later than 29 March 2017. Additional information may be obtained from the Dealer Managers. Dealer Managers: Danske Bank A/S, Helsinki: +358 (0)10 513 8774, liabilitymanagement@danskebank.dk (liabilitymanagement@danskebank.dk) Nordea Bank AB (publ): +45 6161 2996, bibi.larsen@nordea.com / nordealiabilitymanagement@nordea.com Tender Agent: Nordea Bank AB (publ), Finnish Branch For further information, contact:Group Treasurer, Christine Rovelli, tel. +358 9 818 8241, christine.rovelli@finnair.comTreasury Operations Manager, Aku Väliaho, tel. +358 9 818 4372, aku.valiaho@finnair.com  Finnair PlcCommunications Finnair is a network airline specialising in passenger and cargo traffic between Asia and Europe. Helsinki’s geographical location gives Finnair a competitive advantage, since the fastest connections between many European destinations and Asian megacities fly over Finland. Finnair’s vision is to offer its passengers a unique Nordic experience, and its mission is to offer the smoothest, fastest connections in the northern hemisphere via Helsinki and the best network to the world from its home markets. Finnair is the only Nordic carrier with a 4-star Skytrax ranking and a member of the oneworld alliance. In 2016, Finnair’s revenues amounted to EUR 2,317 million and it had a personnel of 4,940 at the year-end. Finnair Plc’s shares are quoted on Nasdaq Helsinki. Disclaimer This release is for informational purposes only and is not to be construed as an offer to purchase or sell or a solicitation of an offer to purchase or sell with respect to any securities of Finnair. The distribution of this release and the related material concerning the Tender Offer are prohibited by law in certain countries. Persons resident outside of Finland may receive this release and the related material concerning the Tender Offer only in compliance with applicable exemptions or restrictions. Persons into whose possession this release and any such material may come are required to inform themselves about and comply with such restrictions. This release and such material may not be distributed or published in any country or jurisdiction if to do so would constitute a violation of the relevant laws of such jurisdiction or would require actions under the laws of a state or jurisdiction other than Finland, including the United States, Australia, Canada, Hong Kong, Japan, New Zealand, Singapore and South Africa. No invitation to tender any Notes is being made pursuant to this release and the information contained in this release shall not constitute an offer to sell or tender, or a solicitation of an offer to buy or sell any of Finnair's securities to any persons in any jurisdiction in which such offer, solicitation or sale or tender would be unlawful. None of Finnair, the Dealer Managers or the Tender Agent or any of their respective affiliates and representatives assume any legal responsibility for such violations, regardless of whether the parties contemplating investing in or divesting Finnair's securities are aware of these restrictions or not. Please refer to the tender offer memorandum for a full description of such restrictions. Any securities referred to herein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or the securities laws of any state of the United States or other jurisdiction and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. Persons (as such terms is defined in Regulation S under the U.S. Securities Act), except pursuant to an exemption from, or in a transaction not subject to the registration requirements of, the securities act and applicable state or local securities laws. The communication of this release and the related material concerning the Tender Offer is not being made and such documents and/or materials have not been, and will not be, approved by an authorised person for the purposes of section 21 of the Financial Services and Markets Act 2000. This release and any such materials may only be distributed to and is only directed at (i) persons who are outside the United Kingdom or (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (iii) high net worth companies falling within Article 49(2)(a) to (d) of the Order, and other persons to whom it may lawfully be communicated (all such persons in (i), (ii) and (iii) above together being referred to as “relevant persons”). Any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this release or any of its contents.

InDex Pharmaceuticals concludes well attended Investigators’ Meeting for the phase IIb study CONDUCT

The meeting gathered physicians, study nurses and study coordinators from 65 clinics in 11 countries together with personnel from InDex and the contract research organization (CRO) PAREXEL. A total of almost 170 attendees participated in the meeting which was held in the Nobel prize lecture hall Aula Medica at Karolinska Institutet in Stockholm, Sweden. The aim of the meeting was for the InDex and PAREXEL study team to meet with the site staff and go through the CONDUCT study, to ensure that it is conducted in compliance with the clinical study protocol, guidelines and applicable regulations. “Investigators’ meetings are critical to the success of clinical trials and we are very pleased with the high attendance and great interest in cobitolimod and the CONDUCT study at our meeting”, said Peter Zerhouni, CEO of InDex Pharmaceuticals. “We really appreciate the attendees taking time from their busy schedules for these two intensive and fruitful days and we would like to thank all participants for making this event a success.” Professor Raja Atreya at the University of Erlangen-Nürnberg and principle investigator of the CONDUCT study added, “It feels great to be part of this important study where we are around 90 clinics in 12 European countries collaborating. I look forward to working with my colleagues from all these places to quickly enrol the patients and to make it the best possible study. Cobitolimod is a very promising novel therapeutic option for this debilitating condition and I hope that we will have a real breakthrough with this study for the benefit of patients.”  The CONDUCT study will include 215 patients with left-sided moderate to severe active ulcerative colitis, divided into four treatment arms receiving different dosages of cobitolimod and one arm receiving placebo. It is a randomised, double blind, placebo controlled study for evaluating cobitolimod’s efficacy and safety in inducing clinical remission compared to placebo. In addition to cobitolimod or placebo, all patients will receive standard of care treatment. The objective is to have the first patient enrolled during the second quarter of 2017 and to have top line results in the fourth quarter of 2018. For more information:Peter Zerhouni, CEOPhone: +46 8 508 847 35E-mail: peter.zerhouni@indexpharma.com  Cobitolimod in briefCobitolimod is a new type of drug that can help patients with moderate to severe ulcerative active colitis back to a normal life. It is a so-called Toll-like receptor 9 (TLR9) agonist, that can provide an anti‐inflammatory effect locally in the large intestine, which may induce mucosal healing and relief of the clinical symptoms in ulcerative colitis. Cobitolimod has achieved clinical proof-of-concept in moderate to severe active ulcerative colitis, with a very favorable safety profile. Data from four placebo-controlled clinical trials indicate that cobitolimod has statistically significant effects on those endpoints that are most relevant in this disease, both from a regulatory and clinical perspective. These endpoints include the key clinical symptoms such as blood in stool, number of stools, and mucosal healing, respectively. Cobitolimod is also known as Kappaproct® and DIMS0150. InDex Pharmaceuticals in briefInDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s foremost asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe active ulcerative colitis - a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases. InDex is based in Stockholm, Sweden. The company’s shares are traded on Nasdaq First North Stockholm. Redeye AB is the company’s Certified Adviser. For more information, please visit www.indexpharma.com

Farstad Shipping ASA – Results of the subsequent offering – mandatory notification of trade

Ålesund, Norway, 22 March 2017 – Reference is made to previous announcements of Farstad Shipping ASA ("Farstad" or the "Company") concerning the subsequent offering in the Company announced on 13 March 2017 (the "Subsequent Offering") and the prospectus dated 13 March 2017 regarding inter alia the Subsequent Offering. Farstad hereby announces the results of the Subsequent Offering. The subscription period in the Subsequent Offering expired on 21 March 2017 at 16:30 hours (CET). Eligible shareholders and eligible bondholders have subscribed for and will be allocated shares in the Company for NOK 29.08 million and NOK 0.21 million respectively, for a total amount of NOK 29.29 million. A total of 142,857,142 new shares ("Offer Shares") are issued in the Subsequent Offering at NOK 0.35 per Offer Share, raising gross proceeds of NOK 50 million. The full subscription of the Subsequent Offering was guaranteed by Aker Capital AS ("Aker") and Hemen Holding Limited ("Hemen") for NOK 25 million each; accordingly, Aker and Hemen will in aggregate be allocated 59,160,877 Offer Shares (29,580,439 shares for Aker and 29,580,438 shares for Hemen) for a total subscription amount of NOK 20.71 million, or NOK 10.35 million each. Following registration of the share capital increase in the Norwegian Register of Business Enterprises, the Company's share capital will be NOK 243,177,033.95 divided into 4,863,540,679 shares, each share having a par value of NOK 0.05. All subscribers being allocated Offer Shares will receive an allocation letter confirming the number of Offer Shares allocated to the subscriber and the corresponding amount to be paid. These allocation letters are expected to be distributed today on 22 March 2017. Payment of the Offer Shares will fall due on or about 27 March 2017 and delivery of the Offer Shares is expected to take place on or about 28 March 2017. The Offer Shares are tradable upon delivery to subscribers. Pursuant to an advance payment agreement entered into with the Company, Aker and Hemen have undertaken to advance payment for the Offer Shares on behalf of the subscribers in the Subsequent Offering. Upon delivery of the shares issued in the Subsequent Offering, Aker will hold 601,009,010 shares out of the total 4,863,540,679 shares issued after the completion of the Subsequent Offering. In addition, Ocean Yield ASA, a subsidiary of Aker's parent company Aker ASA, holds 315,595,760 shares as announced on 9 March 2017. This represents a holding of shares and votes of Farstad of 12.36% for Aker, and a consolidated holding of Aker and Ocean Yield ASA of 18.85%, of which Ocean Yield ASA will hold 6.49%. Upon delivery of the shares issued in the Subsequent Offering, Hemen will hold 601,009,009 shares out of the total 4,863,540,679 shares issued after the completion of the Subsequent Offering. This represents a holding of shares and votes of Farstad of 12.36%. Following completion of the contemplated merger between Farstad, Solstad Offshore ASA ("Solstad") and Deep Sea Supply plc as announced on 6 February 2017, Aker will hold 58,496,302 shares representing approximately 20.0% of the shares and votes in Solstad; Ocean Yield will hold 8,836,681 shares representing approximately 3.0% of the shares and votes in Solstad; Aker and Ocean Yield will in aggregate hold 67,332,983 shares representing approximately 23.0% of the shares and votes in Solstad; and Hemen will hold 46,961,289 shares representing approximately 16.1% of the shares and votes in Solstad. This notification is made inter alia pursuant to Section 4-2 of the Norwegian Securities Trading Act. Mr. Audun Stensvold, investment director of Aker ASA, is a board member of the Company. For further information, please contact: CEO Karl-Johan Bakken – tel. +47 901 05 697 CFO Olav Haugland – tel. +47 915 41 809 Farstad Shipping’s fleet currently consists of 56 vessels (27 AHTS, 22 PSV and 7 SUBSEA). The Company’s operations are managed from Aalesund, Melbourne, Perth, Singapore, Macaé and Rio de Janeiro with a total of 1,500 employees engaged onshore and offshore. The Company’s strategy is to be a leading quality provider of large, modern offshore service vessels to the oil industry. www.farstad.com  This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Welcome to Nordax Annual General Meeting 2017

Shareholders are welcome from 08.00 (CET). Before the meeting, coffee and sandwiches will be served. Notifications etc. Shareholders who wish to attend the Annual General Meeting shall both be registered in the shareholders’ register kept by Euroclear Sweden AB on Friday 21 April 2017, and make a notification to the company to attend the Annual General Meeting not later than Friday 21 April 2017. Notification to attend the Annual General Meeting shall be made either on the website of Nordax www.nordaxgroup.com, or in writing under address Nordax Group AB, c/o Euroclear Sweden AB, “AGM 2017” , P.O. Box 191, SE - 101 23 Stockholm or by telephone at +46 (0)8 402 92 09. The notification shall include the following: name, social security/company registration number, address, telephone number (daytime), registered shareholding, information on potential assistants (maximum two) and where applicable, information on deputies or representatives. Entrance cards, to be presented at the entrance to the meeting, will be sent out from Saturday, 22 April 2017. Read the full notice in the attached document. The notice is also published on www.nordaxgroup.com where notification also can be submitted.  For more information, please contact Andreas Frid, Head of Investor Relations, Nordax Tel: +46 705 29 08 00 E-mail: ir@nordax.se  About Nordax Nordax is a leading niche bank in Northern Europe providing personal loans and deposit accounts to private individuals in Sweden, Norway, Finland, Denmark and Germany. Nordax had nearly 150.000 deposit and lending customers at year-end. Nordax employs about 200 people, all working in its office in Stockholm. The underwriting process is Nordax’s core competency; it is thorough, sound and data driven. Nordax’s customers are financially stable individuals. The typical customer is approximately 50 years old and has an income in line with or above the national average. As of December 31, 2016 lending to the general public amounted to SEK 12.8 billion and deposits amounted to SEK 7.1 billion. Nordax has been supervised by the Swedish Financial Supervisory Authority since 2004 and deposits are covered by the Swedish deposit guarantee scheme. Read more on www.nordaxgroup.com. For more information about Nordax’s customer offerings, read more on each country’s web site: www.nordax.se, www.nordax.no, www.nordax.fi and www.nordax.de.

Notice of Annual General Meeting in Atlas Copco AB

Registration Shareholders, intending to participate in the Meeting, must-              be recorded in the register of shareholders kept by Euroclear Sweden AB (“Euroclear”) on Thursday April 20, 2017, and-              notify the Company in writing of their intent to participate in the Meeting no later than Thursday April 20, 2017, to the registration address Atlas Copco AB, Box 7835, SE-103 98 Stockholm, or by telephone +46 8 402 90 43 work days between 9.00 a.m. to 4.00 p.m. or on the Company’s website www.atlascopcogroup.com/agm. Please see the full Notice below, or visit www.atlascopcogroup.com/agm.  For more information please contact:Håkan Osvald, Senior Vice President, General Counsel+46 8 743 8995hakan.osvald@se.atlascopco.comOla Kinnander, Media Relations Manager+46 8 743 8060 or +46 70 347 2455media@se.atlascopco.com  This information is information that Atlas Copco AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the contact persons set out above, at 8.30 am CET on March 22, 2017.  Atlas Copco is a world-leading provider of sustainable productivity solutions. The Group serves customers with innovative compressors, vacuum solutions and air treatment systems, construction and mining equipment, power tools and assembly systems. Atlas Copco develops products and services focused on productivity, energy efficiency, safety and ergonomics. The company was founded in 1873, is based in Stockholm, Sweden, and has a global reach spanning more than 180 countries. In 2016, Atlas Copco had revenues of BSEK 101 (BEUR 11) and about 45 000 employees. Learn more at www.atlascopcogroup.com. Unofficial Translation  Notice of Annual General Meeting in Atlas Copco AB The Shareholders of Atlas Copco AB (the “Company”) are invited to attend the Annual General Meeting (the “Meeting”) Wednesday April 26, 2017 at 4.00 p.m. (CEST) at Aula Medica, Nobels väg 6, Solna, Sweden. Registration starts at 2.30 p.m. Registration Shareholders, intending to participate in the Meeting, must -          be recorded in the register of shareholders kept by Euroclear Sweden AB (“Euroclear”) on Thursday April 20, 2017, and-          notify the Company in writing of their intent to participate in the Meeting no later than Thursday April 20, 2017, to the registration address Atlas Copco AB, Box 7835, SE-103 98 Stockholm, or by telephone +46 8 402 90 43 work days between 9.00 a.m. to 4.00 p.m. or on the Company’s website www.atlascopcogroup.com/agm Shareholders whose shares are held in trust by a bank or other trustee must temporarily register their shares in their own names in the register of shareholders of Euroclear to be able to participate in the Meeting. Such temporary registration must be recorded by Thursday April 20, 2017. Shareholders should notify their trustees/banks well in advance of this date. Shareholders who are represented by a proxy holder shall submit a proxy. A proxy form is available on www.atlascopcogroup.com/agm. The Company will also send a proxy form to those Shareholders who so request. Representatives of legal entities must be able to present a copy of the registration certificate or other similar authorization document to support the proxy. Please send such proxies and other authorization documents to the Company well in advance to ease the registration process at the Meeting. Personal data obtained from notifications, proxies and the register of shareholders kept by Euroclear will solely be used for the necessary registration and preparation of the voting list for the Meeting. Entrance cards will be sent to the Shareholders who have notified their intention to participate. The proceedings will be simultaneously translated into English. Electronic devices for voting will be used to some extent. The President & CEO’s speech will after the Meeting be available on the Company’s website www.atlascopcogroup.com/agm. Proposed agenda  1. Opening of the Meeting and election of Chair2. Preparation and approval of voting list3. Approval of agenda4. Election of one or two persons to approve the minutes5. Determination whether the Meeting has been properly convened6. Presentation of the Annual Report and the Auditor’s Report as well as the Consolidated Annual Report and the Consolidated Auditor’s Report7. The President & CEO’s speech and questions from Shareholders to the Board of Directors and the Management8. Decisions regarding    a) approval of the Profit and Loss Account and the Balance Sheet and the Consolidated Profit and Loss Account and the Consolidated Balance Sheet    b) discharge from liability of the Board members and the President & CEO    c) the allocation of the Company’s profit according to the approved Balance Sheet    d) record date for dividend9. Determination of the number of    a) Board members and deputy members, and    b) auditors and deputy auditors or registered auditing company10. Election of     a) Board members,     b) Chair of the Board, and     c) Auditors and deputy auditors or registered auditing company11. Determining the remuneration,     a) in cash or partially in the form of synthetic shares, to the Board of Directors, and the remuneration to its committees, and     b) to the auditors or registered auditing company12. The Board’s proposals regarding     a) guiding principles for the remuneration of senior executives     b) a performance based personnel option plan for 201713. The Board’s proposal regarding mandates to     a) acquire series A shares related to personnel option plan for 2017     b) acquire series A shares related to remuneration in the form of synthetic shares     c) transfer series A shares related to personnel option plan for 2017     d) sell series A shares to cover costs related to synthetic shares to Board members     e) sell series A and B shares to cover costs in relation to the performance based personnel option plans for 2012, 2013 and 201414. Closing of the Meeting Item 8 c) and d) - The Board of Directors’ proposals regarding dividend and record date The Board proposes that the dividend for 2016 is decided to be SEK 6.80 per share to be paid in two equal instalments of SEK 3.40. The record date for the first instalment is proposed to be April 28, 2017 and for the second instalment October 30, 2017. If the Meeting decides as proposed, the first instalment is expected to be distributed by Euroclear on May 4, 2017 and the second instalment on November 2, 2017. Item 1, 9 and 10 - Proposals from the Nomination Committee regarding Chair of the Meeting, number of Board members, Chair, and other Board members and registered auditing company The Nomination Committee, consisting of Petra Hedengran, the Chair of the Nomination Committee, Investor AB, Jan Andersson, Swedbank Robur Fonder, Ramsay Brufer, Alecta and Hans Ek, SEB fonder, who together represent more than 30% of the total number of votes in the Company, as well as Hans Stråberg, the Chair of the Board, propose as follows: Item 1: That Hans Stråberg is elected Chair of the Meeting. Item 9: That nine Board members be elected. That one registered auditing company be elected. Item 10: That the following Board members are re-elected: Gunilla Berg, Staffan Bohman, Johan Forssell, Sabine Neuss, Hans Stråberg, Anders Ullberg and Peter Wallenberg Jr and new election of Tina Donikowski and Mats Rahmström. That Hans Stråberg is elected Chair of the Board. That Deloitte AB is re-elected as the auditing company which also is the Audit Committee’s recommendation.   Information regarding all proposed Board members is available on www.atlascopcogroup.com/agm Item 11 – Proposal from the Nomination Committee regarding remuneration to the Board of Directors and for committee work and audit fee Remuneration of SEK 2,100,000 (1,975,000) to the chair and SEK 660,000 (625,000) each to the other Board members not employed by the Company. To the chair of the Audit Committee SEK 250,000 (225,000) and SEK 160,000 (150,000) each to the other members. To the Chair of the Remuneration Committee SEK 100,000 (100,000) and SEK 75,000 (75,000) each to the other members, and remuneration of SEK 60,000 (60,000) to each Board member who, in addition to the above, participates in a committee in accordance with a decision of the Board of Directors. Reflecting the ambition to further enhance the interest for the long term development of the Company, the Nomination Committee proposes that each nominated Board member shall have the possibility to choose between receiving 50% of the remuneration in the form of synthetic shares and the rest in cash and to receive the whole remuneration in cash.    The Board proposes that the obligation of the Company to pay an amount corresponding to the synthetic shares as described above shall be hedged through the purchase of own series A shares. Repurchased shares can be sold on the market in connection with the payment to the Board member in compliance with a request for mandate. The economic difference for the Company if all Board members choose to receive a part of their fee in the form of synthetic shares compared to receive the whole remuneration in cash is assessed to be very limited due to the hedging.  Audit fee is proposed to be as per approved invoice. Item 12 – The Board’s proposals regarding:a) guiding principles for the remuneration of senior executivesb) a performance based personnel option plan for 2017 12 a) guiding principles for the remuneration of senior executivesThe term “senior executives” covers the President & CEO and the other nine members in the Group management team.The proposal of the Board for 2017, is as follows:The remuneration to the senior executives shall consist of a base salary, variable compensation, long term incentive programs, pension premium and additional benefits. For expatriates certain other benefits apply in compliance with the Company’s Conditions for Expatriate Employees.The base salary reflects the position, qualification and individual performance.The size of the variable compensation depends on the extent to which predetermined quantitative and qualitative goals are met. The variable compensation is limited to a maximum of 70% of the base salary for the President & CEO, to 60% for the Business Area Executives and to 50% for the other senior executives.Pension premiums are paid in accordance with a premium based plan within a range of 25-35% of the base salary, depending on age. Additional benefits consist of company car and private health insurance.In case of termination of employment of a senior executive by the Company, the compensation can amount to a maximum of 24 months base salary and a minimum of 12 months base salary depending on age, length of employment and possible income from other economic activity or employment. The Board reserves the right to deviate from these guiding principles if special reasons for such deviation exist in an individual case. 12 b) a performance based personnel option plan for 2017  In the opinion of the Board it is important, and it is also in the best interest of the Shareholders, that key personnel in Atlas Copco have a long term interest in a good value development of the shares of the Company and align their performance in a manner that enhances such a development. In particular this applies to the group of key personnel that consists of the senior executives and the division presidents. It is also the assessment of the Board that a share related option program increases the attractiveness of Atlas Copco on the global market and enhances the possibility to recruit and keep key personnel in the Group. Scope and main principlesGrantingThe Board asks for the right to decide on the issuing of performance stock options that can give a maximum of 335 key personnel in the Group the possibility to acquire a maximum of 2,814,434 series A shares.IssuingThe issuing is dependent on the value increase of the Group expressed as Economic Value Added during 2017. In an interval of SEK 2,000,000,000 the issue varies linear from zero to 100% of the maximum number. The size of the plan and the limits of the interval have been established by the Board and are compatible with the goals in the long term business plan of the Group.The issue of performance stock options is maximized to the following number per person within the respective key group:category 1 –  the President & CEO: 105,363 (351,707) optionscategory 2 –  Business Area Executives (5): 22,126 (59,487) optionscategory 3 –  other members of the Group management and division presidents (32): 14,367 (38,048)  optionscategory 4 –  other key personnel (297): 7,201 (17,977) optionsThe Board shall decide which persons shall be included in category 4 based on position, qualification and individual performance. The issuing of options will take place not later than March 20, 2018.The Board shall have the right to introduce an alternative incentive plan for key personnel in such countries where the granting of options is not feasible. Such alternative incentive solutions (SAR) shall, to the extent possible, have terms and conditions corresponding to the ones applicable to the performance stock option plan.The term of the performance stock optionsThe term of the options shall be seven years from the date of granting. The options are not transferable.ExerciseThe options are exercisable earliest three years from granting. The right to exercise only applies during the period a person is deemed employed.Exercise priceThe exercise price shall be set to an amount corresponding to 110% of the average of the closing rates at Nasdaq Stockholm of series A shares during a period of ten business days next following the date of the publishing of the full-year summary for 2017.   Maximized outcomeA single payment/assignment of shares under the stock option plan can never exceed four times the value of the exercise price.RecalculationIn case there should be a decision at a general shareholders meeting regarding, for example, a reduction or increase of outstanding shares or a dividend beyond the dividend policy of the Company a recalculation can take place to preserve the value of the options.A decision regarding such recalculation shall be taken by the Board.Theoretical Value for the RecipientA theoretical value on a personnel option has been established based on the Black & Scholes model for valuating options. As a base for the calculation, among other factors, a share price of SEK 284.78 and an expected volatility of 30% have been used. The theoretical value is calculated to amount to SEK 52.20 per personnel option or in total a maximum of SEK 146,913,455 for the whole plan.Requirement for senior executives and division presidents regarding own investmentAs prerequisite for the participation of the senior executives and division presidents (38 persons) in the personnel stock option plan 2017 applies that they have invested a maximum of 10% of their respective base salary for 2017, before tax, in series A shares of the Company (20% for expatriates with net salary). The investment may be in cash or by pre-owned shares, however, not by shares that are obtained as part of the participation in the stock option plan for 2015 and 2016. The participation in the plan corresponds proportionally to the investment made. Those who have chosen to invest in series A shares will get, in addition to the proportional participation in the plan, the right to acquire, three years after the investment year, the number of shares (matching shares) that corresponds to the number of shares acquired under 2017 at a price of 75% of the market value upon which the exercise price for the shares in the 2017 plan was based, subject to continued employment and continued ownership of the shares. If the number of the acquired shares has been reduced, the right to matching shares is reduced on a share by share basis.The theoretical value for this is calculated to be SEK 88.60 per matching share or in total approximately SEK 3,427,137.Delivery of sharesThe personnel options shall give the right to acquire already issued series A shares. Item 13 – The Board’s proposal regarding mandates to:a) acquire series A shares related to personnel option plan for 2017b) acquire series A shares related to remuneration in the form of synthetic sharesc) transfer series A shares related to personnel option plan for 2017d) sell series A shares to cover costs related to synthetic shares to Board memberse) sell series A and B shares to cover costs in relation to the performance based personnel option plans for 2012, 2013 and 2014 In order for the resolutions by the Meeting in accordance with 13 a), b), d) and e) above to be adopted, the resolutions must be supported by Shareholders holding at least two-thirds of the votes cast as well as of the shares represented at the Meeting. In order for the resolution by the Meeting in accordance with 13 c) above to be adopted, the resolution must be supported by Shareholders holding at least nine tenths of both the votes cast as well as of the shares represented at the Meeting. Should majority votes not be achieved, the intention of the Company is to hedge the financial exposure in connection with the 2017 personnel option plan and secure delivery of shares by entering into an equity swap agreement with a financial institution. 13 a) acquire series A shares related to personnel option plan for 2017 The Board proposes that the Board is granted the mandate until the next Annual General Meeting to decide, on one or more occasions, on the acquisition of shares in the Company as follows: 1. Acquisition of not more than 2,950,000 series A shares2. The shares may only be acquired on Nasdaq Stockholm3. The shares may only be acquired at a price per share within the registered trading interval, at any given point in time. The acquisition is made with the intention to limit the economic risk caused by an increase of the share value during the period the performance stock options remain outstanding, to be able to fulfil future delivery obligations under personnel option and matching share agreements, to cover alternative solutions and cash settlements as well as to cover, primarily, social charges.   13 b) acquire series A shares related to remuneration in the form of synthetic shares The Board proposes that the Board is granted the mandate until the next Annual General Meeting to decide, on one or more occasions, on the acquisition of shares in the Company as follows: 1. Acquisition of not more than 70,000 series A shares2. The shares may only be acquired on Nasdaq Stockholm3. The shares may only be acquired at a price per share within the registered trading interval, at any given point in time. The acquisition is made with the intention to hedge the obligation of the Company to pay remuneration, including social charges, to a Board member who has chosen to receive 50% of the remuneration in synthetic shares. 13 c) transfer series A shares related to personnel option plan for 2017 The Board further proposes that the Meeting decides to transfer shares in the Company in relation to the Company’s personnel option plan 2017, including the share saving/matching share part, according to the following: 1. A maximum of 2,900,000 series A shares may be transferred. Right to acquire shares is to be granted the persons participating in the Company’s proposed performance stock option plan 2017, with a right for each participant to acquire the maximum number of shares stipulated in the terms and conditions of this plan. The participant’s right to acquire shares is conditional upon all terms and conditions of the Company’s performance stock option plan 2017 being fulfilled. Shares are to be transferred on the terms and conditions stipulated by the plan, meaning inter alia, that what is stated therein regarding price and time during which the participants are to be entitled to use their right to acquire shares is also applicable to the transfer. Participants are to pay for the shares within the time and on the terms stipulated in the performance stock option plan 2017.2. With respect to the number of shares that may be transferred under the Company’s performance stock option plan, customary terms for recalculation as a result of bonus issue, share split, rights issues and similar measures apply in accordance with the terms and conditions of the plan. As reason for the deviation from the Shareholders’ right of first refusal and as the base for the transfer price in connection with the transfer of own shares, the Board states that the transfer of own shares is a part of the proposed performance stock option plan for 2017. 13 d) sale of series A shares to cover costs related to synthetic shares to Board members The Board proposes that the Board is granted the mandate until the next Annual General Meeting to decide, on one or more occasions, to sell not more than 30,000 series A shares in the Company to cover the costs of giving a counter value of earlier issued synthetic shares and to, primarily, cover social charges. Shares proposed to be sold were acquired based on mandates given at the Annual General Meeting each respective year to acquire the share for the stated purpose. The sale shall take place on Nasdaq Stockholm at a price within the registered price interval at any given time.  As reason for the deviation from the Shareholders’ right of first refusal and as the base for the price in connection with the sale of own shares, the Board states that the sale of own shares is a part of the previously adopted decision regarding synthetic shares to the Board. 13 e) sale of series A and B shares to cover costs in relation to the performance based personnel option plans for 2012, 2013 and 2014 The Board proposes that the Board is granted the mandate until the next Annual General Meeting to sell, at one or more occasions, a maximum of 5,100,000 series A and B shares, in connection with the exercise of rights under the above mentioned performance stock option plans and related costs in order to cover costs, primarily cash settlements in Sweden, SAR and social costs. Shares proposed to be sold were acquired each respective year based on mandate given at that year’s Annual General Meeting to acquire the shares for the stated purpose. The sale shall take place on Nasdaq Stockholm at a price within the registered price interval at any given time. As reason for the deviation from the Shareholders’ right of first refusal and as the base for the price in connection with the sale of own shares, the Board states that the sale of own shares is an integrated part of the previously adopted performance stock option plans.  Due to current legislation, this has to be re-approved annually. Shares and Votes The Company has issued in total 1,229,613,104 shares of which 839,394,096 are series A shares and 390,219,008 are series B shares. On March 22, 2017 out of such shares the Company holds 16,658,574 series A shares and 332,659 series B shares. Series A shares have one vote and series B shares have one tenth of a vote whereas the non-represented shares held by the Company corresponds to 16,691,839.9 votes. Information at the Annual General Meeting If a Shareholder so requires and the Board believes that the information can be given without causing harm to the Company, the Board and the President & CEO shall give information regarding an item on the agenda or circumstances that might affect the evaluation thereof or circumstances that could affect the evaluation of the economic position of the Company or a subsidiary Company or the Company’s relation to another Company within the Group. If a Shareholder wishes to submit questions in advance, such should be sent to: Atlas Copco AB, Attn: General Counsel, SE-105 23 Stockholm or to board@se.atlascopco.com. Documentation                                       The Annual Report and the Auditor’s Report as well as the proposals from the Nomination Committee and the Board, information regarding all Board members and the statement by the nomination Committee regarding the Board, statements by the auditor and the Board will be available at the Meeting and is available on www.atlascopcogroup.com/agm and with the Company and will be sent free of charge to the Shareholders who so request and state their address from March 22, 2017. In connection with the Meeting, two awards will be presented; “John Munck Award” for important contributions within the area of product development and “Peter Wallenberg Marketing and Sales Award” for the developing of new marketing and sales methods. Nacka, March 2017 Atlas Copco AB (publ) The Board of Directors

Two new Board members proposed for Atlas Copco AB

The proposal includes re-election of Board members Hans Stråberg, Chair, Anders Ullberg, Staffan Bohman, Johan Forssell, Peter Wallenberg Jr., Sabine Neuβ and Gunilla Berg. As previously communicated on January 16, 2017, Ronnie Leten, President and CEO, will leave the Board. Further, Margareth Øvrum has declined re-election. Tina Donikowski, born 1959, is a United States citizen with a B.Sc. in Industrial Management from Gannon University in the United States. Recently retired, she held the position of Vice President Global Locomotive Business for GE Transportation, a digital industrial leader and supplier to the rail, mining, marine, and drilling industries.  Appointed Corporate Officer of General Electric Corporation in 2009, Tina Donikowski’s former positions include Vice President Propulsion Business, Six Sigma Quality Leader, and General Manager Aftermarket Sales and Service, all with GE Transportation where her career spanned more than 30 years.  Mats Rahmström, born 1965, is a Swedish citizen with an MBA from the Henley Management College in the United Kingdom. He is currently Senior Executive Vice President for Atlas Copco AB and President of Atlas Copco’s Industrial Technique business area. Mats Rahmström began his Atlas Copco career in 1988. Former positions include General Manager for customer centers in Sweden, Canada and the United Kingdom, as well as division president. He is a Board member of Permobil Holding AB and of CIBE Lifts AB. Shareholders will vote on the Nomination Committee’s proposal at Atlas Copco’s Annual General Meeting on April 26, 2017, in Solna, Sweden.

NOTICE OF ANNUAL GENERAL MEETING

RIGHT TO PARTICIPATE AND NOTICE OF ATTENDANCE Those wishing to attend the AGM must: 1.     be entered as a shareholder in the share register kept by Euroclear Sweden AB on Thursday, 13 April 2017, and2.     give notice of attendance to the company no later than on Thursday, 13 April 2017. Notice of attendance can be given in writing to the address Evolution Gaming Group AB (publ), Att. Annual general meeting, Hamngatan 11, 111 47 Stockholm, Sweden, or by email to ir@evolutiongaming.com. When giving notice of attendance, please state name/company name, personal identification number/corporate registration number, address, telephone number (office hours) and, where relevant, number of accompanying persons. SHAREHOLDERS WITH NOMINEE REGISTERED SHARES To be entitled to participate in the meeting, those whose shares are registered in the name of a nominee must register the shares in their own name with the help of the nominee, so that he or she is entered in the share register kept by Euroclear Sweden AB on Thursday, 13 April 2017. This registration may be made temporarily. PROXIES AND PROXY FORMS Those who do not attend the meeting in person may exercise his or her rights at the meeting through a proxy in possession of a written proxy form, signed and dated. A template proxy form is available on the Company’s website, www.evolutiongaming.com. The template proxy form can also be obtained from the Company or can be ordered via email in accordance with the above. A proxy form issued by a legal entity should be accompanied by a copy of the certificate of registration or a corresponding document of authority for the legal entity. To facilitate registration at the meeting, proxy forms, certificates of registration and other documents of authority should be submitted to the company at the address above no later than on Thursday, 13 April 2017. NUMBER OF SHARES AND VOTES At the date the notice is issued, the total number of shares in the company is 35,970,377 which corresponds to a total of 35,970,377 votes. SHAREHOLDERS’ RIGHT TO REQUEST INFORMATION Shareholders attending the annual general meeting may request information in accordance with Chapter 7 Section 32 of the Swedish Companies Act (Sw. aktiebolagslagen (2005:551)). PROPOSED AGENDA 1. Opening of the meeting2. Election of Chairman of the meeting3. Preparation and approval of voting register4. Adoption of agenda5. Election of one or two persons to verify the minutes of the meeting6. Determination of whether the meeting has been duly convened7. Resolutions:              i. adoption of the income statement and balance sheet, as well as the consolidated income statement and the consolidated balance sheet     ii. disposition of the Company’s profit or loss as shown in the adopted balance sheet     iii. discharge of liability for the Board of Directors and the CEO8. Resolution on the number of members of the Board of Directors to be elected at the meeting9. Resolution on the remuneration payable to the Board of Directors and the auditor10. Election of the Board of Directors and, if applicable, auditor11. Resolution on guidelines for compensation to senior management12. Resolution regarding the Nomination Committee13. Closing of the meeting Election of Chairman of the meeting (item 2) The Nomination Committee of Evolution which was appointed in accordance with the resolution of the 2016 AGM and consists of Ian Livingstone, elected by Richard Livingstone, Johan Menckel, elected by JOVB Investment AB, Peter Ihrfelt, Chairman of the Nomination Committee, elected by FROS Ventures AB and Joel Citron, who, at the time of appointment of the Nomination Committee of the 2017 AGM, was Chairman of the Board of Directors (currently a member of the Board of Directors), who together represent approximately 36.7 percent of the shares and votes in the Company, proposes that the Chairman of the Board of Directors, Jens von Bahr, should be the Chairman of the AGM. Resolution on appropriation of the Company’s profit or loss as shown in the adopted balance sheet (item 7 ii) The Board of Directors proposes that the AGM shall resolve upon a dividend of EUR 0.45 per share and that 25 April 2017 shall be the record date for the receipt of dividend. If the AGM resolves in accordance with the proposal, the dividend is expected to be paid by Euroclear Sweden AB on 3 May 2017. Determination of the number of members of the Board of Directors to be elected (item 8) The Nomination Committee proposes that the Board of Directors shall, for the period until the end of the 2018 AGM, consist of six members with no deputy directors. Determination of remuneration to the members of the Board of Directors and the auditor (item 9)  The Nomination Committee proposes that remuneration to each of the members of the Board of Directors who are not employed by the Company shall be EUR 10,000, equivalent to a total remuneration of EUR 40,000. The Nomination Committee proposes that remuneration to the Chairman of the audit committee shall be EUR 20,000. The Nomination Committee proposes that there shall be no additional remuneration for other committee work. The Nomination Committee proposes that the remuneration to the Company’s auditor shall be paid in accordance with approved invoicing. Furthermore, the Nomination Committee notes that an extraordinary general meeting of Evolution, on 24 January 2017, resolved to approve the remunerations which Jens von Bahr, executive chairman, and Fredrik Österberg, Group Chief Strategy Officer, receive from the Company because of their employments and that Jens von Bahr and Fredrik Österberg do not receive any remuneration as members of the Board of Directors since they are employed by the Company. Election of the Board of Directors and, if applicable, auditor (item 10) The Nomination Committee proposes re-election of all members of the Board of Directors; Jens von Bahr, Joel Citron, Jonas Engwall, Cecilia Lager, Ian Livingstone and Fredrik Österberg and re-election of Jens von Bahr as Chairman of the Board of Directors for the period until the end of the 2018 AGM. For information on the proposed members of the Board of Directors, see the information available on the Company’s website, www.evolutiongaming.com. The registered accounting firm Öhrlings PricewaterhouseCoopers AB was appointed the Company’s auditor in connection with its formation in November 2014 until the end of the 2018 AGM. Hence, the Nomination Committee makes no proposal in respect of the election of auditor to the 2017 AGM. Resolution on guidelines for compensation to Senior Management (item 11) The Board of Directors proposes that the 2017 AGM approves the following guidelines for compensation to senior management for the period until the 2018 AGM. Guidelines for compensation to senior management The senior management refers to the CEO and the group management of Evolution and its group (the “Executives”).  For information on the current composition of the group management, please refer to www.evolutiongaming.com. These guidelines are also to be applied for any compensation to board members employed by the Company and what is said regarding Executives shall, to the extent applicable, also apply for board members employed by the Company. The objective of the guidelines is to ensure that Evolution can attract, motivate and retain senior executives with the expertise and experience required to achieve Evolution's operating goals. The remuneration shall be based on conditions that are market competitive and at the same time aligned with shareholders’ interests. Remuneration to the Executives shall consist of a fixed and, for some Executives, variable salary. These components shall create a well-balanced remuneration reflecting individual competence, responsibility and performance, both short-term and long-term, as well as Evolution’s overall performance. Fixed salary The Executives’ fixed salary shall be competitive and based on the individual Executive’s competences, responsibilities and performance. A review of the fixed salary shall be carried out on an annual basis for each calendar year. Variable compensation Executives (but not board members employed by the Company) may receive variable remuneration in addition to fixed salaries. Annual variable remuneration plans will be cash based (however, in 2016 Evolution issued warrants to certain key employees and senior management, including to certain Executives who are not board members) and be based on predetermined and measurable performance criteria of the relevant Executive aimed at promoting Evolution’s long term value creation. The set performance criteria are to be established and documented annually. Depending on the level of performance achieved, annual variable remuneration can vary from no variable payment up to fifty percent of the annual base salary (except that one Executive is entitled to variable compensation up to a hundred percent of his annual base salary under his existing employment agreement). Other benefits Evolution provides other benefits to the Executives in accordance with local practice. Such other benefits can include, for example company health care. Occasionally, housing allowance, paid schooling for under age children or travel allowances could be granted. Notice of termination and severance pay The maximum notice period in any Executive’s contract is twelve months during which time salary payment will continue. Severance compensation may be paid in an amount not greater than 12 months’ fixed salary. Deviations from the guidelines The Board of Directors may deviate from the above guidelines if there, in an individual case, are special circumstances justifying that. In such a case the Board of Directors shall explain the reason for the deviation at the following Annual General Meeting.  Resolution on the Nomination Committee (item 12) For the purpose that the Company’s Nomination Committee shall be compliant with the provisions of the Swedish Corporate Governance Code, the Nomination Committee proposes that the 2017 AGM resolves upon the following instructions regarding the Nomination Committee. The Chairman of the Board of Directors will contact the three largest shareholders in terms of votes based on Euroclear Sweden AB’s list of registered shareholders on the last business day of August. The three largest shareholders will be given the opportunity to elect one representative each to form the Nomination Committee along with one of the members of the Board of Directors who is independent in relation to the Company’s management. If any of these shareholders chooses to waive their right to elect a representative, their right is transferred to the shareholder who, after these shareholders, has the largest share ownership. Unless the members agree otherwise, the Nomination Committee will be chaired by the member who represents the largest shareholder in terms of votes. However, a member of the Board of Directors shall not be Chairman of the Nomination Committee. The majority of the members of the Nomination Committee are to be independent of the Company and its executive management. Neither the chief executive officer nor other members of the executive management are to be members of the Nomination Committee. At least one member of the Nomination Committee is to be independent of the Company’s largest shareholder in terms of votes or any group of shareholders who act in concert in the governance of the Company. Members of the Board of Directors shall not constitute a majority of the Nomination Committee. If more than one member of the Board of Directors is on the Nomination Committee, no more than one of these may be dependent of a major shareholder of the Company. Fees are not to be paid to the members of the Nomination Committee. As required, the Company shall be responsible for reasonable costs for external consultants that the Nomination Committee deems necessary to perform its work. The composition of the Nomination Committee will be announced via a separate press release as soon as the Nomination Committee has been appointed, and no later than six months prior to the AGM. Information will also be made available on the Company’s website, which shall also explain how shareholders can submit proposals to the Nomination Committee. Members of the Nomination Committee must relinquish their places on the committee if the shareholder who originally appointed them is no longer one of the three largest shareholders, following which new shareholders, in order of the size of their holding, will be offered the opportunity to elect a member, however only ten shareholders need be approached in turn. However, unless there are exceptional circumstances, no changes will be made to the composition of the Nomination Committee if only minor changes to voting rights have taken place, or the change occurs later than three months prior to the AGM. If a member of the Nomination Committee steps down voluntarily from the committee before their work is completed, the shareholder who elected that member must appoint a successor, provided that the shareholder is still one of the three largest owners in terms of votes that are represented in the Nomination Committee. The Nomination Committee is entitled, if deemed appropriate, to co-opt members appointed by shareholders who became one of the three shareholders with the largest holdings in the Company after the Nomination Committee was formed, and who are not already represented on the Nomination Committee. Such co-opted members do not participate in the decisions of the Nomination Committee. The Nomination Committee is tasked with presenting proposals prior to the AGM regarding the number of Board members, the Board of Directors, Chairman of the Board of Directors, Board remuneration, any remuneration for committee work, election of auditors and fees to the auditors, as well as a Chairman for the AGM. When the notice of the AGM is issued, the Nomination Committee is to issue a statement on the Company’s website explaining its proposals regarding the board of directors. The Nomination Committee must also present proposals to the AGM regarding the process for establishing the following year’s Nomination Committee. The proposals of the Nomination Committee will be presented in the notice of the AGM and on the Company’s website. The Nomination Committee shall furthermore complete the tasks required by the Nomination Committee in accordance with the Swedish Corporate Governance Code, as applicable from time to time. It is proposed that the resolution on the Nomination Committee should apply until further notice. DOCUMENTSThe annual report, complete resolution proposals and any other documents to be made available prior to the AGM as required by the Swedish Companies Act will be available at the Company and on the Company’s website, www.evolutiongaming.com, no later than as from Friday, 31 March 2017 and will be sent free of charge to those shareholders who so request and provide the Company with their name and address. Stockholm, March 2017 Evolution Gaming Group AB (publ) The Board of Directors

Swedish Steel Prize 2017 finalists lead the way with innovative design concepts

“This year a record number of 102 applications were sent in from 32 different countries around the world. The high overall quality of the applications shows that this prize has an important role in promoting and even encouraging the industry to find new and innovative ways to use high-strength steels for higher performance,” says Eva Petursson, Chairman of the Swedish Steel Prize jury and head of SSAB’s strategic R&D. The four finalists are: Fermel, mining vehicle, South AfricaFermel has developed a unique range of multi-purpose vehicles for safe transportation in mines. The vehicles meet new, more stringent safety legislation and are intended to replace the re-built standard vehicles currently used. Design optimization of the entire vehicle, including the car body, has given superior performance regarding personal safety, higher payload, agility, damage resistance, reliability and service life. All these benefits are achieved by extensive use of advanced high-strength structural and wear-resistant steels. JMG Cranes, electrical pick and carry crane, ItalyJMG Cranes has developed a unique, highly compact crane with an extended field of application. The lean design combined with electric drive train and excellent maneuverability allows it to be used both indoors and outdoors. This powerful pick and carry crane has great lifting capacity. Its high performance to weight ratio has been obtained by optimized boom design utilizing ultra-high-strength steels. Additionally, efficient road transportation is made easy by removable support legs and counter weights. Kiruna Wagon, dumper wagon, SwedenKiruna Wagon has developed an innovative dumper wagon system for long-haul rail transport and efficient unloading of minerals. Use of advanced high-strength structural and wear-resistant steels made it possible to design lightweight wagons combined with a stationary Helix terminal for on-the-fly rotary unloading. With its nearly doubled unloading rate, the Helix system is superior to all conventional solutions and solves many problems related to sticky aggregates. The terminal system is very cost effective, in terms of both investment and operation. Wabash National, rear impact guard, USAWabash National’s new rear impact guard for trucks and semi-trailers exceeds North American standards also for demanding off-set impact. The optimized design utilizing high-strength structural steel has been verified through extensive full-scale testing that shows superior performance in protecting the people in the colliding car. The patented system gives excellent energy absorption, minimum damage to the heavy vehicle as well as highly cost-effective manufacturing and assembly. Read more about the Swedish Steel Prize on www.steelprize.com. For further information, please contact:Eva Petursson, Chairman of the Jury, Swedish Steel Prize, +46 243 712 04Anna Rutkvist, Project Manager, Swedish Steel Prize, +46 243 716 40

Invitation to the Annual General Meeting of Diös Fastigheter AB (publ)

Shareholders who wish to attend the meeting shall; ·be recorded as a shareholder in the share register, kept by Euroclear Sweden AB, (the Swedish Central Securities Depository), on April 20, 2017. ·give notice of participation no later than on April 20, 2017, at 12.00 p.m. Shareholders who have trustee-registered shares should: ·request the bank or broker holding the shares to request temporary owner-registration, so-called voting-right registration, several bank-days prior to April 20, to be entitled to participate in the Meeting. Notice of participation can be submitted in writing to Diös Fastigheter AB, “AGM 2017”, Box 188, 831 22 Östersund, Sweden, or via the registration form on our website, www.dios.se. When giving notice of participation, the shareholder is to state his or her name, personal ID/corporate registration number, address and telephone number, their shareholding in Diös and the names of any advisors they wish to attend. Shareholders who are represented by proxy shall issue a power of attorney to be enclosed with the notice of participation, along with any registration certificates or other proof of authorisation. If you want to be represented by proxy or if you are a legal entity, please contact Andreas Höhling, attorney at law firm Glimstedt, +46 8 566 119 13 or +46 73 516 00 07. Proposed agenda: 1.     Opening of the Meeting. 2.     Election of a Chairman for the Meeting. 3.     Establishment and approval of the register of shareholders. 4.     Approval of the agenda. 5.     Election of one or two members to verify the minutes. 6.     Determination of whether the meeting has been duly convened. 7.     Statement by the CEO. 8.     Presentation of the Annual Report and the Auditors' Report together with the Consolidated Financial Statement and Consolidated Auditors' Report. 9.     Resolutions concerning: 1.the adoption of the income statement and balance sheet together with the consolidated income statement and consolidated balance sheet, 2.the appropriation of the company's profit on the basis of the balance sheet adopted, 3.discharge to the members of the Board and the Managing Director for their activities during the financial year, and 4.the record date, if the Annual General Meeting approves the profit distribution proposal. 10.   Determination of the number of members of the Board and deputy Board members. 11. Approval of the Board of Directors' and the auditor's remuneration. 12. Election of Chairman and members of the Board. 13. Election of auditors. 14. Approval of policies for remuneration and terms of employment for the members of the management team. 15. Approval of policies regarding the composition of the Nominating Committee. 16. Resolution to authorise the Board of Directors to buy back and transfer shares of the company. 17. Resolution to authorise the Board of Directors to resolve on new share issues. 18. Other business. 19. Closing of the meeting. Proposals Election of a Chairman for the Meeting (item 2) The nominating Committee, consisting of Chairman Bo Forsén (Backahill Inter AB), Håkan Sandberg (Pensionskassan SHB Försäkringsförening), Jonas Bengtsson (Bengtssons Tidnings Aktiebolag) and Bob Persson (AB Persson Invest), proposes Bob Persson as Chairman of the AGM. Resolution regarding appropriation of the company’s profit according to the adopted balance sheet (item 9) The Board proposes that the AGM declare a dividend of SEK 2.00 per share for 2016. The proposed record date for the dividend is 28 April 2017. If the AGM adopts the proposal it is expected that the cash dividend will be distributed by Euroclear Sweden AB on 4 May 2017.  Election of members of the Board of Directors, auditors, remuneration, etc. (items 10-13) The Nominating Committee proposes; ·to appoint five regular Board members with no deputies, ·to re-elect existing members Anders Bengtsson, Maud Olofsson, Ragnhild Bengtsson and Bob Persson, ·to elect Anders Nelson as member of the Board of Directors, ·to re-elect Bob Person as Chairman of the Board, ·that Director’s fees be paid to the Board of Directors in a total amount of SEK 800,000: ·SEK 200,000 to the Chairman of the Board, and ·SEK 150,000 to each non-executive Board member, ·as for auditor, after completed procurement and in accordance with the Audit Committee´s recommendation, re-elect Deloitte AB, with authorised auditor Lars Helgesson as responsible auditor, and ·to remunerate the auditors on the basis of approved invoices. Resolution regarding principles for remuneration and other terms of employment for Senior management (item 14) The Board of Directors proposes following guidelines for remuneration of Senior management Remuneration and benefits to the Managing Director are decided by the company's Board of Directors. Remuneration to other senior executives is decided by the Managing Director in consultation with the company's Board of Directors. Variable incentive compensation plans were introduced in 2012 for the company's Managing Director and senior executives, but there are no types of share-based compensation. Variable compensation is capped at one month's salary. The Managing Director is entitled to a company car and insurance and retirement benefits in accordance with the ITP scheme applicable during the period of employment. Individual investment options are available. Insurance and pension premiums are based on cash salary only. The retirement age for the Managing Director is 65 years. The period of notice given by the company to the Managing Director is 12 months. The period of notice given by the Managing Director to the company is 4 months. Remuneration during a period of notice is deducted from income from another employer. Other senior executives are entitled to a company car. During the period of employment with the company, other executives are entitled to insurance and pension benefits in accordance with the ITP scheme applicable at the time. Individual investment options are available. Insurance and pension premiums are based on cash salary only. The retirement age for other senior executives is 65 years. The contracts of other members of Group management are terminable by either party on three to six months’ notice.                              Resolution regarding approval of policies regarding the composition of the Nominating Committee (item 15) The Nominating Committee proposes that a new Nominating Committee for the 2018 AGM be appointed in the same manner as for the present AGM, i.e. that the Committee be appointed no later than six months before the AGM and consist of representatives of the four largest shareholders based on the last known shareholdings at 31 August 2017. Resolution to authorize the Board of Directors to buy back and transfer shares of the company (item 16) The Board of Directors proposes that the Meeting authorise the Board, for a period ending no later than at the next AGM, to on one or more occasions buy back shares in the company and transfer the company’s shares to other parties. Share buybacks are subject to a limit of 10 per cent of the total number of shares outstanding at any time. Acquisitions may be effected on the Nasdaq Exchange Stockholm at a price per share that is within the registered span of share prices at the particular time. All of the treasury shares held by the company at the time of the Board of Directors’ decision may be transferred. The shares may be transferred either on Nasdaq Stockholm or in another manner, disapplication of the pre-emption rights of existing shareholders, at a price per share that is within the registered spread of share prices at the particular time. Payment for transferred shares may take the form of in cash, in kind or by offset of a claim on the company or in another manner subject to terms and conditions. The purpose of the authorisations described above is to ensure that the company is able to continually adapt its capital requirements and thereby increase shareholder value, and to ensure that the company is able to transfer shares as payment for or to fund any future property or corporate acquisitions. Resolution to authorize the Board of Directors to resolve on new share issues (item 17) The Board of Directors proposes that the AGM resolve to authorise the Board during the period up to the next AGM, to decide, on one or several occasions, to issue new shares with or without pre-emption rights for existing share-holders. The number of shares issued under the authorization may not exceed ten (10) percent of the company’s share capital at the time of the Board’s first decision to issue new shares under the authorisation. Payment for new shares may be made in the form of a cash or non-cash consideration or in lieu of debt. New shares may be subscribed for in disapplication of the pre-emption rights of existing shareholders. Existing shareholders’ pre-emption rights may be disapplied for the purposes to enable property or corporate acquisitions in which payment is made in the form of shares of the company or, alternatively, to capitalise the company prior to such acquisitions. The issuance of shares under the authorisation must be made on market terms.  More information Annual report, auditor’s report and complete proposals together with statements according to the Swedish Companies Act, including the auditor’s statement and proxy forms will be available at the head office no later than three weeks before the AGM and can be distributed to shareholders on request. All documents will also be available on our website, www.dios.se Number of shares and votes At the time of this notice the total number of shares and votes in the company amounts to 134,512,438. No shares are treasury shares. Shareholders right to request information The shareholders have the right request information from the Board of Directors or the CEO regarding the financial situation and items on the AGM agenda. The Board of Directors or the CEO shall disclose such information if the Board is of the opinion that it can occur without any significant damage to the Company. ____________________________ Östersund March 2017 Diös Fastigheter AB (publ)Board of Directors

Hoist Finance’s Annual Report for 2016 focuses on the company’s position in the financial ecosystem and the corporate culture and values

Today Hoist Finance released its annual report for 2016. The report can be found on our corporate homepage www.hoistfinance.com. This year, focus has been to describe Hoist Finance’s role in the financial ecosystem, the market and the company's corporate culture and values.  -       We summarise 2016 as another successful and profitable year for Hoist Finance. During the year we continued to strive towards our vision – a leading debt restructuring partner to international banks and financial institutions. At the same time we showed a high and stable growth rate. During the year we entered into a strategic partnership with the Bank of Greece, assisting Greece in restructuring the Greek banking sector. We were assigned a Ba1 long term issuer rating by Moody’s, and we diversified and broadened our funding base through a successful bond issue. We also entered the Spanish market and can now fully support the Spanish banking industry with our high-calibre services, says Jörgen Olsson, CEO Hoist Finance  Copies of the annual report can be ordered by sending an email to info@hoistfinance.com  For further information please contact: Michel Jonson, Group Head of IR  Telephone: +46 (0)8 555 177 19  This information is information that Hoist Finance AB (publ) is obliged to make public pursuant to the Securities Markets Act (Sw: lagen om värdepappersmarknaden). The information was submitted for publication at 10:00 CET on 22 March 2017. 

Japanese biomass power plant boosts efficiency with clean energy through Swedish Climeon

Energy plays a crucial role for achieving almost all the Sustainable Development Goals that were set in Paris 2015. From energy’s role in defeating poverty through advancements in health, education, water supply and industrialization, to combating climate change. Efficient, clean and sustainable energy solutions are a must for helping to achieve these advancements whilst reversing climate change. Japan’s ratification of the sustainability goals set in 2015, alongside the move away from Nuclear energy, has seen a dramatic increase in Biomass power production in the country. The process of generating power from Biomass is one that typically produces low temperature waste heat. In early March 2017, Swedish Climeon signed an agreement with a Japanese power producer with operations in biomass. The solution will increase the efficiency of the plant by converting low-temperature heat to electricity at higher efficiency than previously possible, and at the same time contribute to achieving the sustainability goals set in 2015 to reverse climate change. The Climeon system converts waste heat into 100% clean electricity. The solution is cost efficient, can be managed remotely, but is, above all, a sustainable solution for renewable and clean energy. “Waste heat recovery is a large market in Japan with many foreign and local players present. With this order, we demonstrate that Climeon is bringing a unique offering to the market with a highly efficient solution at a competitive price level.“ says Ruben Havsed Head of Geothermal Sales at Climeon. He continues: “Both biomass and geothermal are important renewable sources that can supply baseload power and therefore work as a an alternative to coal and other fossil fuel based power plants.” Climeons first delivery will take place in the last quarter of 2017 and continue through 2018.    For more information please contactRuben Havsed - Head of Geothermal Sales at ClimeonChristopher Engman CMO/CRO

NOTICE TO ANNUAL GENERAL MEETING 2017 IN SCANDI STANDARD AB (PUBL)

The shareholders in Scandi Standard AB (publ), corporate identification number 556921-0627, are hereby given notice to attend the annual general meeting to be held on Tuesday 25 April 2017 at 1.00 p.m. CET at IVA:s Konferenscenter, Grev Turegatan 16 in Stockholm. The registration opens at noon CET. RIGHT TO PARTICIPATE AND NOTICE OF ATTENDANCE Shareholders who wish to attend the annual general meeting must: (a)      be entered as a shareholder in the share register kept by Euroclear Sweden AB on Wednesday 19 April 2017; and (b)      give notice of attendance to the company not later than on Wednesday 19 April 2017. Notice of attendance may be given by telephone +46 (0) 8 402 90 55 on weekdays between 9.00 a.m. and 4.00 p.m. CET or on the company’s website, www.scandistandard.com. Notice of attendance may also be given i writing to:Scandi Standard AB (publ)c/o Euroclear Sweden ABP.O. Box 191SE-101 23 StockholmSweden The notice of attendance shall state name, date of birth or corporate identification number, address, telephone number and, where relevant, the number of attending advisors (not more than two). The annual general meeting will be held in Swedish. SHARES REGISTERED IN THE NAME OF A NOMINEE In order to be entitled to participate in the annual general meeting, shareholders having their shares registered in the name of a nominee must, in addition to give notice of attendance, have their shares registered in their own name so that he or she is entered in the share register kept by Euroclear Sweden AB not later than on Wednesday 19 April 2017. Such registration may be temporary. PROXIES AND PROXY FORMS Those who do not attend the annual general meeting in person may exercise his or her rights at the meeting through a proxy in possession of a written, signed and dated proxy form. A proxy forms issued by a legal entity must be accompanied by a copy of a certificate of registration or a corresponding document of authority for the legal entity. In order to facilitate the registration at the annual general meeting, proxy forms, certificates of registration and other documents of authority should be submitted to the company at the address above no later than on Wednesday 19 April 2017. Please note that a notice of attendance must be given even if a shareholder wishes to exercise its rights at the meeting through a proxy. A submitted proxy form does not count as a notice if attendance. Template proxy forms in Swedish and English are available on the company’s website, www.scandistandard.com. PROPOSED AGENDA 1. Election of the chairman of the meeting 2. Preparation and approval of the voting register 3. Approval of the agenda 4. Election of two persons to attest the minutes 5. Determination of whether the meeting was duly convened 6. Submission of the annual report and auditor’s report and the consolidated financial statements and auditor’s report for the group 7. Resolutions regarding:(a)    adoption of the income statement and balance sheet and the consolidated income statement and consolidated balance sheet(b)    allocation of the company’s profit and loss according to the adopted balance sheet(c)    discharge from liability for board members and the managing director 8. Resolution on amendments to the instruction for the Nomination Committee 9. Resolution on amendments to the articles of association(a)    The nomination committee’s proposal for amending § 6 of the articles of association(b)    The board of directors’ proposal for amending § 11 of the articles of association10. Determination of the number of members of the board of directors11. Determination of fees for the board of directors12. Election of the board of directors The Nomination Committee’s proposal for board members: (a)    Per Harkjaer (re-election)(b)    Ulf Gundemark (re-election)(c)    Samir Kamal (re-election)(d)    Michael Parker (re-election)(e)    Harald Pousette (re-election)(f)     Asbjörn Reinkind (re-election)(g)    Karsten Slotte (re-election)(h)    Heléne Vibbleus (re-election)(i)     Öystein Engebretsen (new election)The Nomination Committee’s proposal for chairman:(j)     Per Harkjaer (re-election)13. Determination of the number of auditors and deputy auditors14. Determination of fees for the auditors15. Election of accounting firm or auditors16. Resolution on guidelines for remuneration to senior management17. Resolutions regarding:(a) long term incentive program, LTIP 2017(b) authorisation for the board of directors to resolve on acquisition of own shares(c) transfer of own shares18. Closing of the meeting PROPOSED RESOLUTIONS Item 1: Election of chairman of the meeting The nomination committee proposes that Advokat Sven Unger is elected chairman of the meeting. Item 7(b): Resolution regarding allocation of the company’s profit and loss according to the adopted balance sheet The board of directors proposes that the annual general meeting resolves on a dividend of SEK 1.35 per share and that Thursday 27 April 2017 shall be the record day for the dividend. Assuming the proposed date will be the record date, the dividend is expected to be disbursed by Euroclear Sweden AB on Wednesday 3 May 2017. The dividend proposed by the board of directors corresponds to a total amount of SEK 80,186,325.30, based on a dividend to all outstanding shares in the company as of 17 March 2017 except for shares in the company held by the company itself and is therefore be subject to change if the company repurchases additional shares before the record date. Item 8: Resolution on amendments to the instruction of the Nomination Committee The Nomination Committee proposes that the annual general meeting resolves on the following amendments to Section 7. c-d in the instruction of the Nomination Committee: 1. The Company shall have a Nomination Committee with no less than four members. One member shall be the chairman of the Board of Directors, or a board member nominated by the Chairman.  2. Based on the shareholding statistics received by the Company from Euroclear Sweden AB as per the last bank day of August following the Annual General Meeting of Shareholders, the Nomination Committee shall, without unnecessary delay, identify the four largest shareholders by voting power of the Company[1].  3. As soon as reasonably feasible, the Nomination Committee shall, in a suitable manner, contact the identified four largest shareholders and request them, within reasonable time, however not exceeding 30 days, to provide in writing to the Nomination Committee the name of the person that the respective shareholder wishes to appoint as a member of the Nomination Committee.Should a shareholder, among the four contacted, abstain from its right to appoint a member or fail to appoint a member within the prescribed time, the right to appoint a member shall transfer to the subsequent largest shareholder by voting power provided such shareholder has not already appointed a member of the Nomination Committee or previously abstained from such right . 4. The chairman of the Nomination Committee shall be the member that represents the largest shareholder(s) by voting power, provided the Nomination Committee does not unanimously resolve to appoint another member. Notwithstanding the foregoing, neither the chairman of the Board of Directors nor a member of the Board of Directors may be appointed as the Chairman of the Nomination Committee.  5. As soon as all the members and the chairman of the Nomination Committee have been appointed, the Nomination Committee shall inform the Company to that effect and also provide required information on the members and chairman of the Nomination Committee including the name of the appointing shareholder(s). The Company shall, without unnecessary delay, make public the constitution of the Nomination Committee by releasing a separate press release and post the information on the Company’s web site not later than six months ahead of the Annual General Meeting of Shareholders.  6. The Nomination Committee shall be considered appointed and its mandate period shall start when the information has been released in a separate press release. The mandate period of the Nomination Committee extends for the period until the next Nomination Committee has been appointed and its mandate period starts, see item 2-5 above.  7. The Nomination Committee shall remain unchanged unless: a. a member wishes to resign prematurely, in the case of which such a request shall be sent to the Chairman of the Nomination Committee (or in case it is the Chairman who wishes to resign, to another member of the Nomination Committee) and the receipt imply that the request has been effected, or b. a nominating shareholder wishes to change its representative on the Nomination Committee against another person, in the case of which such a request (containing the two relevant names) shall be the sent to the Chairman of the Nomination Committee (or in case it is the Chairman who shall resign, to another member of the Nomination Committee) and the receipt imply that the request has been effected, or c. a nominating shareholder no longer is among the four largest shareholder by voting power, in the case of which the member representing such nominating shareholder shall be deemed to have resigned from the Nomination Committee automatically, or d. the Nomination Committee, to reflect the ownership structure in the Company, at its own discretion resolves to offer places on the Nomination Committee to shareholders or shareholders’ representatives who in addition to the four nominating shareholders, are largest by voting power or follow immediately after to them, provided that such shareholder has not already appointed a member of the Nomination Committee or previously abstained from such right.  8. Should the Nomination Committee at any point in time consist of less than four members, the Nomination Committee shall nevertheless be authorized to fulfil its assignment according to this instruction.  9. The Nomination Committee shall perform its assignment in accordance with this instruction and applicable rules.The assignment includes provision of proposals for:- chairman at the Annual General Meeting of Shareholders; - chairman of the Board of Directors and other members of the Board of Directors appointed by the Annual General Meeting of Shareholders; - fees payable to non-employed members of the Board of Directors; - when applicable, election of auditor and fees payable to the auditor; and - to the extent deemed necessary, amendments to this instruction for the Nomination Committee. 10. No remuneration shall be paid to the members of the Nomination Committee. However, the Company shall bear the reasonable expenses of the Nomination Committee. 11. This instruction for the Nomination Committee applies until the General Meeting of Shareholders resolve otherwise. Item 9(a): Resolution on the nomination committee’s proposal for amending § 6 of the articles of association According to the articles of association, the board shall consist of no less than three and no more than eight board members, without deputies. To better reflect the ownership structure of the company, the Nomination Committee proposes that the number of board members elected by the Annual General Meeting of Shareholders shall be increased to nine as opposed to the current eight without deputies and that § 6 of the articles of association be amended accordingly. Current Proposed wording:wording:   § 6 § 6   The board The board of directors shall consist of not less than three andof not more than nine members without deputy directors.directorsshallconsist ofnot lessthan threeand notmore thaneightmemberswithoutdeputydirectors. Item 9(b): Resolution on the board of directors’ proposal for amending § 11 of the articles of association The board of directors proposes that § 11 of the articles of association is amended to reflect the new name of the Swedish central securities depositories and financial instruments accounts act. Current Proposed wording:wording:   § 11 § 11   The The company’s shares shall be registered with a central securitycompany’s depository register, pursuant to the Swedish central securitiesshares depositories and financial instruments accounts act (SFSshall be 1998:1479).registeredwith acentralsecuritydepositoryregister,pursuant tothe Swedishfinancialinstrumentsaccountsact (SFS1998:1479). Item 10: Determination of the number of members of the board of directors According to the articles of association, the board shall consist of no less than three and no more than eight board members, without deputies. To better reflect the ownership structure of the company, the Nomination Committee proposes that the number of board members elected by the Annual General Meeting of Shareholders shall be increased to nine as opposed to the current eight without deputies and that § 6 of the Articles of Association be amended accordingly. Item 11: Determination of fees for the board of directors It is important that board fees are maintained at an appropriate level to make it possible to recruit the best possible international competence to the board of directors of Scandi Standard and to make it possible to keep such competence. The Nomination Committee has, using independently prepared benchmarking, compared the board fees in Scandi Standard with board fees in other mid-market comparable companies on Nasdaq Stockholm. The Nomination Committee has concluded that compared with the board fees in companies of equal size and complexity, the proposed fees are in line. Consequently, the Nomination Committee proposes that total fees to the board members, for the period until the next Annual General Meeting, shall be increased to SEK 2,750,000. The fee to the chairman of the board shall remain SEK 550,000 and the individual fee payable to the other eight non-employed board members elected by the Annual General Meeting shall remain SEK 275,000. The Nomination Committee proposes that total fees to committees of the board, for the period until the next Annual General Meeting, shall remain SEK 330,000. This comprises an individual annual fee of SEK 130,000 for the Chairman of the Audit Committee, SEK 50,000 for each of the two other members of the Audit Committee, SEK 50,000 for the chairman of the Remuneration Committee and SEK 25,000 for each of the two other members of the Remuneration Committee. The Nomination Committee considers that the fees for committee work are reasonable. Item 12: Election of the board of directors The Nomination Committee proposes that the following persons be elected. Board members (a)    Per Harkjaer (re-election)(b)    Ulf Gundemark (re-election)(c)    Samir Kamal (re-election)(d)    Michael Parker (re-election)(e)    Harald Pousette (re-election)(f)     Asbjörn Reinkind (re-election)(g)    Karsten Slotte (re-election)(h)    Heléne Vibbleus (re-election)(i)     Öystein Engebretsen (new election) Chairman of the board: (j)     Per Harkjaer (re-election) Öystein Engebretsen (new board member) Born: 1980Education: BI Norwegian School of Management (Sandvika/Oslo), Master of Science in Business, Major in Finance. Other appointments: Member of the board of directors in Projektengagemang Sweden AB. Holdings in the company: 3,000 shares. Principal work experience: Investment AB Öresund, Investment manager, Member of the board of directors of Investment AB Öresund, Project manager at Viking Sverige AB and HQ Bank, Corporate Finance. In the composition of the board of directors, the Nomination Committee considers, among others, necessary experience and competence, the value of diversity, age, gender balance, reflection of the ownership structure of the company and renewal and assesses the appropriateness of the number of members of the board. The Nomination Committee takes into account the competence and experience of each individual member along with the individual member’s contribution to the board work as a whole in its appraisal of qualifications and performance of the individual board members. The Nomination Committee considers it important that board members can devote the necessary time and care required to fulfil their tasks as board members in Scandi Standard, and has therefore also familiarized itself with the proposed Board members’ engagements outside of Scandi Standard and the time they require. The Nomination Committee considers that the current Board and Board work is well functioning and that the board fulfils high expectations in terms of composition and that the Board as well as the individual board members fulfil high expectations in terms of expertise. All Board members contribute meritoriously with their respective expertise. The Nomination Committee has noted that board members in Scandi Standard have high board meeting attendance and that they are well prepared at the meetings. Based on thorough discussions and assessments, the Nomination Committee considers that the proposed Board well balances the desire to reflect the ownership structure of the company while taking continuity into account. Moreover, the Nomination Committee considers that the proposed board members have sufficient skills and time to fulfil their tasks as board members of Scandi Standard. Information on the proposed board members Information regarding the proposed board members is presented in Exhibit 2 of the Nomination Committee proposal, which can be found on Scandi Standard’s website, www.scandistandard.com. The independence of the board members In terms of applicable Swedish independence requirements, the Nomination Committee has made the following assessments. (a)    The Nomination Committee considers that all of the board members are independent of Scandi Standard and its senior management.(b)    From among the board members reported in a. above, the Nomination Committee considers that at least the following are independent of Scandi Standard’s major shareholders: Per HarkjaerMike ParkerSamir KamalAsbjörn ReinkindKarsten SlotteHelene Vibbleus Item 13: Determination of the number of auditors and deputy auditors According to the articles of association, Scandi Standard shall have no less than one and no more than two auditors with no more than two deputies. As auditor and, when applicable deputy auditor, shall an authorized public accountant or a registered public accounting firm be elected. The Nomination Committee proposes that Scandi Standard shall have one auditor without deputy auditor. Item 14: Determination of fees for the auditors The Nomination Committee proposes that the auditor fees be paid against approved account. Item 15: Election of accounting firm or auditors The Nomination Committee proposes that PricewaterhouseCoopers AB be re-elected as auditor for the period as of the end of the Annual General Meeting 2017 until the end of the Annual General Meeting 2018. Item 16: Resolution on guidelines for remuneration to senior management The board of directors proposes that the annual general meeting resolves to approve the board of director’s proposal regarding guidelines for remuneration for the senior management as set forth below which shall apply until the annual general meeting 2018. In this context, the senior management means the managing director of the company and the executives in the company and other group companies who, from time to time, are reporting to the managing director or the CFO and who are also members of the senior management, as well as members of the board of directors of the company that has entered into an employment or consulting agreement. Salaries and other terms and conditions of employment shall be sufficient for the company to recruit and retain skilled senior managers at a reasonable cost. The remuneration to the senior managers shall consist of a fixed salary, variable salary, pension and other benefits, and it shall be based on principles of performance, competitiveness and fairness. Each senior manager shall be offered a fixed salary in line with market conditions and based on the senior manager’s responsibility, expertise and performance. All senior managers may, from time to time, be offered variable salary (cash bonuses). The variable salary shall be based on a set of financial and personal objectives determined in advance by the board of directors. The variable salary may not amount to more than 75% of the fixed annual salary (in this context, fixed annual salary means cash salary earned during the year, excluding pension, supplements, benefits and similar). To the extent a board of director performs work for the company, in addition to board work, a market-based consulting fee may be paid. In addition, the annual general meeting may resolve on long-term incentive programs such as share and share price-related incentive programs. These incentive programs shall be intended to contribute to long-term value growth and provide a shared interest in value growth for shareholders and employees. Agreements regarding pensions shall, where applicable, be premium based and shall be designed in accordance with the level and practice applicable in the country in which the member of senior management is employed. Fixed salary during notice periods and severance payment, including payments for any restrictions on competition, shall in aggregate not exceed an amount equivalent to the fixed salary for two years. The total severance payment shall for all members of the management be limited to the existing monthly salary for the remaining months up to the age of 65. The board of directors resolve upon principles for remuneration of the senior management based upon the guidelines adopted by the annual general meeting. The board of directors may resolve to deviate from the guidelines if the board of directors, in an individual case, is of the opinion that there are special circumstances justifying that. Item 17(a): Resolution on long term incentive program, LTIP 2017 Background and summary Salaries and other terms and conditions of employment in Scandi Standard AB (publ) (“Scandi Standard”) and any of its subsidiaries (Scandi Standard and its subsidiaries are hereinafter jointly referred to as the “Group”) shall be sufficient for the Group to recruit and retain skilled employees at reasonable costs to the Group. Remuneration shall be based on principles of performance, competitiveness and fairness. The board of directors of Scandi Standard has decided to propose to the annual general meeting the below Long Term Incentive Program 2017 (“LTIP 2017”) for key employees, which is intended to contribute to long term value growth and provide a shared interest in value growth between shareholders and employees. Performance share rights shall be allotted free of charge to the participants of LTIP 2017, who are key employees in the Group, in relation to a fixed percentage of their base salary. After a three-year vesting period commencing in connection with the implementation of LTIP 2017 and provided that certain conditions are fulfilled, the participants may exercise their performance share rights through which they will be allotted shares in Scandi Standard free of charge. In order to ensure the delivery of shares under LTIP 2017 and for the purpose of hedging social security charges under LTIP 2017, the board of directors proposes that the board of directors be authorized to acquire a maximum of 294,773 shares in Scandi Standard on Nasdaq Stockholm. In addition, the board of directors proposes that the annual general meeting resolves to transfer a maximum of 251,386 own shares to the participants of LTIP 2017 in accordance with the terms of LTIP 2017. The intention is that a program similar to LTIP 2017 shall be adopted annually, at the annual general meetings the coming years. Proposal The board of directors proposes that the annual general meeting resolve on the implementation of LTIP 2017 principally based on the terms and conditions set out below. 1. Participants and allotment under LTIP 2017 LTIP 2017 comprises a maximum of 22 participants divided into four (4) categories. · Category 1 consists of the CEO  · Category 2 consists of the CFO and the Group COO  · Category 3 consists of the country managers and the chief of live operations  · Category 4 consists of other key employees The participants shall free of charge be allotted performance share rights entitling to allotment of shares in Scandi Standard. The number of performance share rights allotted to a participant shall be calculated as a percentage of the relevant participant’s base salary plus any social security charges attributable to such amount divided by 53.58, which was the average share price during the period 6 March 2017 to 17 March 2017. The percentage of the base salary forming the basis for allotment of performance share rights depends on which category the participant belongs to, in accordance with the following: · Category 1: 100 percent of the base salary for 2017  · Category 2: 75 percent of the base salary for 2017  · Category 3: 50 percent of the base salary for 2017  · Category 4: 25 percent of the base salary for 2017 The above percentages will be adjusted so that participants who have been employed with the Group for less than a year will receive less than 100 percent of the numbers illustrated above. Provided that the conditions set out in item 2 below are fulfilled, the performance share rights shall entitle to allotment of shares in Scandi Standard in accordance with what is described below. Allotment of shares on the basis of performance share rights shall be made at the earliest three years after the implementation of LTIP 2017 (the "Vesting Period"). 2. Performance share rights Following the Vesting Period, each performance share right shall entitle to allotment of up to one (1) share. The conditions for allotment of shares are described in the following. Vesting requirement In order for performance share rights to entitle to allotment of shares, it shall be required that the relevant participant remains employed and has not given or been given notice of termination of employment within the Group during the Vesting Period. If this condition is not fulfilled, no shares shall be allotted. However, in case a participant’s employment has terminated prior to the end of the Vesting Period due to such participant’s death or disability or if the employer has given notice of termination of the participant’s employment without cause (including, for the avoidance of doubt, notice of termination due to redundancy/shortage of work (Sw. arbetsbrist)), 1/3 of the right to allotment of shares shall be vested at each anniversary of the implementation of LTIP 2017. Performance requirement In addition, allotment of shares shall be conditional upon satisfaction of a financial target set by the board of directors of Scandi Standard, being the compound annual growth rate of earnings per share (“EPS CAGR”). The EPS CAGR shall be calculated by the board of directors on the basis of the Group’s quarterly financial statements, which are adjusted for non-comparables. EPS for the financial year 2016 was SEK 2.50. In order for full allotment of shares to occur, the average EPS CAGR during the period 1 January 2017 – 31 December 2019 must be at least 12.5 percent. If the average EPS CAGR during the period 1 January 2017 – 31 December 2019 is 5 percent, the participants shall be allotted shares for 25 percent of their performance share rights. If the average EPS CAGR during the period 1 January 2017 – 31 December 2019 is more than 5 percent but less than 12.5 percent, the participants shall receive linear allotment. If the average EPS CAGR during the period 1 January 2017 – 31 December 2019 is less than 5 percent, no shares shall be allotted. 3. Terms and conditions for the performance share rights In addition to what has been stated above, the following terms and conditions shall apply for the performance share rights: · The performance share rights are allotted free of charge.  · The participants are not entitled to transfer, pledge, or dispose the performance share rights or perform any shareholder’s rights regarding the performance share rights during the Vesting Period.  · Execution of the performance share rights may take place at the earliest three years after LTIP 2017 was implemented.  · Scandi Standard will not compensate the participants for any dividends. 4. Detailed terms and administration The board of directors, or a certain committee appointed by the board of directors, shall be responsible for determining the detailed terms and the administration of LTIP 2017, within the scope of the terms and guidelines given by the general meeting. By way of example, the board of directors shall be authorized to decide that, despite the conditions under item 2 above being fulfilled, no allotment of shares shall be made to a participant in case of fraud, other criminal activity or gross misconduct by such participant. In connection with any rights issues, splits, reverse splits and similar dispositions, the board of directors shall be authorized to recalculate EPS CAGR as well as the number of shares that the performance share rights shall entitle to. In case a public offer for all shares in Scandi Standard is completed resulting in the offeror owning more than 90 percent of the shares in Scandi Standard, the board of directors shall be authorized to resolve upon the close-down of LTIP 2017, including but not limited to approving earlier execution of performance share rights, amending the vesting requirements and shorten the periods for application of the EPS CAGR thresholds for determination of to which extent the performance requirement is fulfilled. If delivery of shares cannot be accomplished at reasonable costs, with reasonable administrative effort and without regulatory problems, the board of directors shall be authorized to decide that the participants may instead be offered a cash-based settlement. Further, the board of directors shall be authorized to decide on other adjustments in the event that major changes in the Group, the market or otherwise in the industry would occur, which would entail that resolved conditions for allotment and the possibility to use the performance share rights under LTIP 2017 would no longer be appropriate. 5. Hedging of commitments according to LTIP 2017 – Acquisitions and transfers of own shares The board of directors proposes that the annual general meeting resolve to authorize the board of directors to acquire maximum 294,773 shares for the following purposes: (1)    Securing delivery of shares at exercise of the performance share rights. (2)    Securing and covering social security charges triggered by LTIP 2017. Acquisitions shall be made on Nasdaq Stockholm on one or several occasions and until the next annual general meeting at a price within the band of prices applying on the exchange. The full proposal regarding authorization for the board of directors to acquire own shares is included in item 17 b. of the notice. Further, the board of directors proposes that the annual general meeting resolves to transfer a maximum of 251,386 shares acquired in accordance with the foregoing. Transfers shall be made to the participants of LTIP 2017 in accordance with the terms of LTIP 2017. The full proposal regarding transfers of own shares is included in item 17 c. of the notice. 6. The value of and the estimated costs for LTIP 2017 Assuming 100 percent vesting, full fulfilment of the EPS requirement and a share price at the time of exercise of the performance share rights of SEK 56.50, LTIP 2017 will result in the allocation of 251,386 shares in Scandi Standard, representing a value of SEK 16,654,699. LTIP 2017 will cause costs for the Group in the form of social security charges. Social security charges shall be expensed and allocated to the periods during which the participants’ services were performed. The social security charges are expected to amount to in average approximately 17 percent of the market value of the shares allocated upon exercise of the performance share rights. The board of directors has proposed that the effect on cash flow that may arise as a result of social security charges payable when the performance share rights are exercised be hedged by way of acquisitions of own shares in the market. In addition, the performance share rights will give rise to accounting costs in accordance with IFRS 2. These costs shall be determined on the allotment date and be allocated over the Vesting Period. In accordance with IFRS 2, the theoretical value of the performance share rights shall form the basis of the calculation of these costs. The theoretical value shall not be re-valued in subsequent reporting periods, although adjustments shall be made in conjunction with every financial report for the performance share rights that have not been vested. In this manner, the accumulated costs at the end of the Vesting Period will correspond to the number of performance share rights that fulfil the conditions. 7. Dilution and effects on key ratios No new shares will be issued in Scandi Standard due to LTIP 2017. However, Scandi Standard will need to acquire 294,773 own shares, corresponding to approximately 0.5 percent of the outstanding shares and votes in Scandi Standard in order to secure delivery of shares under LTIP 2017 and to secure and cover social security charges. The costs for LTIP 2017 are expected to have a marginal effect on the Group’s key ratios. 8. The objectives of the proposal and reasons for deviations from the shareholders’ preferential rights The board of directors considers the existence of effective share-related incentive programs for key employees of Scandi Standard to be of material importance for the development of Scandi Standard. The proposed program creates a common Group focus for the key employees in the different parts of the Group. By linking the key employees’ remuneration to Scandi Standard’s earnings, long term increase in value is rewarded and thus an alignment of interest of the key employees and shareholders is achieved. In light of these circumstances, the board of directors considers that LTIP 2017, with regard to the terms and conditions, the size of the allotment and other circumstances, is reasonable and advantageous for Scandi Standard and its shareholders. Preparation of proposal The proposal has been prepared by the remuneration committee in consultation with the board of directors and external advisors. The resolution to propose LTIP 2017 to the annual general meeting has been taken by the board of directors. Outstanding incentive programs in Scandi Standard The AGM 2016 adopted a long-term incentive plan for 19 senior executives and key employees, which has essentially the same design as the now proposed LTIP 2017. A maximum of 209,976 shares may be awarded under LTIP 2016. Majority vote requirement A resolution in accordance with the board of directors’ proposal regarding the implementation of LTIP 2017 requires support from shareholders representing more than half of the votes cast at the meeting. A resolution in accordance with the board of directors’ proposal regarding authorization to the board of directors to acquire shares requires support from shareholders representing at least 2/3 of the votes cast as well as shares represented at the meeting. A resolution in accordance with the board of directors’ proposal regarding resolution to transfer shares to the participants of LTIP 2017 requires support from shareholders representing at least 9/10 of the votes cast as well as shares represented at the meeting. Item 17(b): Resolution regarding authorisation for the board of directors to resolve on acquisition of own shares The board of directors proposes, for the purposes of (1) securing delivery of shares to the participants of LTIP 2017 at exercise of the performance share rights, and (2) securing and covering costs that can be triggered by the LTIP 2017 (e.g. social security charges and tax), that the annual general meeting resolves to authorize the board of directors to, on one or several occasions and until the next annual general meeting, resolve on acquisition of shares in the company, in accordance with the following. (1)      A maximum of 294,773 shares in the company may be acquired, however only to such extent that, following each acquisition, the company holds a maximum of 10 per cent of all shares issued by the company.(2)      Acquisitions shall be made on Nasdaq Stockholm.(3)      Acquisitions shall be made at a price per share contained within the at each time prevailing price interval for the share.(4)      Payment for the shares shall be made in cash. The board of directors has issued a reasoned statement pursuant to Chapter 19, Section 22 of the Swedish Companies Act. Item 17(c): Resolution regarding transfer of own shares The board of directors proposes that, in order to secure delivery of shares at exercise of the performance share rights under LTIP 2017, the annual general meeting resolves to transfer own shares to the participants in LTIP 2017 in accordance with the following. Transfers of a maximum of 251,386 own shares may occur on the following terms and conditions. (1)      The right to receive shares shall, with deviation from the shareholders’ preferential rights, be granted to the participants in LTIP 2017, with right for each of the participants to receive no more than the maximum number of shares allowed under the terms and conditions for LTIP 2017. Furthermore, subsidiaries within the Scandi Standard Group shall have the right to receive shares, free of consideration, and such subsidiaries shall be obligated to immediately transfer, free of consideration, such shares to the participants in LTIP 2017 in accordance with the terms and conditions of the program.(2)      The participants’ right to receive shares are conditional upon the fulfillment of all terms and conditions of LTIP 2017.(3)      The shares shall be transferred within the time period set out in the terms and conditions of LTIP 2017.(4)      The shares shall be transferred free of charge.(5)      The number of shares that may be transferred to the participants in LTIP 2017 may be recalculated due to share issues, splits, reverse splits and/or similar dispositions in accordance with the terms and conditions of LTIP 2017. The rationale for the proposed transfers of own shares and for the deviation from the shareholders’ preferential rights is to enable delivery of shares to the participants in LTIP 2017. SPECIAL MAJORITY RULES A resolution in accordance with item 9(a) and 9(b) and item 17(b) above requires that the annual general meeting’s resolution is supported by at least two thirds of the votes cast as well as the shares represented at the meeting. A resolution in accordance with item 17(c) above requires that the annual general meeting’s resolution is supported by at least nine tenth of the votes cast and the shares represented at the meeting. NUMBER OF SHARES AND VOTES At the date of this notice, the total number shares and votes in the company amounts to 60,060,890. The company holds 663,612 of its own shares, corresponding to 663,612 votes. SHAREHOLDER’S RIGHT TO REQUEST INFORMATION The board of directors and the managing director shall, if any shareholder so requests and the board of directors believes that it can be done without material harm to the company, provide information regarding circumstances that may affect the assessment of an item on the agenda and circumstances that can affect the assessment of the company’s or its subsidiaries’ financial situation and the company’s relation to other companies within the group. DOCUMENTATION The complete proposals and other documents that shall be made available prior to the annual general meeting pursuant to the Swedish Companies Act will be made available at the company and at the company’s website, www.scandistandard.com, no later than three weeks prior to the annual general meeting. The documents will also be sent free of charge to shareholders who so request and provide their address to the company. * * *  Stockholm in March 2017 The board of directors  ---------------------------------------------------------------------- [1] The shareholding statistics used shall be sorted by voting power (grouped by owners) and cover the 25 largest in Sweden direct registered shareholders, i.e. shareholders having registered an account with Euroclear Sweden AB in their own name or shareholders holding a custody account with a nominee that have reported the identity of the shareholder to Euroclear Sweden AB.

Infiana Wins ICE Europe Anniversary Award

Munich – A strong start into 2017 for Infiana: the business was honored in the opening hours of the International Converting Exhibition Europe (ICE) for its antistatic film products. Innovative Abilities DemonstratedThe organizers of Europe’s most important trade show for the conversion and processing of paper, films, and nonwovens presented ICE Awards to four companies in total. An expert jury of exhibitors and visitors recognized Infiana’s extraordinary achievements in the “Converting Solutions for New Materials” category. A total of 39 companies had been submitted their products and services for consideration. ”We are very pleased to be receiving this ICE Award. It is a confirmation of our hard work, and – by virtue of the fact that it was voted on by converting industry insiders – shows that even other market players acknowledge and acclaim our competencies and accomplishments,” celebrated Peter K. Wahsner, CEO of Infiana. A Convincing Case for Antistatic FilmWith its antistatic solution, Infiana can prevent electric discharges from occurring when a roll is unwound. The release films are typically siliconized on one or both sides, and will function even at environmental humidity levels of 50 percent or lower – and that permanently. Unexpected discharges during processing or potentially dangerous shocks on contact with a film roll are thus a thing of the past. Infiana’s antistatically equipped release liners are available as LDPE and PP films. “Infiana’s release liners with permanent antistatic equipment offer clear advantages in terms of product quality, and reduce potential dangers when handling web-shaped materials,” notes Dr. Jürgen Panhans, Senior Application Manager PSM. Numerous Recent HonorsThe ICE Award is just one of several awards Infiana’s innovations have recently garnered. The company was previously honored by Germany’s WirtschaftsWoche magazine as well as at the TOP 100 and Marcum Innovator Awards.

Resolutions of Citycon Oyj’s Annual General Meeting

Citycon Oyj’s Annual General Meeting (AGM) took place in Helsinki, Finland, today. The General Meeting approved all the proposals of the Board of Directors to the General Meeting.The General Meeting adopted the company’s financial statements and discharged the members of the Board of Directors and the Chief Executive Officer from liability for the financial year 2016. The General Meeting decided that no dividend is distributed by a resolution of the AGM and authorised the Board of Directors to decide in its discretion on the distribution of dividend and assets from the invested unrestricted equity fund as follows: Based on the authorisation the maximum amount of dividend to be distributed shall not exceed EUR 0.01 per share and the maximum amount of equity repayment distributed from the invested unrestricted equity fund shall not exceed EUR 0.12 per share.The authorisation is valid until the opening of the next AGM.Unless the Board of Directors decides otherwise for a justified reason, the authorisation will be used to distribute dividend and/or equity repayment four times during the period of validity of the authorisation. In this case, the Board of Directors will make separate resolutions on each distribution of the dividend and/or equity repayment so that the preliminary record and payment dates will be as stated below. Citycon shall make separate announcements of such Board resolutions. Preliminary payment date Preliminary record date31 March 2017 24 March 201730 June 2017 22 June 201729 September 2017 22 September 201729 December 2017 14 December 2017 The dividend and/or equity repayment based on a resolution of the Board of Directors will be paid to a shareholder registered in the company’s shareholders’ register maintained by Euroclear Finland Ltd on the record date for the dividend and/or equity repayment.Members of the Board of Directors and their remunerationThe number of members of the Board of Directors was resolved to be ten. Chaim Katzman, Bernd Knobloch, Arnold de Haan, Kirsi Komi, Rachel Lavine, Andrea Orlandi, Claes Ottosson, Per-Anders Ovin and Ariella Zochovitzky were re-elected to the Board of Directors and David R. Lukes was elected as new member to the Board of Directors for a term that will continue until the close of the next AGM. The Directors’ personal details are available on the company’s website at www.citycon.com/board.The General Meeting decided that the Chairman of the Board of Directors be paid an annual fee of EUR 160,000, the Deputy Chairmen EUR 70,000 and the ordinary members of the Board EUR 50,000. The Chairmen of the Board of Directors’ Committees would be paid an additional annual fee of EUR 5,000.In addition, the General Meeting decided that the Chairmen of the meetings of the Board’s Committees shall be paid a meeting fee of EUR 800 and other Board and Committee members EUR 600 per meeting. The Chairman of the Board shall be paid no meeting fees.The members of the Board of Directors shall be compensated accrued travel and lodging expenses as well as other potential costs related to Board and Committee work.AuditorErnst & Young Oy, a firm of authorized public accountants, was re-elected as the auditor of the company with authorised public accountant (APA) Mikko Rytilahti as the auditor with principal responsibility. The audit fee shall be paid according to the auditor’s invoice.Authorising the Board of Directors to decide on the issuance of shares as well as the issuance of special rights entitling to sharesThe General Meeting authorised the Board of Directors to decide on the issuance of shares as well as the issuance of special rights entitling to shares referred to in Chapter 10 Section 1 of the Finnish Companies Act by one or several decisions as follows:The amount of shares to be issued shall not exceed 85 million shares, which corresponds to approximately 9.55 percent of all the current shares in the company. Shares potentially issued by virtue of the special rights entitling to shares are included in the aforesaid maximum number of shares.The Board of Directors decides on all the conditions of the issuance of shares and special rights entitling to shares. The authorisation concerns both the issuance of new shares as well as the transfer of own shares held by the company. The issuance of shares and special rights entitling to shares may be carried out in deviation from the shareholders' pre-emptive rights by way of a directed issue.The authorisation is valid until the close of next AGM, however, no longer than until 30 June 2018.Authorising the Board of Directors to Decide on the Repurchase and/or on the Acceptance as Pledge of the Company’s Own SharesThe General Meeting authorised the Board of Directors to decide on the repurchase and/or on the acceptance as pledge of the company's own shares in one or several tranches as follows:The amount of own shares to be repurchased and/or accepted as pledge shall not exceed 50 million shares, which corresponds to approximately 5.61 per cent of all the current shares in the company. Only the unrestricted equity of the company can be used to repurchase own shares on the basis of the authorisation.Own shares can be repurchased at a price formed in public trading on the date of the repurchase or otherwise at a price formed on the market.The Board of Directors decides how own shares will be repurchased and/or accepted as pledge. Own shares can be repurchased using, inter alia, derivatives. Own shares can be repurchased otherwise than in proportion to the shareholdings of the shareholders (directed repurchase).The authorisation is valid until the close of next AGM, however, no longer than until 30 June 2018.Helsinki, 22 March 2017CITYCON OYJFor further information, please contact:Marcel Kokkeel, CEOTel. +358 40 154 6760marcel.kokkeel@citycon.com   Eero Sihvonen, Executive Vice President and CFOTel. +358 40 557 9137eero.sihvonen@citycon.com

Farstad Shipping ASA – Registration of share capital increase and listing of offer shares

Ålesund, Norway, 22 March 2017 – Reference is made to previous announcements of Farstad Shipping ASA ("Farstad" or the "Company") concerning the subsequent offering in the Company announced on 13 March 2017 (the "Subsequent Offering") and the prospectus dated 13 March 2017 regarding inter alia the Subsequent Offering. Pursuant to an advance payment agreement entered into with the Company, Aker Capital AS and Hemen Holding Limited have undertaken to advance payment for the Offer Shares on behalf of the subscribers in the Subsequent Offering. The advance payment was made by Aker Capital AS and Hemen Holding Limited on 21 March 2017. Accordingly, the share capital increase pertaining to the Subsequent Offering has been duly registered in the Norwegian Register of Business Enterprises, and the Offer Shares have been admitted to listing on the Oslo Stock Exchange. Following registration of the share capital increase, the Company's share capital is NOK 243,177,033.95 divided into 4,863,540,679 shares, each share having a par value of NOK 0.05. The shares have been delivered to a preliminary VPS account, and are expected to be delivered to subscribers' VPS accounts on or about 28 March 2017, subject to due payment from the subscribers. The Offer Shares are tradable upon delivery to subscribers. For further information, please contact: CEO Karl-Johan Bakken – tel. +47 901 05 697 CFO Olav Haugland – tel. +47 915 41 809 Farstad Shipping’s fleet currently consists of 56 vessels (27 AHTS, 22 PSV and 7 SUBSEA). The Company’s operations are managed from Aalesund, Melbourne, Perth, Singapore, Macaé and Rio de Janeiro with a total of 1,500 employees engaged onshore and offshore. The Company’s strategy is to be a leading quality provider of large, modern offshore service vessels to the oil industry. www.farstad.com  This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Nordax publishes the Annual Report for 2016

As an integral part of the Annual Report, Nordax for the first time present a Sustainability report in accordance with Global Reporting Initiative, version G4, core level.   For more information, please contact Andreas Frid, Head of Investor Relations, Nordax Tel: +46 705 29 08 00 E-mail: ir@nordax.se  About Nordax Nordax is a leading niche bank in Northern Europe providing personal loans and deposit accounts to private individuals in Sweden, Norway, Finland, Denmark and Germany. Nordax had nearly 150.000 deposit and lending customers at year-end. Nordax employs about 200 people, all working in its office in Stockholm. The underwriting process is Nordax’s core competency; it is thorough, sound and data driven. Nordax’s customers are financially stable individuals. The typical customer is approximately 50 years old and has an income in line with or above the national average. As of December 31, 2016 lending to the general public amounted to SEK 12.8 billion and deposits amounted to SEK 7.1 billion. Nordax has been supervised by the Swedish Financial Supervisory Authority since 2004 and deposits are covered by the Swedish deposit guarantee scheme. Read more on www.nordaxgroup.com. For more information about Nordax’s customer offerings, read more on each country’s web site: www.nordax.se, www.nordax.no, www.nordax.fi and www.nordax.de. This information is information that Nordax Group AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 14.30 CET on 22 March 2017.

Citycon decided on a quarterly distribution

The Board of Directors of Citycon Oyj has today decided, on the basis of the authorisation by the Annual General Meeting 2017, that a dividend of EUR 0.01 per share be distributed from retained earnings and an equity repayment of EUR 0.0225 per share be distributed from the invested unrestricted equity fund of the company. The dividend and equity repayment will be paid to a shareholder registered in the company’s shareholders’ register maintained by Euroclear Finland Ltd on the record date for the dividend and equity repayment 24 March 2017. The dividend and equity repayment will be paid on 31 March 2017.Citycon’s Annual General Meeting held earlier on same day, 22 March 2017, resolved to authorise the Board of Directors to decide in its discretion on the distribution of dividend and equity repayment. Based on the authorisation the total amount of the dividend to be distributed shall not exceed EUR 0.01 per share and the maximum amount of equity repayment distributed from the invested unrestricted equity fund shall not exceed EUR 0.12 per share. Unless the Board of Directors decides otherwise for a justified reason, the authorisation will be used to distribute dividend and/or equity repayment four times during the period of validity of the authorisation. The authorisation is valid until the opening of the Annual General Meeting 2018.Following the asset distribution on 31 March 2017, the remaining authorisation of Citycon’s Board of Directors is EUR 0.0975 per share.Helsinki, 22 March 2017CITYCON OYJFor further information, please contact:Marcel Kokkeel, CEOTel. +358 40 154 6760marcel.kokkeel@citycon.comEero Sihvonen, Executive Vice President and CFOTel. +358 50 557 9137eero.sihvonen@citycon.com Citycon Oyj (Nasdaq Helsinki: CTY1S) is a leading owner, developer and manager of urban grocery-anchored shopping centres in the Nordic and Baltic regions, managing assets that total approximately EUR 5 billion and with market capitalisation of over EUR 2 billion. For more information about Citycon, please visit www.citycon.com 

Press information: Airia RAW - Speed Hacked Racing Flat launch on Kickstarter, today 4 p.m. CET/11 a.m. EST

Airia Running launched their first running shoe, Airia One, in 2014. Airia Running focuses on performance oriented runners with shoes designed for increasing running speed and improve biomechanical efficiency. The origin of the designs is own patents and several years of research and field tests. The new lightweight racing flat, Airia RAW, has four distinguishing properties aiming the shoe at performance oriented runners: - one of the lightest on the market, 129 g/4.6 oz.- an outsole made from M-bound, a sole material returning kinetic energy to the kick- the shape of the outsole, Airias own patented Biospeed, helping an energy efficient ground contact phase of the stride- a unique seamless design for an optimal run feeling  Mattias Geisler, founder and CEO of Airia Running, comments on the choice to go with Kickstarter for Airia RAW: "The main reason to go with Kickstarter is that we think that we can build a good platform for finding and adressing a niche of really performance oriented and competetive runners. We also like the close and direct contact with the backers that you get from crowdsourcing projects. I have myself backed more than 30 innovation oriented projects on Kickstarter and Indiegogo."  The Kickstarter campaign will run 30 days from today. The goal is to reach 70 000 $ during this period, by backing of different offers and rewards. The funds will be used to kickstart the production process of Airia RAW. If the campaign doesn´t reach the goals, the project is called off and no costs will be charged to the backers. Access the Kickstarter campaign here: https://www.kickstarter.com/projects/airia/airia-raw-speed-hacked-racing-flat

NOTICE OF ANNUAL GENERAL MEETING IN SEAMLESS DISTRIBUTION AB (publ)

The shareholders of Seamless Distribution AB (publ) (”Seamless” or the ”Company”) are hereby summoned to the annual general meeting (the “Meeting”) to be held on Thursday 20 April 2017 at 10.00 CEST in Elite Palace’s office premises, Gästrikesalen, address Elite Palace Hotell, S:t Eriksgatan 115, 100 31 Stockholm. Right to participate at the Meeting To be entitled to participate at the Meeting, shareholders shall - be recorded in the register of shareholders maintained by Euroclear Sweden AB (the Central Securities Deposit) on Wednesday 12 April 2017, and - notify the Company of their intention to attend the Meeting no later than at 12.00 CEST on Wednesday 12 April 2017. The notification must be sent in writing to Seamless Distribution AB (publ), S:t Eriksgatan 121, 113 43 Stockholm, via e-mail to info@seamless.se or per facsimile to +468‑564 878 23. When notifying the Company of its intention to attend the Meeting, shareholders shall provide their name, social security number/company registration number, shareholding, address, daytime telephone number and, where applicable, information regarding advisors (a maximum of two allowed) and, where applicable, information regarding proxy.   Proxies  Shareholders who are represented by a proxy must authorise the proxy by issuing a dated power of attorney. The power of attorney is valid one year from issuance, or such longer period as specified in the power of attorney, however maximum five years from issuance. If such authorisation is issued by a legal entity, a certified copy of a certificate of registration or similar must be attached. The original power of attorney and certificate of registration, where applicable, should be sent to the Company well in advance of the Meeting to the address stated above. A proxy form is available on the Company’s website www.seamless.se or is sent to shareholders who so request. Nominee registered shares Shareholders whose shares are registered in the name of a nominee through the trust department of a bank or similar institution must, in order to be entitled to participate in the Meeting, request that their shares are temporarily re-registered in their own names in the register of shareholders maintained by Euroclear Sweden AB. Such registration must be effected on Wednesday 12 April 2017. Shareholders are requested to inform their nominees in good time prior to this date. Number of shares and votes Per the date of this notice there are in aggregate 58,765,305 issued shares and votes in the Company. Per the day of this notice, the Company holds 1,000,000 treasury shares. Proposed Agenda 1. Opening of the Meeting 2. Election of the chairman of the Meeting 3. Drawing-up and approval of the voting list 4. Approval of the agenda 5. Election of at least one person to approve the minutes 6. Resolution on whether the Meeting has been duly convened 7. Presentation of the annual report and the audit report as well as the consolidated accounts and audit report on the consolidated accounts 8. Resolution regarding adoption of the profit and loss statement and the balance sheet as well as the consolidated income statement and the consolidated balance sheet 9. Resolution regarding appropriation of the Company’s results in accordance with the approved balance sheet10. Resolution regarding discharge from liability of the members of the Board of Directors and the CEO11. The Nomination Committee’s proposal and motivated statement regarding their proposal of Board of Directors12. Resolution on the number of members and deputy members of the Board of Directors and the number of auditors and deputy auditors13. Resolution on the remuneration that shall be paid to the members of the Board of Directors and the auditor14. Election of chairman and other members of the Board of Directors as well as auditors15. Resolution on guidelines for remuneration of the management16. Resolution on nomination committee for the next annual general meeting17. Resolution to authorise the Board of Directors to resolve upon issues of shares and/or warrants and/or convertibles18. Resolution to authorise the Board of Directors to acquire and sell treasury shares19. Resolution on stock options program and resolution to authorise the Board of Directors to issue warrants20. Resolution on amendment of the articles of association21. Resolution to authorise the Board of Directors to divest the subsidiary Seamless Distribution System AB22. Closing of the Meeting THE NOMINATION COMMITTEE’S PROPOSALS  Seamless’ Nomination Committee, consisting of the chairman Pehr-Olof Malmström (representing Danske Bank Capital AB), Hein Pretorius (the Chairman of the Board of Directors), Stefan de Hevesy (representing Peter Fredell), Franco Danesi (representing Investment AB Kinnevik) and Gunnar Jardelöv (representing himself), proposes the following. Chairman of the Meeting (item 2) The Nomination Committee proposes Charlotte Levin (member of the Swedish bar) as the chairman of the Meeting. Number of members and deputy members of the Board of Directors and the number of auditors and deputy auditors (item 12) It is proposed that, the Board of Directors shall consist of five (5) members without any deputy members. The number of auditors shall be one without deputies. Remuneration to be paid to the members of the Board of Directors and the auditor (item 13) It is proposed that remuneration to the Board of Directors shall be paid in an aggregate amount of SEK 1,700,000, of which SEK 500,000 shall be paid to the Chairman and SEK 400,000 shall be paid to each of the other members of the Board of Directors. However, Peter Fredell, shall not receive any remuneration in his capacity as member of the Board of Directors as he also serves as CEO of the Company. Further, it is proposed that the members of the Board of Directors are to be reimbursed for reasonable travel expenses in connection with meetings of the Board of Directors. It is proposed that no remuneration shall be paid for committee work. Auditor’s fees are proposed to be paid as per current account. If possible from a tax perspective, and provided that it is cost neutral to the Company, it is proposed that a member of the Board of Directors may invoice the fees for the board work, through a company owned by the member of the Board of Directors. If a member of the Board of Directors invoices the Company through a company, the remuneration shall be increased to cover statutory social security contributions and value added tax in accordance with applicable law. Election of Chairman and other members of the Board of Directors and auditors (item 14) It is proposed that, for the period until the end of the next Meeting, Peter Fredell, Robin Saunders and Tomas Klevbo are re-elected and John Lunghurst, also proposed as Chairman of the Board of Directors, and Petra Sas are newly-elected as member of the Board of Directors. John Lunghurst John's background spans 30 years of global manufacturing/defence/media industry investments, geo-political and defence/cyber advisory, and hands-on experience advising and running small growth companies. He has worked with James Capel & Co and UBS (1986-1996), Capital Group Companies of Los Angeles, one of the world's top-10 investment management companies by equity assets, (1996-2011), was first equity research Director at PIMCO, one of the world's top-5 largest active investment asset managers, (2011-2013). Since leaving investment management services, John has maintained his global network in defence/cyber via his proprietorship of a leading defence/aerospace advisory company, Tangent Link, his role in Israel Japan Advisors, and regular papers/speeches on geo-strategic/cyber issues. John is also a Board member of the Cyber Policy Institute in Estonia. He Chairs and advises on the growth, management and funding challenges of a range of small companies in UK, Estonia and Norway, covering industries including; optical technology, beverages, defence, agri-tech and storage solutions. In 2012, John was voted by Defence News (America’s leading defence industry publication) as one of the top-100 most influential people in the U.S. Defence industry. Petra Sas Petra Sas has held various positions within the Swedish financial industry for the past 18 years. Petra is currently CEO at Remium Nordic, a financial services company specialised in small and medium sized companies in Sweden, and she is also a Board Member of the Swedish Securities Dealers Association (SSDA). Öhrlings PricewaterhouseCoopers AB is proposed to be re-elected as auditor for a term of four years. It should be noted that Nicklas Renström will be the auditor in charge. Nomination Committee for the next Meeting (item 16)   The Nomination Committee proposes that the Meeting shall resolve to adopt the same principles for the appointment of a Nomination Committee for the annual general meeting 2018 as for the annual general meeting 2017. This entails that the Chairman of the Board of Directors shall contact the four largest shareholders recorded in the register of shareholders or otherwise known to the Company as per 1 August 2017 and request that they each appoint one member of the Nomination Committee. If any such shareholder declines to exercise its right to appoint a member of the Nomination Committee the thereafter largest shareholder recorded in the register of shareholders or otherwise known to the Company, that has not already appointed a member of the Nomination Committee, shall be asked to do so, etc. The Nomination Committee consists of these four members together with the Chairman of the Board of Directors. Thus, the Nomination Committee shall consist of a total of five members. Should one member of the Nomination Committee resign from the committee before it has submitted its proposal, a successor shall, if considered necessary, be named by the shareholder who appointed the resigning member. If the shareholder that appointed the resigning member no longer is among the four largest shareholders recorded in the register of shareholders or otherwise known to the Company, the largest shareholder recorded in the register of shareholders or otherwise known to the Company that has not already appointed a member of the Nomination Committee, shall be entitled to appoint a successor. The Nomination Committee shall elect a chairman among its members. However, the Chairman of the Board of Directors or any other member of the Board of Directors may not be appointed chairman of the Nomination Committee. The names of the members of the Nomination Committee, together with information regarding who the chairman of the Nomination Committee is, shall be announced on the Company’s webpage at the latest six months prior to the annual general meeting 2018. The Nomination Committee shall submit proposals regarding the Chairman of the Board of Directors and other members of the Board of Directors, fees and other remuneration for each member of the Board of Directors. The Nomination Committee is also to submit proposals for the election and fees of the auditor. The mandate is valid until a new Nomination Committee has been appointed. No remuneration is to be paid to the members of the Nomination Committee. The Nomination Committee shall have the right to upon request receive personnel resources such as secretarial services from the Company, and to charge the Company with costs for recruitment consultants and related travel if deemed necessary. THE BOARD OF DIRECTOR’S PROPOSALS Resolution regarding appropriation of the Company’s results in accordance with the approved balance sheet (item 9) The Board of Directors proposes that no dividend is paid to the shareholders and that the Company’s results are carried forward. Resolution regarding guidelines for remuneration of the management (item 15) The remuneration of the management shall be in line with current market practice. The remuneration of the management shall consist of fixed salary, variable remuneration, pension and certain other customary benefits. The category “senior executives” consists of members of the Company's group management. Fixed salary and variable remuneration The fixed salary, which is individual and differentiated considering responsibility and performance, is determined based on market principles and is revised annually. Variable remuneration shall be linked to predetermined and measurable criteria based on the Company's earnings and sales. These criteria are designed with the aim of promoting long-term value creation. Variable compensation is conditional upon fulfilment of annually determined targets. These targets are related to the Company's earnings and to measurable goals within the individual’s area of responsibility. The annual variable salary may not exceed 100 percent of the fixed annual salary. Variable compensation may also be paid in the form of shares in the Company through participation in share-based incentive programs including offers for the acquisition of stock options and / or warrants. Pension and other benefits The basic principle concerning pension arrangements shall be that conditions are in accordance with market practice in the country where the senior executive is domiciled. The retirement age for senior executives varies depending on local practice. For the CEO, the Company shall allocate an amount equal to 18 percent of the pension-bearing yearly salary for pension and insurance solutions. Pensions and benefits for all other senior executives shall follow local practice regarding pension agreements or equivalent. Other pension allocations are made in accordance with local practice, after approval by HR and the CEO. Other benefits such as company car, health insurance, etc. shall be determined by what is considered reasonable in relation to market practice and, where such benefits exist, only as a limited portion of total remuneration. Termination of employment and severance pay The notice period for the CEO shall be twelve months, and for other senior executives three to six months. Neither the CEO, nor the other senior executives are entitled to severance pay upon termination. The members by the Board of Directors, appointed by the general meeting, shall in individual cases be granted remuneration for assignments within their specific field of competence, which is in addition to their board assignment. The total remuneration, for these assignments, shall correspond to the prevailing market conditions as well as be approved by the Board of Directors. The Board of Directors is entitled to deviate from these guidelines in individual cases should special justifications exists. If any deviation occurs, information with regard to the deviation as well as the reason to the deviation shall be reported at the next Meeting. The corporate governance report included in the annual report pertaining to 2016 contains a description of existing guidelines for remuneration of the management for 2016. Authorisation of the Board of Directors to resolve upon issues of shares and/or warrants and/or convertibles (item 17) The Board of Directors of Seamless proposes that the Meeting authorises the Board of Directors to, prior to the next Meeting, on one or several occasions, with or without deviating from the shareholder’s preferential rights, resolve to issue new shares and/or warrants and/or convertibles resulting in a maximum increase of 20 million shares in the Company. The Board of Directors shall have the right to resolve that shares and/or warrants and/or convertibles shall be paid for in kind or on conditions set out in Chapter 2 Section 5 paragraph 1 – 3 and 5 of the Swedish Companies Act or that shares and/or warrants and/or convertibles shall be subscribed for by way of set-off. The purpose of the authorisation is to, in a fast and efficient way, enable financing of the Company’s operations, acquire companies, businesses or parts thereof or broadening the ownership structure of the Company. Authorisation of the Board of Directors to acquire and sell treasury shares (item 18) The Board of Directors proposes that the Meeting authorises the Board of Directors to, for the period up until the next Meeting, pass a resolution on one or more occasions on purchasing so many shares that the Company’s holding does not at any time exceed 10 percent of the total number of shares in the Company. The purchase of shares shall take place on the Nasdaq Stockholm and may only occur at a price within the share price interval registered at that time, where share price interval means the difference between the highest buying price and lowest selling price. Furthermore, it is proposed that that the Meeting authorises the Board of Directors to resolve on one or more occasions to transfer the Company’s own shares on Nasdaq Stockholm or in connection with the acquisition of companies, businesses or parts thereof. The purpose of the proposed authorisations is to provide the Board of Directors with greater opportunities to affect the Company’s capital structure and enable the Company to finance acquisitions with treasury shares. Resolution on stock options program and resolution to authorise the Board of Directors to issue warrants (item 19) The Board of Directors proposes that the Meeting resolves to adopt a stock option plan (the “Plan”) for senior executives and other key employees in the group. The Plan will consist of one series, series 2017/2020, and will encompass a maximum of 5 million stock options. The purpose of the Plan is to attract, retain and motivate employees of the Seamless group, provide competitive remuneration packages and to align the interests of the senior executives and key employees with the interests for Seamless business. Against this background, the Board of Directors is of the opinion that the adoption of the Plan as set out above will have a positive effect on the Seamless group future development and thus be beneficial for both the Company and its shareholders. According to the Plan, the Company will allot the stock options to employees in the group, free of charge. The stock options may not be transferred or pledged and as a main rule the stock options may only be exercised if the holder is still employed within the group. Each stock option entitles the employee to acquire one share in Seamless for an exercise price set at 120 per cent of the volume weighted average price of the Seamless share for ten trading days after 1 July 2017. The stock options will vest following the publication of the interim report for the period January - March 2020 and may be exercised each quarter until publication of the interim report for the period January - March 2022. For senior executives, the vesting of stock options will be conditional upon fulfilment of financial and operational targets as determined by the Board of Directors. The targets are related to the Company's earnings and to measurable goals within the individual’s area of responsibility designed with the aim of promoting long-term value creation. The results hereof will be published in the Company’s annual report for 2020 and on the Company’s web site. The Board of Directors, with the assistance of the Company’s remuneration committee, shall be responsible for preparing the detailed terms and conditions of the Plan, in accordance with the mentioned terms and guidelines. To this end, the Board of Directors shall be entitled to make adjustments to meet foreign regulations or market conditions. The Board of Directors may also make other adjustments if significant changes in the Seamless group, or its operating environment, would result in a situation where the decided terms and conditions for the allotment and vesting of stock options under the Plan become irrelevant. Furthermore, if special reasons are at hand, the Board of Directors may resolve that options can be kept and exercised even though the employment within the group has ceased, by example due to illness or if the participant maintains other assignments for the group. The Plan is proposed to comprise up to 5 million stock options. The participants will be divided into two different groups for the purpose of resolving on the grant of options: · The CEO of the Company is entitled to not more than 1.5 million stock options. · Other senior executives and other key employees employed in the group are each entitled to not more than 500,000 stock options. Granting of stock options will only be allowed to the extent the number of options under this Plan does not exceed 5 million stock options. To ensure the delivery of shares under the Plan, the Board of Directors proposes that, with deviation from the shareholders’ preferential rights, the Board of Directors is authorised to, at one or more occasions, resolve to issue not more than 5 million warrants. The warrants will be issued without consideration and may only be subscribed by the subsidiary The Mollet AB. Exercise of all warrants to be issued to secure the obligations under the Plan corresponds to a dilution of 7.8 per cent of all shares and votes outstanding in the Company. Resolution on amendment of the articles of association (item 20)  The Board of Directors proposes that the Meeting resolve on amendment of the articles of association of the Company, whereby the share capital and the number of shares in the Company will be changed so the share capital shall be not less than SEK 25,000,000 and not more than SEK 100,000,000 and the number of shares shall be not less than 50,000,000 and not more than 200,000,000. Resolution to authorise the Board of Directors to divest the subsidiary Seamless Distribution System AB (item 21) The Board of Directors proposes that the Meeting resolves to authorise the Board of Directors to divest the Company’s wholly owned subsidiary Seamless Distribution Systems AB (“SDS”). The divestment is envisaged to be carried out either (i) through a purchase offer and subsequent listing of the SDS share on Nasdaq First North, whereby the Company’s shareholders are granted purchase rights (Sw. Inköpsrätter) for shares in SDS pro rata in relation to their holdings in the Company; or (ii) to a third-party buyer, subject to the purchase price of all outstanding shares in SDS being higher than what the Board of Directors, with support from its advisors, has estimated as the fair trading value of the SDS shares upon listing. More information and background to the Board’s proposal and financial figures for the Company excluding SDS and for SDS as an independent unit will be held available on the Company’s website, www.seamless.se. Other A resolution in accordance with item 17, 18 and 20 is only valid where supported by not less than two-thirds (2/3) of both the votes cast and the shares represented at the Meeting and a proposal in accordance with item 19 is only valid where supported by not less than nine-tenths (9/10) of both the votes cast and the shares represented at the Meeting.   _____________________ The shareholders are reminded of their right to require information in accordance with Chapter 7 Section 32 of the Swedish Companies Act. The annual report and the auditor's report pertaining to the financial year 2016, as well as the complete proposals will be held available at the Company's office on St: Eriksgatan 121 in Stockholm and on the Company’s web page, www.seamless.se, at least three weeks before the Meeting. Further, the Nomination Committee’s motivated statement will be available at the address stated above as well as at the web page stated above at least four weeks before the Meeting. Copies of the documents will be sent to the shareholders who so request and who inform the Company of their postal address. Stockholm in March 2017 Seamless Distribution AB (publ) The Board of Directors This information is information that Seamless Distribution AB (publ) is obliged to make public pursuant to the EU Market. Abuse Regulation. This information was submitted for publication, through the agency of the contact person set out above, at 04.40 p.m. CET on March 22, 2017. Seamless Distribution AB, Box 6234, 102 34 Stockholm | Visiting address: St Eriksgatan 121 D | Org. no: 556610-2660 Phone: 08-564 878 00 | Fax: 08-564 878 23 | www.seamless.se

Sonera becomes Telia

“Rebranding our Finnish operations is another step in our journey towards becoming one New Generation Telco under one brand in all our countries, and I am delighted to welcome my Finnish colleagues and customers to the Telia family. The change will enable us to better serve our Finnish customers by combining the international strength of Telia Company with the local expertise and position of Sonera”, says Johan Dennelind, president and CEO of Telia Company. The history of the company now known as Telia in Finland dates back to 1855, and since 1998 the company has been operating under the Sonera name. Each year, the company invests about EUR 200 million in Finland and employs about 3,300 people directly and thousands more indirectly. Today’s announcement means that all fully-owned subsidiaries of Telia Company now operate under the Telia brand. In Latvia, Telia Company offers mobile services through the mobile operator LMT which the company owns 60.3 percent of. Telia Company also owns 49 percent of the fixed network company Lattelecom.  For more information, please contact our press office +46 771 77 58 30, visit our Newsroom  or follow us on Twitter @Teliacompany .  We’re Telia Company, the New Generation Telco. Our 21,000 talented colleagues serve millions of customers every day in one of the world’s most connected regions. With a strong connectivity base, we’re the hub in the digital ecosystem, empowering people, companies and societies to stay in touch with everything that matters 24/7/365 - on their terms. Headquartered in Stockholm, the heart of innovation and technology, we’re set to change the industry and bring the world even closer for our customers. Read more at www.teliacompany.com.

Alligator announces completion of first phase I study with CD40 agonistic immuno-oncology antibody ADC-1013

The phase I trial, which began in April 2015, is a dose-escalation study involving intratumoral and intravenous administration of ADC-1013 at five clinical sites in Sweden, Denmark and the UK (ClinicalTrials.gov: NCT02379741). The study is sponsored by Alligator and includes 24 patients and ten different tumor types. The data will now be analyzed, focusing on safety and tolerability, pharmacokinetics, immunogenicity, biomarker response and clinical response evaluation. The aim is to present the results during the fourth quarter of 2017 at a scientific meeting, followed by a publication in a scientific journal. “The study has progressed very well and we look forward to evaluating the data,” said Per Norlén, CEO at Alligator Bioscience. “I would like to extend my warmest gratitude to all the patients and their families, as well as the investigators and clinical study staff who enabled this study to be successfully completed ahead of time.” In August 2015, Alligator entered a collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, which has the global development rights to ADC-1013.             In October 2016, Janssen Biotech Inc. started a second phase I clinical study (ClinicalTrials: NCT02829099). This study is an intravenous dose escalation study with ADC-1013 (JNJ-64457107). WebcastThe webcast can be accessed live on the link below and will be available on the company website 30 minutes after the broadcast. https://wonderland.videosync.fi/2017-03-23-alligator-bioscience-press-conference Phone numbers for participants from:UK: +44  2030089806SE: +46856642669US: +18558315944 For further information, please contact:Per Norlén, CEOTelephone: + 46 46 286 42 80 (switchboard)E-mail: per.norlen@alligatorbioscience.com Rein Piir, VP Investor RelationsTelephone: +46 708 537292E-mail: rein.piir@alligatorbioscience.com Per-Olof Schrewelius, CFOTelephone: +46 46 286 42 85E-mail: per-olof.schrewelius@alligatorbioscience.com The information in the press release is such that Alligator Bioscience AB is required to disclose pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, at 08.00 CET on 23 March, 2017. About Alligator BioscienceAlligator is a biotechnology company that develops innovative immune activating antibody drugs for tumor-directed immunotherapy. The Company has a pipeline of lead clinical and preclinical product candidates: ADC-1013, ATOR-1015 and ATOR-1016 as well as various research candidates. In August 2015, ADC-1013 was out-licensed to Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for further development and commercialization. The Company’s shares are listed on Nasdaq Stockholm under the ticker “ATORX”. The Company is headquartered in Lund, Sweden, and has approximately 40 employees. For more information, please visit www.alligatorbioscience.com. About ADC-1013ADC-1013 is a human, monospecific, agonistic, IgG1 antibody intended for immunotherapy of cancer. The drug candidate targets the co-stimulatory receptor CD40, which is expressed on, for example, antigen-presenting dendritic cells. The dendritic cells reside in blood vessels and various tissues where they discover and digest proteins from viruses, bacteria or cancer cells. Next, the digested proteins are presented to so-called T-cells which are activated and kill the infected cells or the cancer cells. ADC-1013 activates CD40 on dendritic cells, enabling them to activate T-cells more effectively and thereby increasing the immune system's attack of the cancer.

Concentric AB secures order for new electric oil pump technology with leading global OEM

This exciting new product reinforces the company’s reputation for reducing fuel consumption, increasing system efficiency, providing high power density and reducing noise. Concentric's electric oil pump offers system power savings through its variable pressure and speed control capability with the additional benefits of low noise. It also offers on-demand flow and variable speed capability. The new electric oil pump product allows CAN Bus communication between the motor and the vehicle's main control system so as to control pressure and flow on demand. This significantly reduces system losses compared to traditional mechanical drive systems, ensuring optimum performance. David Woolley, President and CEO of Concentric AB, commented: “This first major nomination for Concentric’s new electric oil pump technology is another significant breakthrough in a market driven by increased electrification and control.  Our modular design strategy is ideally suited for a wide range of applications for emerging hybrid electric vehicles and demonstrates our ongoing commitment to innovation that enables our customers to achieve sustainable solutions.” The Concentric electric oil pump has been developed in collaboration with a leading supplier of electric motors, resulting in a permanent magnet, brushless DC motor with integrated motor drive electronics. The elimination of brush wear contributes to the unit's ability to operate continuously and trouble-free. Concentric AB is an innovator in flow control and fluid power, supplying proprietary systems and components to the world’s truck, agricultural machinery, construction equipment and industrial applications end-markets.  The company has manufacturing facilities in the UK, USA, Germany, Sweden, India, China and Argentina. In addition to supplying oil, fuel transfer and water pumps for diesel engines, the group also manufactures lubrication pumps for transmissions and compressors within its range of engine products.

Notice of Annual General Meeting of Shareholders in NeuroVive Pharmaceutical AB

Please see the attached notification, which is being announced within short in Svenska Dagbladet and Post- och Inrikes Tidningar. Lund, March 23, 2017NeuroVive Pharmaceutical AB (PUBL)THE BOARD OF DIRECTORS About NeuroVive NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine. The company is committed to the discovery and development of medicines that preserve mitochondrial integrity and function in areas of unmet medical need. The company’s strategy is to take drugs for rare diseases through clinical development and into the market. The strategy for projects within larger indications outside the core focus area is out-licensing in the preclinical phase. NeuroVive enhances the value of its projects in an organization that includes strong international partnerships and a network of mitochondrial research institutions, as well as expertise with capacities within drug development and production. NeuroVive has a project in early clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®). NeuroSTAT has orphan drug designation in Europe and in the US. The R&D portfolio consists of several late stage research programs in areas ranging from genetic mitochondrial disorders to cancer and metabolic diseases such as NASH. NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF). NeuroVive Pharmaceutical AB (publ)Medicon Village, SE-223 81 Lund, SwedenTel: +46 (0)46 275 62 20 (switchboard)www.neurovive.com This information is information that NeuroVive Pharmaceutical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:30 a.m. CET on March 23, 2017. Notice of Annual General Meeting of NeuroVive Pharmaceutical AB (publ) The shareholders of NeuroVive Pharmaceutical AB (publ), corporate identity number 556595-6538, are hereby convened to the Annual General Meeting, held at 4 p.m. on Thursday, 27 April 2017 at Medicon Village, Scheelevägen 2, in Lund, Sweden, with admission for registration from 3:30 p.m. Entitlement to participate and notificationShareholders that wish to participate at the Annual General Meeting should · be included in the share register maintained by Euroclear Sweden AB on Friday 21 April 2017, and · notify the Company by email to anmalan@neurovive.com or, in writing to NeuroVive Pharmaceutical AB, Medicon Village, Scheelevägen 2, 223 81 Lund, Sweden, no later than Friday, 21 April 2017. Notifications must state full names, personal or corporate identity numbers, shareholdings, address, daytime telephone number, and where applicable, information on deputies or assistants (maximum of two). Where applicable, notifications should also enclose powers of attorney, certificates of registration and other legitimacy papers. Nominee-registered shares For entitlement to participate at the Annual General Meeting, shareholders with nominee-registered holdings with banks or other administrators must temporarily re-register their shares in their own name with Euroclear Sweden AB. Such re-registration must be complete by no later than Friday 21 April 2017, which means that shareholders that wish to conduct such re-registration must inform their administrator thereof in good time prior to the aforementioned date. Proxies etc.   If shareholders attend by proxy, such proxy must bring a written power of attorney, dated and signed by the shareholder to the Meeting. This power of attorney may not be older than one year, unless a longer term of validity (although subject to a maximum of five years) is stated in the power of attorney. If the power of attorney has been issued by a legal entity, the proxy should also bring the relevant certificate of registration or corresponding legitimacy papers for the legal entity. To facilitate entry, a copy of the power of attorney and other legitimacy papers should be attached to the notification of attendance of the Meeting. Power of attorney forms are available from the Company’s website www.neurovive.se and can be sent by mail to shareholders that contact the Company stating their mail address. Number of shares and votes   At the time of publication of this Notice, the total number of shares and votes of the Company is 49,458,645. The Company does not hold any treasury shares. Proposed agenda:    0.     Opening the Meeting.  1.     Election of a Chair of the Meeting.  2.     Preparation and approval of the voting list.  3.     Approval of the agenda.  4.     Election or two persons to verify the minutes.  5.     Consideration of whether the Meeting has been duly convened.  6.     Chief Executive Officer's address.  7.     Submission of the Annual Accounts and Audit Report and the Consolidated Accounts and Consolidated Audit Report.  8.     Resolutions         a)     On adopting the Income Statement and Balance Sheet and the Consolidated Income Statement and Consolidated Balance Sheet.         b)     On appropriation of the Company's earnings in accordance with the adopted Balance Sheet.         c)      On discharging the Board members and Chief Executive Officer from liability.  9.    Determination of the number of Board members and Auditors.  10.   Determination of Directors' and audit fees.  11.   Election of a Board of Directors and Auditors.  12.   Resolution on guidelines for remuneration to senior executives.  13.   Resolution on guidelines for the Nomination Committee.  14.   Resolution on authorizing the Board of Directors to decide on the new issue of shares, warrants and/or convertibles.  15.   Closing the Meeting. Proposed resolutions in brief: Election of a Chairman of the Meeting (point 1)   The Nomination Committee proposes that the Annual General Meeting appoints Lawyer Annika Andersson, Law firm Lindahls, as Chair of the Meeting. Appropriation of profits (point 8 b)   The Board of Directors proposes that the Annual General Meeting disposes over the Company’s earnings in accordance with the Board of Directors’ proposal in the Annual Accounts. Additionally, the Board of Directors proposes that no dividend is paid for the financial year 2016. Determination of the number of Board members and determination of Directors’ and audit fees (point 9 and 10) The Nomination Committee proposes that the Annual General Meeting resolves that the number of Board members shall be five. The Nomination Committee also proposes that fees to Board members elected by the Annual General Meeting not employed by the Company and members of the Board of Directors’ various Committees not employed by the Company shall be payable as follows: · SEK 300,000 to the Chairman of the Board; · SEK 150,000 each to other Board members; · SEK 100,000 to the Chairman of the Audit Committee; · SEK 50,000 each to other members of the Audit Committee; · SEK 40,000 to the Chairman of the Remuneration Committee; · SEK 20,000 each to other members of the Remuneration Committee. Having considered the Company’s and the Board of Directors’ appraisal of the auditors’ work, the Nomination Committee proposes that as in the previous year, audit fees should be in accordance with approved account pursuant to customary billing terms. No fees shall be payable to members of the Nomination Committee. Election of the Board of Directors and Auditors (point 11)   The Nomination Committee proposes that the Annual General Meeting approves re-election of the following Board members: Gregory Batcheller, Marcus Keep, and David Laskow-Pooley. The Nomination Committee also proposes the election of Jan Törnell and David Bejker as Board members. The Nomination Committee proposes that Gregory Batcheller is re-elected as Chairman of the Board. Jan Törnell, born 1960, is Associate Professor and Medical doctor with 20 years’ experience from different senior positions within the pharmaceutical industry, both in Sweden and internationally. Jan has held the position as Vice President in AstraZeneca Oncology & Infection 2009-2011 and Vice President Translational Science 2006-2008. He was Director at AstraZeneca Discovery 1999-2005 and Astra 1996-1999. Jan is Editor-in-Chief for Drug Discovery Today –Disease Models published by Elsevier. Principal supervisor of several students resulting in PhD theses. Author of 80 scientific publications and innovator on 6 patents. Currently, Jan is adjunct Professor at the Institute of Neuroscience and Physiology, Sahlgrenska Academy, Gothenburg University. Chairman of the Board at LIDDS AB, Glactone Pharma AB and Glactone Pharma Development AB. Director of the Board at Stayble AB and Diaprost AB. CEO at Oncorena AB and Innoext AB. Partner of P.U.L.S. AB.  David Bejker, born 1975, has an MSc from Stockholm School of Economics. David Bejker is the CEO of Affibody Medical AB, a company that develops innovative biopharmaceuticals, since 2008. He has many years of industry experience both from an investor perspective, through employment in HealthCap, and also operating as a business developer of Affibody AB during 2003 to 2005. David Bejker has been CEO of Affibody in a period when the company successfully focused its strategy to become a financially strong biopharmaceutical company with projects in clinical development and a large number of global licensing and collaboration deals. Affibody has under his leadership also secured major grants from the EU, the NCI and Vinnova. Resolution on guidelines for remuneration to senior executives (point 12) The Board of Directors proposes that the Annual General Meeting approves the following guidelines for remuneration to senior executives:   Guidelines for remuneration and other employment terms for management primarily imply that the Company should offer its senior executives market remuneration, that the remuneration shall be subject to consultation by a dedicated Remuneration Committee within the Board of Directors, that the associated criteria shall constitute the senior executive’s responsibilities, role, competence and position. Remuneration to senior executives is decided by the Board of Directors excluding any Board members affiliated to the Company and management. The guidelines shall be applied to new agreements, or amendments to existing agreements reached between senior executives after the guidelines have been adopted, and until new or revised guidelines are determined. What is stipulated for NeuroVive also applies to the Group, where applicable. This proposal is basically identical to the guidelines approved for remuneration to senior executives in the previous year.   1.     Basic principleSalary and other remuneration, as well as any share-related incentive programs, shall be on market terms and shall be structured so that NeuroVive can attract and retain competent senior executives.  2.     Fixed remunerationSenior executives shall be offered fixed remuneration that is on market terms and based on the senior executive's responsibilities, roll, competence and position. Fixed remuneration shall be subject to annual review.  3.     Variable remuneration 3.1. Short-Term Incentive (STI Bonus) From time to time, senior executives and other key individuals may be offered variable remuneration. Such variable remuneration shall be on market terms and shall be based on the outcome of predetermined financial and individual targets. The terms and conditions and basis of computation of variable remuneration shall be determined for each financial year. Variable compensation is settled in the year after vesting and may either be paid as salary or as a lump-sum pension premium. Payment as a lump-sum pension premium is subject to indexation so the total cost for NeuroVive is neutral. The board shall decide on the amount of STI Bonus. The basic principle is that the yearly STI Bonus is capped at an amount corresponding to a portion of the fixed annual compensation for the current year: +---+----------+-----------------+|CEO|Management|Other key persons|+---+----------+-----------------+|30%|20% |10% |+---+----------+-----------------+ The total of the variable remuneration for senior executives (CEO and Management) may amount to a total maximum of SEK 2,000,000. The amount could increase in the event the company hires additional employees. 3.2 Long-Term Incentive (LTI Bonus) In order to incentivize senior executives and other key individuals on a longer term and to encourage investment in NeuroVive shares, a cash bonus share savings opportunity should be implemented (the “LTI Bonus”). The LTI Bonus is a cash program in which the participants commit to use the cash paid out by the Company to acquire shares in the Company. The shares are acquired by the participants on the stock market. This shall apply in addition to the STI Bonus. The decision regarding the annual amount available as LTI Bonus will be built into the yearly bonus appraisal process to link yearly achievements to long term goals, to build employee shareholding in NeuroVive, and to retain employees. The amount of possible LTI Bonus will depend on the employee’s position and the ability to influence the performance of NeuroVive. The participants should use the full amount of the LTI Bonus, net after income tax to acquire NeuroVive shares on the stock market. The company will pay the social security costs. The shares acquired for the LTI Bonus will be locked in for a period of 3 years after the acquisition. An employee who resigns, is terminated or otherwise leaves the Company will be obliged to hold the shares acquired within the LTI Bonus for the full period of 3 years after acquisition notwithstanding the termination of their employment.  In the event an employee or former employee breaches the terms of the LTI Bonus program, such as for example by failing to provide information on the status of their shareholding or prematurely disposing of their shareholding they will be subject to contractual sanctions including a penalty equal to the full amount of the LTI Bonus (including income tax, but excluding social security contributions thereon). The board shall decide on the amount of LTI Bonus. The maximum amount in the LTI Bonus is capped at an amount corresponding to a portion of the fixed annual compensation for the current year: +---+----------+-----------------+|CEO|Management|Other key persons|+---+----------+-----------------+|15%|10% |5% |+---+----------+-----------------+ The total maximum cost for the above LTI Bonus is SEK 1,000,000. The amount could increase in the event the company hires additional employees. 3.3 General principles for STI and LTI When structuring variable remuneration that is payable to management in cash, the Board of Directors should consider introducing provisions such as: · disqualification from future LTI Bonus in relation to an individual who sells his/her shares during the 3 year qualification period, · making payment of a predetermined portion of such remuneration conditional so the performance on which vesting is based is demonstrably sustainable over time, and · offers the Company the opportunity to reclaim such remuneration paid on the basis of information that subsequently proves manifestly erroneous. 4.     Non-monetary benefitsWhere the Board of Directors considers it appropriate and/or after individual consideration of an overall salary and remuneration structure, a senior executive may be entitled to additional healthcare insurance  5.     PensionSenior executives are entitled to market-based pension solutions in accordance with collective bargaining agreements and/or agreements with NeuroVive. All pension obligations should be defined contribution. Salary waivers may be utilized to increase pension provisions through lump-sum pension premiums, providing the total cost for NeuroVive is neutral.  6.     Notice periodFrom NeuroVive’s side, the maximum notice period shall be six months for the Chief Executive Officer and a maximum of six months for other senior executives. The notice period from the Chief Executive Officer’s side shall be a minimum of six months, and from other senior executives’ side, shall be a minimum of three months. In addition to this notice period, severance pay subject to a maximum of six months’ salary plus fringe benefits may be payable to the CEO.  7.     The consultative and decision-making process of the Board of DirectorsThe Board of Directors' Remuneration Committee consults on proposals for decision regarding salary and other employment terms for senior executives. Remuneration to senior executives is then decided by the Board of Directors, excluding any Board members who are affiliated to the Company and its management.  8.     Share-related incentive programs approved by shareholders’ meetings Through its Nomination Committee, the Board of Directors shall consider the need for share-related incentive programs yearly, and where necessary, submit a proposal for resolution to the Annual General Meeting regarding a well-considered share-related incentive program for senior executives and/or other employees. Resolutions regarding any share and share price-related incentive programs targeted at senior executives shall be made by shareholders’ meetings  9.     Information on previously approved remuneration that is not due for paymentThere is no remuneration decided that is not due for payment.  10.   Information on departure from the guidelines resolved by the Annual General MeetingThere has been no departure from the guidelines.   11.   Other The Board of Directors shall be entitled to depart from the above guidelines if the Board of Directors judges that there are special circumstances justifying this in an individual case. Resolution on the guidelines for the Nomination Committee (point 13)  The Nomination Committee proposes that the work of the Nomination Committee for the Annual General Meeting 2018 should be conducted as follows: · The Company shall have a Nomination Committee that shall consist of a member for each of the three largest shareholders in terms of votes, based on the shareholder statistics as of 30 September 2017, which the Company obtains from Euroclear Sweden AB. If such shareholder does not exercise its right to appoint a member, the right to appoint a member of the Nomination Committee shall transfer to the next largest shareholder in terms of votes. Coincident with the appointment of a new Nomination Committee, in an appropriate manner, the Chairman of the Board shall contact the three largest shareholders identified and request them to nominate the person said shareholder intends to appoint as a member of the Nomination Committee in writing within a reasonable period in the circumstances, although not exceeding 30 days.The majority of the Nomination Committee's members should be non-affiliated to the Company and its management. The Chief Executive Officer or other member of management should not be a member of the Nomination Committee. At least one of the members of the Nomination Committee should be non-affiliated to the largest shareholder of the Company in terms of votes, or group of shareholders that cooperate on the Company’s administration. Board members may be members of the Nomination Committee, but should not constitute a majority of Nomination Committee members. The Chairman of the Board or other Board members should not be the Chairman of the Nomination Committee. If more than one member is a member of the Nomination Committee, a maximum of one of these people should be affiliated to the Company’s largest shareholder.Information on the definitively appointed Nomination Committee shall include the name of the three appointed members, as well as the name of those shareholders that appointed them, and shall be published by no later than six months prior to the scheduled Annual General Meeting. The Nomination Committee’s term of office extends until a new Nomination Committee has been appointed. Unless the members agree otherwise, the chairman of the Nomination Committee should be that member appointed by the largest shareholder in terms of votes. · If one or more of the shareholders that have appointed members of the Nomination Committee are no longer one of the three largest shareholders in terms of votes, members appointed by such shareholders shall put their places on the Nomination Committee at the Committee’s disposal, and that, or those, shareholders that have become one of the three largest shareholders in terms of the vote shall be entitled to appoint members. However, unless there are special circumstances, there shall be no changes to the composition of the Nomination Committee if only marginal changes to the number of votes have occurred, or any such change occurs later than two months prior to the Annual General Meeting. Shareholders that have appointed members of the Nomination Committee are entitled to dismiss such member, and appoint a new member of the Nomination Committee if the member appointed by said shareholder decides to leave the Nomination Committee. Changes to the composition of the Nomination Committee shall be published as soon as they have occurred. · The Nomination Committee shall prepare proposals on the following issues to be submitted to the Annual General Meeting for resolution:            a)     a proposal regarding a Chairman of the Meeting;            b)     a proposal regarding the number of Board members elected by the Annual General Meeting, and where applicable, the number of auditors;            c)      a proposal regarding fees to Board members not employed by the Company, and members of the Board’s various Committees not employed by the Company;            d)     a proposal regarding audit fees;            e)     a proposal regarding election of the Chairman of the Board and other Board members, and where applicable, election of auditors;            f)      a proposal regarding guidelines for appointing members of the Nomination Committee, and for the duties of the Nomination Committee;           g)     a proposal regarding fees to members of the Nomination Committee. · The Company’s Chairman convenes the first meeting and shall ensure that the Nomination Committee receives relevant information regarding the results of the Board of Directors’ review of its work without delay. Such information shall be presented by January at the latest and shall contain information about the Board of Directors working methods and how effective its work is. Furthermore, the Chairman shall be co-opted to the Nomination Committee’s meetings when required. · On request from the Nomination Committee, the Company shall provide personnel, e.g. secretarial services in order to facilitate the work of the Nomination Committee. When required, the Company shall reimburse the Nomination Committee’s reasonable expenses, such as the cost of recruitment, and for any external consultants the Nomination Committee deems necessary in order to complete its assignment. Resolution on authorization for the Board of Directors to decide on the new issue of shares, warrants and/or convertibles (point 14) The Board of Directors proposes that the Annual General Meeting resolves to authorize the Board of Directors to decide on the new issue of shares, warrants and/or convertibles, with or without waiving the preferential rights of shareholders on one or more occasions in the period until the next Annual General Meeting. The number of shares issued through this authorization may correspond to an increase of share capital of a maximum of fifteen per cent (15%) based on the total share capital of the Company at the time the Boards of Directors at first exploits the authorization. Share issues should be at market subscription price, subject to reservation for a market discount where applicable, and apart from cash, payment may be as assets contributed in kind or through offset or subject to other terms and conditions. The purpose of this authorization and the rationale for eventual waiving of shareholders' preferential rights, should be to raise working capital for the Company and/or to add new owners of strategic importance to the Company and/or acquisitions of other companies or operations. In order for such a resolution to be valid, the proposal must have the support of shareholders representing at least two-thirds of the votes cast and shares represented at the Meeting. Other   The Annual Accounts and Audit Report of the Company and Group, as well as complete proposals for resolution and the auditor's statement pursuant to chap. 8, § 54 of the Swedish Companies Act, will be available at the Company's offices, Medicon Village, Scheelevägen 2, Lund, Sweden, and at the Company’s website www.neurovive.se by no later than three weeks prior to the Annual General Meeting, and will be sent to those shareholders that so request and state their mail address. Shareholders attending the Annual General Meeting are entitled to request disclosures regarding matters on the agenda or the Company’s or Group’s financial position in accordance with chap. 7 § 32 of the Swedish Companies Act (2005:551) THE BOARD OF DIRECTORSNeuroVive Pharmaceutical AB (publ)Lund, Sweden, March 2017

ChromoGenics share and warrant TO1 start trading today on Nasdaq First North, Stockholm

In the recently completed rights issue (the "Offering"), a total of 13,800,000 shares and 13,921,312 TO1 were issued. The number of shares may be increased by a maximum of 121 312 for the event that it decided allotment option would be fully utilized. The price per "Unit" in the Offering consisting of one share and one TO1 amounted to SEK 8.50, corresponding to issue proceeds of SEK 117.3 million before issue costs. After completion of the Offer, the number of outstanding shares in ChromoGenics is 23,214,326 shares, prior to exercise of the over-allotment option. Shares in the Offer thus comprises approximately 59.4 percent of the total shares of the Company and the market value of the Company's shares is approximately 197.3 MSEK. The share's ticker name is CHRO, ISIN code: SE0009496268The warrant’s ticker name is CHRO TO1, ISIN code: SE0009554470 Conditions for CHRO TO1 is that possession of four (4) TO1 entitles the holder to subscribe for one (1) new share in ChromoGenics at the rate of SEK 10.20 during the period 1 to 31 May 2018. The last trading day with TO1 is May 29, 2018. The main shareholders K-Svets Venture AB and New Energy Solutions II K/S will after completion of the Offer remain as the major shareholders of ChromoGenics. K-Svets Venture AB will hold approximately 22 percent and New Energy Solutions II K/S around 19 percent of the shares in the company. Within the framework of the Offer, the main owners converted the bridge loan of approximately 23.2 MSEK corresponding to 2,725,443 Units G&W Fondkommission is the financial advisor to ChromoGenics in connection with the transaction and appointed as Certified Adviser for the planned listing on Nasdaq First North Stockholm. This information is such that ChromoGenics AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and according to the Act (1991: 980) regarding trading with financial instruments. The information was submitted for publication, through the agency of the contact person set out below, at 08:30 CET on March 23, 2017.  Every care has been taken in the translation of this interim report. In the event of discrepancies, the Swedish original will supersede the English translation. Contact:Thomas Almesjö, CEOSusanne Andersson, CFO & Head of CommunicationsTel: +46 18 430 0430E-mail: info@chromogenics.com  About ChromoGenicsChromoGenics is a leader in dynamic glass with controllable heat- and light transmission. The company’s unique electrochromic technology ConverLight™, provides sustainable solar control with increased indoor comfort and energy efficiency. In 2016 the company started commercial sales to real estate projects in Scandinavia. ChromoGenics is located in Uppsala and has about 20 employees. The technology is derived from the world leading research center at Ångström Laboratory at Uppsala University. The plant has been partly financed by a conditional loan from the Swedish Energy Agency. ChromoGenics share (CHRO) will be listed on Nasdaq First North Stockholm from March 23rd 2017. G&W Fondkommission is appointed Certified Adviser. www.chromogenics.com  Important information StabilizationIn connection with the Offering, Erik Penser can implement measures that stabilize or maintain the share price. The warrants will not in any case be subject to any stabilization measures. These stabilization measures will not be implemented at higher prices than the offer price, 8.50 SEK. Such stabilization is intended to support the market price of the shares in order to balance any sales pressure that may be present and may be implemented in a period from the first day of trading in the Company's shares on Nasdaq First North to the date that falls 30 calendar days thereafter. Stabilization Measures include transactions that stabilize, maintain or otherwise affect the market price of the shares. Stabilization transactions consist of certain bids or purchases made for the purpose of preventing or retarding a decline in the shares' market price. Erik Penser is not obliged to take stabilization measures. Thus, there is no guarantee that the stabilization measures will be taken. If stabilization measures, the measures can at any time be terminated by Erik Penser Bank decision without notice. Erik Penser Bank's acquisition of shares in connection with the stabilization measures, at Erik Penser Bank's request neutralized by a reduced allotment. Stabilization Measures should not mean that Erik Penser in total acquire more than 121,312 shares. Neutralization by reducing the allotment may result in the number of warrants issued can not exceed the number of shares issued under the Offer up to 121,312. Within one week after the end of the period during which stabilization measures can be taken, it will be published by Erik Penser whether stabilization measures were carried out or not, the date on which stabilization started, the date of the last stabilization operation was performed and the price range within which stabilization was carried out (for each of the dates during which stabilization measures were carried out).

NeuroVive Pharmaceutical AB publishes 2016 Annual report

About NeuroVive NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine. The company is committed to the discovery and development of medicines that preserve mitochondrial integrity and function in areas of unmet medical need. The company’s strategy is to take drugs for rare diseases through clinical development and into the market. The strategy for projects within larger indications outside the core focus area is out-licensing in the preclinical phase. NeuroVive enhances the value of its projects in an organization that includes strong international partnerships and a network of mitochondrial research institutions, as well as expertise with capacities within drug development and production. NeuroVive has a project in early clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®). NeuroSTAT has orphan drug designation in Europe and in the US. The R&D portfolio consists of several late stage research programs in areas ranging from genetic mitochondrial disorders to cancer and metabolic diseases such as NASH. NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF). For investor relations and media questions, please contact: Cecilia Hofvander, NeuroVive, Tel: +46 (0)46 275 62 21 or ir@neurovive.com NeuroVive Pharmaceutical AB (publ)Medicon Village, SE-223 81 Lund, SwedenTel: +46 (0)46 275 62 20 (switchboard)www.neurovive.com This information is information that NeuroVive Pharmaceutical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:35 a.m. CET on March 23, 2017.

Coor signs agreement with Novozymes in Denmark

Coor has won a five-year contract with Novozymes, a global leader in biology, on development and delivery of operating and maintenance for Novozymes 275,000 sqm. buildings in Bagsværd, Kalundborg and Fuglebakken in Copenhagen. Previously, Novozymes outsourced all property services to a variety of suppliers, but the choice of Coor as strategic partner fulfils the company´s new strategy for the operation and maintenance of their properties. -       Several parameters made Coor the top choice. With Coor´s Energy Management solution we expect to be able to optimize energy in our buildings and lower the energy usage, not least by a behavioral change among our 2,600 employees in Denmark. But the most important aspect was a partnership where we can benefit from mutual learning in close cooperation. In addition to this, we also see a great strength in the overall data picture we now will get as basis for strategic decisions, René Jacobsen, Facility Manager, EMEA & Global Security Officer at Novozymes. The delivery to Novozymes starts on May, 1. Coor in Denmark will hire 15 – 20 new employees to the assignment. -       We’re so pleased about this assignment. Coor is the Nordic market leader in integrated facility management (IFM), but in the last few years, has also started to focus on property services, cleaning and food & beverage segments. We’ve sharpened our offering in these segments, and this assignment advances our positioning in hard FM, commented Jørgen Utzon, President of Coor Denmark. For more information, press images etc., please visit www.coor.com or contact: Jørgen Utzon, President, Coor in Denmark, +45 2363 7178, jorgen.utzon@coor.com  Åsvor Brynnel, Communications and Sustainability Director, Coor Group, + 46 10 559 54 04, asvor.brynnel@coor.com

Notice Convening the AGM of Beijer Electronics (publ)

Notice will be done through advertisement in The Official Swedish Gazette (Post- och Inrikes Tidningar) and by making the notice available on the company website www.beijerelectronics.com/ir. The notice is sent to shareholders who so request and state their address. Such request may be made in the same way as the notification shall be made according to below. Entitlement to participate at the Meeting Shareholders entitled to participate at the Meeting shall · Firstly, be included in the share register maintained by Euroclear Sweden AB (the Swedish Central Securities Depository & Clearing Organization) on Friday, April 21, 2017;   · Secondly, have notified the company of their intention to participate by no later than Friday April 21, 2017.   Notifications can be made via the company’s website, www.beijerelectronics.com/ir, by telephone on +46 (0)40 35 86 44, by e-mail arsstamma@beijerelectronics.com or by mail to Annika Johnsson, Beijer Electronics AB (publ), Box 426, 201 24 Malmö, Sweden (please mark the envelope ‘AGM’). Notifications shall state the shareholders’ name, personal or corporate identity number, address, telephone number, shareholding and potential proxies/assistants. If participation is by power of attorney, a dated original shall be sent to the company. Power of attorney forms are available on the company’s website. Business/proposed agenda 1. Electing a Chairman of the Meeting   2. Preparing and approving the voting list   3. Approval of the agenda 4. Appointment of two people to verify the minutes  5. Consideration of whether the Meeting has been duly convened  6. Review of Board of Directors’ activities  7. Statement by the Chief Executive Officer  8. Submission of the annual accounts and audit report and the consolidated accounts and consolidated audit report   9. Resolutions in the matters of:a)    Adopting the Income Statement and Balance Sheet and the Consolidated Income Statement and Consolidated Balance Sheetb)    Appropriation of the company’s profits pursuant to the adopted Balance Sheetc)    Discharging the Board members and Chief Executive Officer from liability   10. Determining the number of Board members 11. Determining fees to the Board of Directors and Auditors 12. Electing the Board of Directors 13. Electing the Auditors 14. Resolution regarding remuneration guidelines for senior managers 15. Resolution on authorization for the Board of Directors to reach decisions on new share issues 16. Resolution on (A) implementation of a long-term share based incentive program for 2017 (LTI 2017/2020) and (B) hedging including resolution on (1) amendment of the articles of association, (2) authorization for the Board of Directors to resolve decisions on a directed issue of series C shares, (3) authorization for the Board of Directors to repurchase all issued series C shares and (4) transfer of own ordinary shares to participants in LTI 2017/2020 17. Resolution on amendment of the Articles of Association 18. Closing the Meeting Nominee-registered holdings In order to participate at the meeting, shareholders’ with nominee-registered holdings must temporarily register their shares in their own name. This re-registration must be complete by April 21, 2017, and shareholders should notify their nominees in good time before this date. Welcome to the Meeting! The Board of DirectorsBeijer Electronics AB (publ)Registraton No. 556025-1851Malmö, Sweden, March 2017

YIT to start the construction of two apartment buildings in Tallinn, Estonia

YIT starts the construction of two apartment building projects in Tallinn, Estonia. The total value of the projects is approximately EUR 12 million, and the start-ups are recorded in the order backlog in the first quarter. The construction work of both projects starts in April. Algi 59 is a new project to be implemented in one phase. The project is located in Kristiine district. Algi 59 will comprise 76 apartments in four buildings of with total area of approximately 4,500 square metres. The project will be completed in summer 2018. Mäepealse 13/1 is the 11th phase of Mäepealse area development project, that will comprise 38 apartments with total area of approximately 2,000 square metres. The project is located in a peaceful area close to good transportation connections and services. The second phase will be completed in spring 2018. The projects are supporting YIT’s strategy to grow in the growth centres in Finland and CEE countries, Tallinn being one of these. For further information, please contact: Hanna Jaakkola, Vice President, Investor Relations, YIT Corporation, tel. +358 40 5666 070, hanna.jaakkola@yit.fi Tom Sandvik, Head of the Baltic countries and Central Eastern Europe business division, YIT Construction Ltd., tel. +358 400 617 807, tom.sandvik@yit.fi   YIT CORPORATION Hanna Jaakkola Vice President, Investor Relations Distribution: Nasdaq Helsinki, major media, www.yitgroup.com YIT creates better living environment by developing and constructing housing, business premises, infrastructure and entire areas. Our vision is to bring more life in sustainable cities. We want to focus on caring for customer, visionary urban development, passionate execution and inspiring leadership. Our growth engine is urban development involving partners. Our operating area covers Finland, Russia, the Baltic countries, the Czech Republic, Slovakia and Poland. In 2016, our revenue amounted to nearly EUR 1.8 billion, and we employ about 5,300 employees. Our share is listed on Nasdaq Helsinki. www.yitgroup.com

Dome Energy acquires oil field in Wyoming

Dome Energy AB.  (herein after “Dome” and/or “the Company”) today announces that the Company acquires oil field in Wyoming. Internal calculations estimates; · Total reserves of 1.4mm barrels, whereof 450,000 barrels are proven · Future discounted cash flow of $ 17mm at current oil price · Potential daily field production of more than 600 BOPD · Potential wells to re-enter for immediate production start Acquisition cost less than $50,000 Paul Morch, CEO: “We are happy to announce this small acquisition with big economic potential that we have been able to finalize. Our team out of Wyoming first examined this opportunity back in 2012, but was unable to close a deal with the previous owner. The acreage became available since it was no longer HBP “held by production” and we proposed the acreage for public auction. Our local presence and previous analysis allowed us to buy this at a very low price. We will aim to restart production in the coming months, and present a development program shortly after.”    For further information, please contact:Paul MorchPhone: +1 713 385 4104E-mail: pm@domeenergy.com  This information is the kind of information that Dome Energy AB (publ) is obliged to publicize according to EU Market Abuse Regulations (MAR). The information was publicized, by the above contact person March 23, 2017 14.45 CET.    About Dome EnergyDome Energy AB. is an independent Oil & Gas Company publicly traded on the Nasdaq First North exchange in Sweden (Ticker: DOME ). Mangold Fondkommission AB, phone: +46 8 503 01 550, is the Company’s Certified Adviser. Headquartered in Houston, Texas, the Company’s focus is on the development and production of existing onshore Oil & Gas reserves in the United States. For more information visit www.domeenergy.com.

SSAB announces Tender Offer regarding notes and considers issuance of new notes

SSAB AB (publ) (the “Issuer”) has mandated Danske Bank, DNB and SEB (the “Joint Bookrunners”) to arrange a series of fixed income investor meetings commencing on March 27, 2017. Subject to, inter alia, the prevailing market conditions and the final decision of the Issuer, a SEK 5-year fixed and/or floating rate senior unsecured bond transaction will follow (the “New Issue”). In addition and subject to the conditions stated below, the Issuer hereby announces a Tender Offer directed to holders of its SEK denominated floating and fixed rate notes with ISIN SE0004950517 and SE0004950525 issued on December 13, 2012 and maturing on December 13, 2017 (the “December 2017 Notes”) and to holders of its SEK denominated floating and fixed rate notes, ISIN SE0005757523 and SE0005757515, issued on February 25, 2014 and maturing on February 25, 2019 (the “February 2019 Notes”). As part of the Issuer’s continuous liability management efforts, the purpose of the Tender Offer is to proactively manage upcoming debt redemptions and to extend the debt maturity profile of the Issuer. The Tender Offer Conditional upon the New Issue, the Issuer is hereby offering to repurchase any and all of the outstanding December 2017 Notes and February 2019 Notes for cash (the “Tender Offer”). The Issuer offers to pay a cash purchase price for the December 2017 Notes and February 2019 Notes tendered equal to the following amounts: December 2017 Notes · for the floating rate notes (ISIN: SE0004950517), 102.20% of the nominal principal amount of each note (plus accrued and unpaid interest from (but excluding) the previous day of interest payment and including the relevant settlement date); and · for the fixed rate notes (ISIN: SE0004950525), 103.50% of the nominal principal amount of each note (plus accrued and unpaid interest from (but excluding) the previous day of interest payment and including the relevant settlement date) February 2019 Notes · for the floating rate notes (ISIN: SE0005757523), 101.90% of the nominal principal amount of each note (plus accrued and unpaid interest from (but excluding) the previous day of interest payment and including the relevant settlement date); and · for the fixed rate notes (ISIN: SE0005757515), 105.70% of the nominal principal amount of each note (plus accrued and unpaid interest from (but excluding) the previous day of interest payment and including the relevant settlement date) Holders who participate in the Tender Offer and express an interest in participating in the New Issue may be given priority allocation in the New Issue. The Issuer reserves the right to not proceed with the New Issue. Preliminary Timeline The Tender Offer is expected to close on March 29, 2017. However, the Issuer reserves the right to extend, withdraw or terminate the period of acceptance for the Tender Offer. The Issuer will announce the results and whether any of the December 2017 Notes and/or February 2019 Notes will be accepted for the offer after the pricing of the New Issue. The anticipated settlement date for the Tender Offer and New Issue is on or about April 5, 2017. Participation We kindly ask you to contact your custody bank or your sales contact at one of the Joint Bookrunners if you wish to tender your notes and/or if you have any questions related to the Tender Offer or the New Issue. Joint Bookrunners Danske BankContact person: Johan HansenEmail: liabilitymanagement@danskebank.seTelephone: +46 8 568 805 54 DNBContact person: Henrik KansmarkEmail: henrik.kansmark@dnb.seTelelphone: +46 8 473 4816 SEBContact person: Peter SwärdEmail:  SEBliabilitymanagement@seb.seTelephone: +46 8 506 232 18 For further information please contact: Henrik G. Welch, Vice President, Head of Group TreasuryTelephone: +46 70 2638399E-mail: henrik.welch@ssab.com Peter Nordquist, Head of Funding and Markets OperationsTelephone: +46 8 454 5745E-mail: peter.nordquist@ssab.com  This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States or in any other jurisdiction in which, or to or from any person to or from whom, it is unlawful to make such invitation under applicable securities laws. The securities to which this announcement relates have not been, and will not be, registered under the US Securities Act of 1933, as amended (the "Securities Act") or the securities laws of any state or other jurisdiction of the United States and may not be offered or sold in the United States or to US persons (as such term is defined in Regulation S under the Securities Act), except pursuant to registration or an exemption from the registration requirements of the Securities Act. There will be no public offer of securities in the United States. This communication is being distributed outside the United States solely to non-US persons as defined under Regulation S. This announcement is not being made, and this announcement has not been approved, by an authorised person for the purposes of Section 21 of the Financial Services and Markets Act 2000 (the "FSMA"). This announcement is not an invitation nor is it intended to be an inducement to engage in investment activity for the purpose of Section 21 of the FSMA. Accordingly, this announcement is not being distributed to, and must not be passed on to, the general public in the United Kingdom. Rather, this announcement is being distributed on the basis it is only directed at: (i) persons who are outside the United Kingdom; (ii) persons who are investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) of the United Kingdom; or (iii) any other persons to whom this announcement for the purposes of Section 21 of FSMA can otherwise lawfully be made (all such persons together being referred to as "relevant persons"), and must not be acted on or relied upon by persons other than relevant persons. Any invitation or inducement to engage in any investment activity included within the announcement is available only to relevant persons and will be engaged in only with relevant persons.  Anyone other than a relevant person must not rely on this announcement.

Regional Jet OÜ takes over ATR production for SAS

SAS has concluded an agreement with Regional Jet OÜ, which will mainly operate routes to and from Copenhagen with four ATR72-600s. The other Jet Time production will be solved by a reduction in services and by redistributing existing capacity to other types of aircraft. “We have now found the right collaborative partner to take over Jet Time’s flights. We look forward to working with Regional Jet OÜ, which is a competent and reliable partner and a key contribution to our wet lease strategy,” says Mikael Wångdahl, VP External Production at SAS. Since November 2016 when the agreements with Jet Time were wound up, the company has been working to find a new wet lease operator which can operate SAS’s regional services with ATR72s. A number of airlines have been involved in negotiations for the contract but the choice has fallen on Regional Jet OÜ on the basis of a number of parameters. Among other things, audits of SAS’s Quality and Compliance Monitoring have yielded excellent results. The agreement with Regional Jet OÜ spans six years but can be terminated after three. The four ATR72-600s that will be flying for SAS, in SAS’s colors, will be staffed mainly by Copenhagen-based crews on local agreements. Regional Jet OÜ was founded in 2015 as an independent company, supplying wet lease services to other companies. The company is owned by Nordic Aviation Group (Nordica) and LOT Polish Airlines (LOT). Today it operates three aircraft for LOT and five for Nordica and will thereby expand its fleet by four aircraft to operate flights for SAS.

Announcement from Sotkamo Silver AB AGM on 23 March 2017

Sotkamo Silver AB (publ) held its Annual General Meeting (AGM) on Thursday 23 March 2017 in Stockholm.The following main decisions were made at the AGM:The income statement and the balance sheet for both the parent company and the group regarding the financial year 2016 were adopted by the AGM. The AGM decided that no dividend would be paid out for the financial year 2016. The members of the Board and the CEO were granted discharge from liability for the financial year 2016.The AGM decided that the Board would comprise of five ordinary members without deputy directors. Mauri Visuri, Teuvo Jurvansuu and Jarmo Vesanto were re-elected as directors and Ilkka Tuokko and Matti Rusanen were elected as directors. Mauri Visuri was re-elected chairman of the Board.The AGM resolved to re-elect the auditing company PWC until the end of the AGM 2018, with Anna Rosendal as the head auditor for the time being.The guidelines for remuneration for the management and the procedure for appointing the members of the nomination committee were approved in accordance with the proposals from the Board.The AGM approved the nomination committee’s proposal for annual fees to the Board with a total of SEK 850,000.The AGM resolved, for the period until the next AGM, to authorize the Board, at one or several occasions, to issue new shares or other financial instruments. The authorization is limited to a maximum dilution of ten (10) percent of the total number of shares outstanding at the time of the first Board resolution in accordance with the authorization.Stockholm on 23 March 2017SOTKAMO SILVER AB (publ)Timo Lindborg, CEOSotkamo Silver AB discloses the information provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act.The official Stock Exchange Releases are given in Swedish and there may be differences in the translated versions.About Sotkamo Silver AB:Sotkamo Silver AB´s business concept is to exploit mineral deposits in the Nordic countries with positive social and environmental benefits. Sotkamo Silver owns mineral deposits, which contain silver and gold in Finland as well as zinc and gold in Norway. The Company’s main development project is the Silver Mine project in the municipality of Sotkamo, Finland.Sotkamo Silver applies SveMin’s & FinnMin’s respective rules of reporting for public mining & exploration companies. Sotkamo Silver has chosen to report mineral resources and ore reserves according to the internationally accepted JORC or NI 43-101 code. The company applies International Financial Reporting Standards (IFRS) as approved by the European Union.The number of shares and votes in the company are 105,966,095.The ticker symbol is SOSI in NGM Equity in Stockholm and SOSI1 in NASDAQ OMX Helsinki.ISIN-code for Sotkamo Silver shares is SE0001057910.ISIN- code for share warrants series 2016/2017 are SE0008373880Legal Entity Identifier (LEI): 213800R2TQW1OZGYDX93Read more about Sotkamo Silver on www.sotkamosilver.com or www.silver.fiRead more about Mining Associates on www.miningassociates.com

Decisions by Stockmann’s Annual General Meeting

STOCKMANN plc, Decisions of general meeting 23.3.2017 at 16:45 EET The Annual General Meeting of Stockmann plc, held in Helsinki on 23 March 2017, adopted the financial statements for the financial year 1 January - 31 December 2016, granted discharge from liability to the responsible officers and, in accordance with the proposal of the Board of Directors, resolved not to pay a dividend for the financial year 2016. The General Meeting also decided on the composition and remuneration of the Board of Directors and the selection and remuneration of the auditor in accordance with the proposals presented. A permanent Shareholders' Nomination Board will be appointed to yearly prepare proposals on the composition and remuneration of the Board of Directors to the Annual General Meeting, and if necessary to an Extraordinary General Meeting. CEO’s review At the Annual General Meeting, Stockmann’s CEO Lauri Veijalainen gave an overview of Stockmann’s strategy implementation and financial performance in 2016. During the year, the company withdrew from several non-core businesses, which helped the company to reach a positive operating result after two years of losses. The department store operations in Russia were divested on 1 February 2016 and Hobby Hall on 31 December 2016. The company now focuses on retail operations under the Stockmann and Lindex brands and real estate business. All options are investigated also in the future to improve profitability and value of the company. Stockmann’s efficiency programme had an annual cost savings target of EUR 50 million, which was achieved by the end of 2016. Additional measures launched in summer 2016 will bring more than EUR 20 million of further savings beginning from this year. The Stockmann Group’s positive operating result in 2016 is proof that the chosen direction is right. Stockmann expects the Group’s adjusted operating profit in 2017 to improve, compared with 2016. Composition and remuneration of the Board of Directors In accordance with the proposal of the Shareholders' Nomination Board, the Annual General Meeting resolved that eight members be elected to the Board of Directors. In accordance with the Nomination Board’s proposal, Kaj-Gustaf Bergh, Jukka Hienonen, Susanne Najafi, Leena Niemistö, Michael Rosenlew, Per Sjödell and Dag Wallgren were re-elected as members of the Board of Directors. Following the announcement by Torborg Chetkovich that she will no longer be available as member, Esa Lager was elected as a new Board member. The Board members’ term of office will continue until the end of the next Annual General Meeting. It was resolved to keep the Board members’ fixed annual remuneration unchanged, and the remuneration will continue to be paid mainly in shares. The members of the Board are also paid a meeting remuneration for each Board and committee meeting, as decided by the Annual General Meeting. Auditors Henrik Holmbom, Authorized Public Accountant, and Marcus Tötterman, Authorized Public Accountant, were re-elected as regular auditors. KPMG Oy Ab, a firm of authorised public accountants, will continue as the deputy auditor. The auditors will be paid in accordance with approved invoices. Organisational meeting of the Board of Directors The Board of Directors, which convened after the Annual General Meeting, elected Jukka Hienonen as its Chairman, and Leena Niemistö as its Vice Chairman. The Board has assessed the independence of its members in accordance with Recommendation 10 in the Finnish Corporate Governance Code 2015. According to the assessment six of the members of the Board are independent of the company (Jukka Hienonen, Leena Niemistö, Kaj-Gustaf Bergh, Esa Lager, Michael Rosenlew and Dag Wallgren). Five of the company's board members are independent of major shareholders (Jukka Hienonen, Esa Lager, Susanne Najafi, Leena Niemistö, and Per Sjödell). The Board of Directors decided to establish an Audit Committee and a Compensation Committee among its members. Dag Wallgren was elected as Chairman of the Audit Committee, and Esa Lager and Michael Rosenlew were elected as the other members of the committee. Jukka Hienonen was elected as Chairman of the Compensation Committee and Kaj-Gustaf Bergh and Leena Niemistö as the other members of the committee. Further information:Jukka Naulapää, Director, Legal Affairs, tel. +358 9 121 3850 www.stockmanngroup.com STOCKMANN plc Lauri VeijalainenCEO Distribution:Nasdaq HelsinkiPrincipal media

Tieto Corporation Decisions of the Annual General Meeting on 23 March 2017

Tieto Corporation STOCK EXCHANGE RELEASE 23 March 2017, 19.00 EETTieto Corporation's Annual General Meeting of Shareholders approved the financial statements for 2016, decided to distribute a dividend of EUR 1.37 per share (ordinary dividend of EUR 1.15 and additional dividend of EUR 0.22) and discharge the company's officers from liability for the financial year 2016. The dividend settlement date is 27 March 2017 and the dividend will be paid as from 6 April 2017.In addition, the Annual General Meeting made the following decisions:Board composition and remunerationThe meeting decided that the Board of Directors shall consist of eight members and re-elected the Board's current members Kurt Jofs, Johanna Lamminen, Harri-Pekka Kaukonen, Sari Pajari, Endre Rangnes and Jonas Synnergren. Timo Ahopelto and Jonas Wiström were elected as new members. Kurt Jofs was elected as the Chairman of the Board of Directors.In addition to the above, the company's personnel appoints two members, each with a personal deputy, to the Board of Directors. The term of office for the personnel representatives is two years. Esa Koskinen (deputy Ilpo Waljus) and Anders Palklint (deputy Robert Spinelli) have been appointed to the Board until the Annual General Meeting 2018.The meeting approved that the fixed annual remuneration of the Board of Directors will be as follows: EUR 91 000 to the Chairman, EUR 55 000 to the Deputy Chairman and EUR 36 000 to the ordinary members of the Board of Directors. The same fee as to the Board Deputy Chairman will be paid to the Chairman of a Board Committee unless the same individual is also the Chairman or Deputy Chairman of the Board. In addition, a remuneration of EUR 800 is paid for each Board meeting and for each permanent or temporary committee meeting. It is the company's practice not to pay fees to Board members who are also employees of the Tieto Group.The meeting approved that 40% of the fixed annual remuneration be paid in Tieto Corporation’s shares purchased from the market. The shares will be purchased within two weeks from the release of the interim report 1 January–31 March 2017 of Tieto Corporation. The Annual General Meeting resolved to acquire the shares directly on behalf of the members of the Board which is an approved manner to acquire the company’s shares in accordance with the applicable insider rules.AuditorThe meeting re-elected the firm of authorized public accountants PricewaterhouseCoopers Oy as the company's auditor for the financial year 2017. The auditor shall be reimbursed according to the auditor’s invoice and in compliance with the purchase principles approved by the Audit and Risk Committee.Amendment of the company’s Articles of AssociationThe meeting decided that Articles 1 and 6 of the Articles of Association of the company be amended as follows:“1 § Company name and domicileThe company name in Finnish is Tieto Oyj, in Swedish Tieto Abp and in English Tieto Corporation.The domicile of the company is Espoo.”"6 § AuditorThe company has one ordinary auditor who shall be an audit firm with a KHT auditor as the auditor with principal responsibility.The term of office of the auditor expires at the closing of the first Annual General Meeting following his election."Authorizing the Board of Directors to decide on the repurchase of the company's own sharesThe Board of Directors was authorized to decide on the repurchase of the company's own shares as follows:The amount of own shares to be repurchased shall not exceed 7 400 000 shares, which currently corresponds to approximately 10% of all the shares in the company. Only the unrestricted equity of the company can be used to repurchase own shares.Own shares can be repurchased at a price formed in public trading on the date of the repurchase or at a price otherwise formed on the market.The Board of Directors decides how the share repurchase will be carried out. Own shares can be repurchased inter alia by using derivatives. The company’s own shares can be repurchased otherwise than in proportion to the shareholdings of the shareholders (directed repurchase).The authorization cancels previous unused authorizations to decide on the repurchase of the company’s own shares. The authorization is effective until the next Annual General Meeting, however, no longer than until 30 April 2018.Authorizing the Board of Directors to decide on the issuance of shares as well as options and other special rights entitling to sharesThe Board of Directors was authorized to decide on the issuance of shares as well as on the issuance of option rights and other special rights entitling to shares referred to in chapter 10 section 1 of the Companies Act in one or more tranches as follows:The amount of shares to be issued based on the authorization (including shares to be issued based on the special rights) shall not exceed 7 400 000 shares, which currently corresponds to approximately 10% of all the shares in the company. However, out of the above maximum amount of shares to be issued no more than 700 000 shares, currently corresponding to less than 1% of all of the shares in the company, may be issued as part of the company’s share-based incentive programs.The Board of Directors decides on the terms and conditions of the issuance of shares, option rights and other special rights entitling to shares. The authorization concerns both the issuance of new shares as well as the transfer of treasury shares. The issuance of shares and of special rights entitling to shares may be carried out in deviation from the shareholders’ pre-emptive right (directed issue).The authorization cancels previous unused authorizations to decide on the issuance of shares and on the issuance of options and other special rights entitling to shares. The authorization is effective until the next Annual General Meeting, however, no longer than until 30 April 2018.There were 532 shareholders represented at the meeting representing altogether 47 792 617 shares and votes. All decisions were made without voting.For further information, please contact: Deputy General Counsel Esa Hyttinen, tel. +358 40 766 6196, firstname.lastname (at) tieto.comDISTRIBUTIONNASDAQ HelsinkiPrincipal Media

Nordic Nanovector publishes Annual Report 2016

Oslo, Norway, 24 March 2017 The Board of Directors of Nordic Nanovector ASA (OSE: NANO) has approved the company’s Annual Report 2016 including the complete 2016 Annual Accounts with notes. The report is attached to this announcement and available on Nordic Nanovector’s website in the section Investor Relations/Reports and presentations/Annual Reports. For further information, please contact: IR enquiries:Tone Kvåle, Chief Financial OfficerCell: +47 91 51 95 76Email: ir@nordicnanovector.com Media enquiries:Mark Swallow/David Dible (Citigate Dewe Rogerson)Tel: +44 207 282 2948/+44 207 282 2949Email: nordicnanovector@citigatedr.co.uk About Nordic Nanovector:Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to improve upon and complement current options for the treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing market forecast to be worth nearly USD 20 billion by 2024. The Company aims to rapidly develop Betalutin®, alone and in combination with other cancer therapies, for the treatment of major types of NHL, targeting first regulatory submission in relapsed/refractory follicular lymphoma in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. The Company is also advancing a pipeline of ARCs and other immunotherapies for multiple cancer indications.Further information about the Company can be found at www.nordicnanovector.com Forward-looking statementsThis announcement may contain certain forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on Nordic Nanovector’s business, financial condition and results of operations. The terms “anticipates”, “assumes”, “believes”, “can”, “could”, “estimates”, “expects”, “forecasts”, “intends”, “may”, “might”, “plans”, “should”, “projects”, “will”, “would” or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statement. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in a forward-looking statement or affect the extent to which a particular projection is realised. Factors that could cause these differences include, but are not limited to, implementation of Nordic Nanovector’s strategy and its ability to further grow, risks associated with the development and/or approval of Nordic Nanovector’s products candidates, ongoing clinical trials and expected trial results, the ability to commercialise Betalutin®, technology changes and new products in Nordic Nanovector’s potential market and industry, the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors. No assurance can be given that such expectations will prove to have been correct. Nordic Nanovector disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This information is subject to a duty of disclosure pursuant to Section 5-12 of the Securities Trading Act.

Bulletin from AB Electrolux Annual General Meeting 2017

Petra Hedengran, Hasse Johansson, Ronnie Leten, Ulla Litzén, Bert Nordberg, Fredrik Persson, David Porter, Jonas Samuelson and Ulrika Saxon were re-elected to the Board of Directors. Kai Wärn was elected new Board member. Ronnie Leten was re-elected Chairman of the Board. The proposed dividend of SEK 7.50 per share was adopted. The AGM adopted the proposal that the dividend shall be paid in two equal installments of SEK 3.75 per installment and share, the first with the record date Monday, March 27, 2017, and the second with the record date Wednesday September 27, 2017. The first installment of the dividend is expected to be paid by Euroclear Sweden AB on Thursday, March 30, 2017 and the second installment on Monday, October 2, 2017. The parent company’s and the Group’s income statements and balance sheets were adopted. The Board of Directors and the President were discharged from liability for the financial year 2016. The Meeting resolved to adopt the remunerations to the Board that were proposed in the notice convening the AGM. The proposal for remuneration guidelines for Group Management was also approved, as well as the scope of and the principles for Electrolux performance based, long-term share program for 2017. The Meeting authorized the Board of Directors to resolve on acquisitions of Electrolux B shares up to a maximum amount of 10 percent of all shares issued by the company. The Board was also authorized to transfer own shares on account of company acquisitions and to cover costs that may arise as a result of the share program for 2015. These authorizations are effective during the period until next year’s AGM. Full details on the proposals adopted by the AGM can be downloaded at www.electroluxgroup.com/agm2017.

Storytel expanding to four new markets

“Whenever we enter a new country or region, we make long-term investments and build from the ground up,” says Storytel’s CEO Jonas Tellander. “Cooperating with leading publishers is important, and so is our local staff: we hand-pick employees in order to fit Storytel’s entrepreneurial corporate culture. This is a sustainable and goal-oriented strategy which has served us well in our existing markets.” First up will be Russia, where Storytel goes online this spring. The focus will be on lighter fiction, but non-fiction will also be offered among the 1,500 audio books first available. By the end of the year, the Russian catalogue will have grown to 4,000 titles. “We’re breaking new ground and intend to make audio books a major force in Russia. Our local team has a strong set-up, and will work hard to make sure Storytel achieves its goals,” says CEO Tellander. Storytel currently produces about 2,000 audio books in about ten languages per year, which makes the company one of the world’s largest audio-book producers. “Stories written by local authors are often more popular, which is why we’ve been developing and producing Stoytel Original-content through our local teams. However in Russia we’ll be satisfied strictly distributing and producing previously published material. We’re aware of the limitations of freedom of speech in Russia and that’s why we have, for the time being, decided against offering original content there,” says Tellander. With the range of audio books in local languages increasing, in the autumn of 2017 Storytel plans to open shop in the Spanish, Indian and Arabic markets. Storytel’s overseas expansion has already been budgeted for during the current fiscal year, for which the concern accordingly made a secondary stock offering worth 100 million Swedish crowns last autumn. For more information, please contact: Jonas Tellander, CEO and founder: 0046 70 261 6136 The information in this press release is information which Storytel AB (publ) is required to disclose under EU Market Abuse Regulation (EU). The information was provided by the below contact persons for publication on March 24, 2017.

Capio to acquire a German eye specialist clinic in Bremen

Augenklinik Universitätsallee is located centrally in Bremen and performs annually about 6,000 surger­ies and 6,000 other treatments. The clinic serves both publicly remunerated and private pay patients, and to some extent also international patients. Around 70% of sales is publicly remunerated, while the remaining 30% refers to private pay patients. One of the two former owners of Augenklinik Universi­tätsallee will continue his involvement in the company and secure continuity and knowledge transfer. “We are very pleased with the opportunity to acquire Augenklinik Universitätsallee, which is a well-established ophthalmology business focused on Modern Medicine. Capio already today offers ophthalmology treatments in several markets, and is through Capio Medocular one of the largest private companies within ophthalmology treatments in the Nordics. The acquisition of Augenklinik Universitätsallee opens up for further exchange of knowledge and experience between operations in different countries, and improvements of quality and productivity – for the benefit of our patients”, says Thomas Berglund, President and CEO of Capio. The size of the German market for ophthalmology is estimated around EUR 3 billion (2014). The market is relatively fragmented and the market share for single practices is in total around 75% and there are no large players of substantial size. Two types of treatments, of cataracts and age-related macular degenera­tion, account for about 64% of eye surgery expenditures in Germany. Eye diseases are to a large extent age related, and the market is consequently expected to grow with the forecasted demographic development in Germany (with an increasing share of the population being elderly). An ageing population combined with a higher prevalence of eye diseases from lifestyle effects (such as e.g. diabetes), is expected to lead to a general increase in the demand for eye treatments. Enterprise value, i.e. purchase price plus acquired net debt, is approximately MEUR 10, corresponding to about MSEK 95. The acquisition also includes an agreed possible future earn-out of maximum MEUR 3 based on the future financial performance. The acquisition is expected to be closed and included in Capio from April 2017, and is expected to contribute positively to Capio’s earnings during 2017. For information, please contact: Kristina Ekeblad, IR managerTelephone: +46 708 31 19 40  Henrik Brehmer, SVP Group Communication and Public AffairsTelephone: +46 761 11 34 14    This information is information that Capio AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:30 CET on March 24, 2017. 

Finnair selected as Best European Airline at TTG China Travel Awards

Finnair has been selected as the Best European Airline at the 10th annual TTG China Travel Awards for the second year in a row. The TTG China Travel Awards recognizes Greater China’s best companies in the travel industry, including airlines, hotels and resorts, serviced residences and travel services. The selection is done by TTG readers and travel industry professionals. Commenced in 2007, TTG China Travel Awards has become one of the most popular and influential travel industry awards in Greater China. “We are honored to receive this prestigious award and I would like to thank all TTG readers and contributors in China,” says Juha Järvinen, Chief Commercial Officer, Finnair. “We want to offer a Unique Nordic experience and the best long-haul business class among European carriers. We will continue to invest in customer service, meals, entertainment, lounges and aircraft cabin to maintain and improve our high customer satisfaction level. We have also recently launched a pilot program on our Beijing and Shanghai routes, where customers can use Alipay mobile payment onboard for easy shopping, and the feedback has been very positive.” Finnair is focused on fast Europe-Asia connections, and currently connects six destinations in Greater China to its network of over 70 European destinations. Finnair has year-round flights to Beijing, Chongqing, Hong Kong and Shanghai, and a summer service to Xi'an and Guangzhou.

Farstad Shipping ASA – Signed plans to merge Solstad Offshore ASA, Farstad Shipping ASA and Deep Sea Supply Plc.

Skudeneshavn, Ålesund and Limassol, 24 March, 2017 Reference is made to previous announcements concerning the planned combination of Solstad Offshore ASA ("SOFF" or "Solstad"), Farstad Shipping ASA ("Farstad") and Deep Sea Supply Plc ("DESSC") as first announced on 6 February 2017, and most recently the announcement of 13 March 2017 regarding inter alia the status of the merger plans. The statutory merger plans have today been approved and signed by the boards of Solstad, Farstad, DESSC and Solstad's relevant subsidiaries, into which Farstad and DESSC will be merged. The exchange ratio for Farstad's shares is 0.028 SOFF shares per Farstad share (corresponding to 0.35:12.50). The exchange ratio for DESSC shares is 0.1052631578947368 SOFF shares per DESSC share (corresponding to 1.31578947368421:12.50). Each of Solstad, Farstad and DESSC will immediately after this release also issue a separate release which will contain the relevant technical details on the mergers. Assuming completion of the mergers and transactions ancillary thereto, the issued number of shares in SOFF is expected to be increased to 291,532,299 on the basis that the existing outstanding warrants in DESSC will be continued as warrants in SOFF, in total 1,052,631, instead of being exercised in DESSC. All shares will be of the same class. Aker Capital AS ("Aker"), a subsidiary of Aker ASA, will hold 58,496,302 shares representing 20.1 % of the shares and votes, and Ocean Yield ASA ("Ocean Yield"), a subsidiary of Aker, will hold 8,836,681 shares, representing 3.0 % of the shares and votes. The aggregate holding of Aker and Ocean Yield will be 67,332,983 shares, representing 23.1 % of the shares and votes. Hemen Holding Limited will hold 46,961,289 shares, representing 16.1 % of the shares and votes. The Solstad family will, through its related companies SOFF Invest AS and Ivan II AS, hold 21,066,965 shares, representing approximately 7.2 % of the shares and votes. On a consolidated basis, the Farstad family will hold a total of 4,470,909 shares, representing a consolidated holding of 1.5 % of the shares and votes. Ellen Solstad and Lars Peder Solstad of the Solstad family, who through their related companies hold shares in Solstad Offshore ASA, are a member of the board of directors and the Chief Executive Officer, respectively, of Solstad Offshore ASA. Mr. Frank Ove Reite, CFO of Aker ASA, is a member of the board of directors of Solstad Offshore ASA. Mr. Audun Stensvold, Investment Director of Aker ASA, is a member of the board of directors of Farstad Shipping ASA. *** For further information, please contact: Lars Peder Solstad, Chief Executive Officer of Solstad Offshore ASA at +47 913 18 585 or Sven Stakkestad, Deputy Chief Executive Officer of Solstad Offshore ASA at +47 905 15 802. Karl-Johan Bakken, Chief Executive Officer of Farstad Shipping ASA at +47 901 05 697 or Olav Haugland, Chief Financial Officer of Farstad Shipping ASA at +47 915 41 809 Anders Hall Jomaas, Chief Financial Officer of Deep Sea Supply Plc at +47 400 42 918 This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Oncology Venture to evaluate Eisai oncology drug for in-license to 2X Oncology Inc.

“Oncology Venture is thrilled to work with Eisai and develop a Drug Response Predictor (DRP™) for the compound, and if successful, the drug will be in-licensed for further DRP™-guided clinical development as a precision therapy for Women’s Cancers in 2X Oncology Inc. – a co-owned spinout from Oncology Venture,” said Peter Buhl Jensen, M.D., CEO of Oncology Venture.   About the Drug Response Predictor (DRP™) biomarker platform Oncology Venture uses the Medical Prognosis Institute (MPI) multi gene DRP™ to select those patients that by the genetic signature in their cancer is found to have a high likelihood of response to the drug. The goal is to develop the drug for the right patients and by screening patients before treatment the response rate can be significantly increased. This DRP™ method builds on the comparison of sensitive vs. resistant human cancer cell lines including genomic information from cell lines combined with clinical tumor biology and clinical correlates in a systems biology network. The DRP™ is based on messenger RNA from the patients biopsies. The DRP™ platform (i.e. the DRP™ and the PRP™ biomarkers) can be used in all cancer types, and is patented for more than 70 anti-cancer drugs in the US. The PRP™ is used by MPI for Personalized Medicine. The DRP™ is used in Oncology Venture for drug development. For further information, please contact Ulla Hald Buhl, COO and                   Peter Buhl Jensen, CEOChief IR &     Or           Mobile: +45 21 60 89 22Communications    E-mail: pbj@oncologyventure.com Mobile: +45 2170 1049uhb@oncologyventure.com This information is information that Oncology Venture Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on March 24th 2017. About Oncology Venture Sweden AB Oncology Venture Sweden AB is engaged in the research and development of anti-cancer drugs via its wholly owned Danish subsidiary Oncology Venture ApS. Oncology Venture has an exclusive license to use the Drug Response Predictor (DRP™) technology in order to significantly increase the probability of success in clinical trials. DRP™ has proven its ability to provide a statistically significant prediction of clinical outcomes from drug treatment in cancer patients in 29 of the 37 clinical studies that were examined. The Company uses a model that alters the odds in comparison with traditional pharmaceutical development. Instead of treating all patients with a particular type of cancer, patients’ tumors’ genes are screened first with DRP™ and only those who are most likely to respond to the treatment will be treated. Via a more well-defined patient group, the risk and costs are reduced while the development process becomes more efficient. The current product portfolio: LiPlaCis® for Breast Cancer in collaboration with Cadila Pharmaceuticals, Irofulven developed from a fungus for prostate cancer and APO010 – an immuno-oncology product for Multiple Myeloma. Oncology Venture has spun out two companies in Special Purpose Vehicles: 2X Oncology Inc. a US based company focusing on Precision medicine for women’s cancers with a pipeline of three promising phase 2 product candidates and Danish OV-SPV 2 will test and potentially develop an oral phase 2 Tyrosine Kinase inhibitor.

Rovio Entertainment and Mikael Hed recognized with Hulda Award

The Angry Birds Movie is the most internationally successful Finnish film of all time – circling nearly $300 million in worldwide box office. It is also the second highest-grossing movie based on a game of all time. “Last year a delightfully high number of Finnish projects became international successes but there was never any deliberation as to who the winner was. The Angry Birds Movie’s stratospheric success set a new bar for what was possible for us Finns. It’s also a fantastic example of a best-case scenario of where an unwavering, well thought-out brand architecture can take you,” says Johanna Karppinen, CEO, Audiovisual Finland.“In addition to its financial success, the jury was impressed with how the film moved forward under Mikael Hed’s leadership. Its development process reflected determination and an ambitious vision, as well as courage to take large financial risks. The team had the foresight to gather the top international talents in the business whilst also making sure the knowledge capital was amassed and utilized in Finland,” Karppinen summarizes jury’s argumentation. The award will be presented by Finland’s Minister of Economic Affairs Mika Lintilä at the annual Finnish film industry event, Jussi Gaala, taking place on Friday, March 24. “We are extremely grateful for the recognition. The Angry Birds Movie production, led by Mikael Hed, and its worldwide success has been a remarkable and unique achievement for our company. The Angry Birds brand awareness is higher than ever,“ says Kati Levoranta, CEO, Rovio Entertainment, who will be accepting the award on behalf of Rovio Entertainment.

DNB has sold its part of Dakota Access Pipeline loan

“By selling our stake, we wish to signal how important it is that the affected indigenous population is involved and that their opinions are heard in these types of projects. Although there have been attempts at consultation by the project parties, the outcome of the process suggests that these have been inadequate," says Harald Serck-Hanssen, group executive vice president and head of Large Corporates and International in DNB.   DNB Asset Management chose to sell their mutual fund investments in the companies behind the pipeline in November 2016. Several other Norwegian financial institutions followed suit and have since also sold their investments. At that time, DNB communicated that a sale of the project financing was one of the options under review, but that such a sale would take longer than the sale of shareholdings. In the meantime, DNB has used its position as a lender to try to influence the process, call for a lower level of conflict and took the initiative to carry out an independent investigation of how indigenous people's rights are being safeguarded.  “During the process, we have met several interest groups and listened to their suggestions. We have met, among others, representatives from the Standing Rock Sioux Tribe. We have also engaged in an ongoing dialogue with the company building the pipeline. Many of our customers have contacted us and expressed what they expect from us as a Norwegian bank. In our evaluations, we have taken account of all the input we have received,” says Serck-Hanssen.  Following the sale of the loan, DNB no longer has any direct financial exposure to the Dakota Access Pipeline.  Press contacts:Even Westerveld, EVP, Corporate Communications tel. no. (+47) 400 16 744Pictures: https://dnbfeed.no/bildebank/harald-serck-hanssen/

Albin Rännar will become the new Vice President and CFO of the subsidiary Seamless Distribution Systems (SDS)

Albin Rännar will become the new Vice President and CFO of the subsidiary Seamless Distribution Systems (SDS). His task will be to strengthen the work of preparing the company for the proposed spin-off and continued profitable growth as a stand-alone company. About Albin Rännar: Albin Rännar is 42 years old and until recently held the position as Head of Market Surveillance at the Swedish Shareholders’ Association, where he has been since 2013. Amongst his responsibilities was monitoring the listed companies from a quality perspective. Prior to that, Albin was an entrepreneur since the year 2002. He was co-founder and CEO of Nordic Investor Services, which offers advice to institutional shareholders on corporate governance. Albin is a Master of Science in Economics and Business from the Stockholm School of Economics, specialising in accounting and finance. He has also worked in the areas of venture capital, corporate finance and as a management consultant, both in Sweden and internationally. “I’m looking forward to be able to contribute with my experience and knowledge of orderliness and transparency in publicly listed companies. SDS is a stable, profitable company that processes electronic transactions in emerging markets and contributes to the creation of effective financial markets. This is FinTech that works, for the benefit of ordinary people. We have 675,000 resellers in 28 markets who have an opportunity to earn an income. This is profitable sustainability in emerging markets. It will be an exciting journey, piloting SDS to become a spinned-off, independent company that is valued on its own merits.” “We’re delighted to be able to complete the management team with the arrival of Albin as new Vice President and CFO ahead of the proposed departure from the Seamless Group and Seqr. Albin enjoys a high level of confidence among investors as an incorruptible scrutinizer of listed companies, so his engagement with us represents a hallmark of quality”, says Tommy Eriksson, CEO of SDS. A proposal will be put forward to the general meeting of the parent company on April 20 to authorise the board to decide on the sale of the subsidiary, either through a separate listing on Nasdaq First North or to a third party. Albin will assume the position of Vice President and CFO on April 5.  About Seamless Seamless is one of the world’s largest suppliers of payment systems for mobile phones. Founded in 2001 and active in 35 countries, Seamless handles more than 5.3 billion transactions annually through 675 000 active sales outlets. Seamless has three main business areas including the transaction switch, the technology provider for the distribution of e-products and the mobile payment platform Seqr. www.seamless.se Seamless Distribution AB, Box 6234, 102 34 Stockholm | Visiting address: St Eriksgatan 121 D | Org. no: 556610-2660 Phone: 08-564 878 00 | Fax: 08-564 878 23 | www.seamless.se

NORDIC NANOVECTOR ASA - FINANCIAL CALENDAR

Oslo, Norway, 27 March 2017 FINANCIAL YEAR 2017 Quarterly Report - Q1 - 24.05.2017Quarterly Report - Q2 - 23.08.2017Quarterly Report - Q3 - 22.11.2017 Annual General Meeting - 24.05.2017Capital Markets Day - 27.09.2017 The dates are subject to change. The time and location of the presentations will be announced in due time. For further information, please contact: IR enquiries:Tone Kvåle, Chief Financial OfficerCell: +47 91 51 95 76Email: ir@nordicnanovector.com About Nordic Nanovector:Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to improve upon and complement current options for the treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing market forecast to be worth nearly USD 20 billion by 2024. The Company aims to rapidly develop Betalutin®, alone and in combination with other cancer therapies, for the treatment of major types of NHL, targeting first regulatory submission in relapsed/refractory follicular lymphoma in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. The Company is also advancing a pipeline of ARCs and other immunotherapies for multiple cancer indications.Further information about the Company can be found at www.nordicnanovector.com Forward-looking statementsThis announcement may contain certain forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on Nordic Nanovector’s business, financial condition and results of operations. The terms “anticipates”, “assumes”, “believes”, “can”, “could”, “estimates”, “expects”, “forecasts”, “intends”, “may”, “might”, “plans”, “should”, “projects”, “will”, “would” or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statement. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in a forward-looking statement or affect the extent to which a particular projection is realised. Factors that could cause these differences include, but are not limited to, implementation of Nordic Nanovector’s strategy and its ability to further grow, risks associated with the development and/or approval of Nordic Nanovector’s products candidates, ongoing clinical trials and expected trial results, the ability to commercialise Betalutin®, technology changes and new products in Nordic Nanovector’s potential market and industry, the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors. No assurance can be given that such expectations will prove to have been correct. Nordic Nanovector disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This information is subject to a duty of disclosure pursuant to Section 5-12 of the Securities Trading Act.

ASETEK – New Datacenter Customer in South Korea

Asetek today announced confirmation of an initial order from Intech & Company, Inc., based in Seoul, South Korea, a new customer for our datacenter business. “I am delighted to have Intech & Company come onboard as a new customer. As we continue to expand our datacenter business, I am particularly pleased to have a partner with such strong potential for growing our business in South Korea,” said André Sloth Eriksen, CEO and founder of Asetek. "In Asetek we have found a partner with strong potential for future growth. We are excited to be able to bring Asetek's pioneering liquid cooling technology to our customers and strengthening the datacenter business together," said Jum Sik Kim, CEO of Intech & Company, Inc. This initial order is for sealed loops and therefore comes without Asetek’s standard RackCDU infrastructure. Asetek expects the business with Intech & Company to grow to include both sealed loops and RackCDU/D2C products going forward. This order will result in revenue to Asetek in the range of USD 25,000 with delivery in Q2 2017. About Intech & Company, Inc.Intech & Company, Inc. distributes PC and server components, EMC storage products, and APC power supplies in South Korea. It also provides IT solutions and services for customers. The company was founded in 1981 and is based in Seoul, South Korea. For more information, visit www.intechn.com About AsetekAsetek (ASETEK.OL) is the global leader in liquid cooling solutions for data centers, servers and PCs. Founded in 2000, Asetek is headquartered in Denmark and has operations in California, Texas, China and Taiwan. Asetek is listed on the Oslo Stock Exchange. For more information, visit www.asetek.com For further information, please contact:      André S. Eriksen, Chief Executive OfficerMobile: +45 2125 7076, e-mail: ceo@asetek.com

Ripasso Energy publishes annual report for 2016

In 2016, Ripasso Energy saw major progress. A framework agreement with our Italian-based partner and customer Horizon was entered, allowing us to develop a clear strategic path for the commercialization of our product. The agreement itself stipulates a maximum of 600 engines annually and during the last six months of 2017, we are expecting an order of the first 100 units for delivery in 2018. Moreover, in the first half of 2017, a facility will be constructed at the university of Palermo for demonstration purposes. The past year has further brought significant technological development, in particular with regard to our hybridization technology. We have successfully demonstrated that our Stirling engine can be powered with alternative fuels, complementing the sun when it is not available. This puts us in a unique position as the sole supplier of a renewable-based solution that can reliably provide electricity at any time of day or year. The development in this department has been so substantial that in March 9, 2017, we filed a total of three patent applications to the European Patent Office (EPO). The protection offered by these patents will serve to reinforce our leading position in our business field. Last year was also the year Ripasso Energy became a public company. Following an over-subscribed stock emission, the company was listed at NGM Nordic MTF in Stockholm and traded for the first time on November 28, 2016. The listing has resulted in over 3000 new shareholders and provided us with sufficient funds to now have the capitalization requirements covered well in to 2018. As the company was made public, an agreement with Finwire Media was entered in late 2016. Together with them, we will produce a number of videos detailing the progress of the company. The purpose of this is to provide shareholders with periodic updates of the current matters in Ripasso Energy and as of today, two such movies have been made available. They can be viewed at: https://ripassoenergy.com/en/media/. In addition to these videos, the company is also participates in a number of shareholders’ meetings and fairs, most recently InvestorDagen in Copenhagen with an estimated 1500 visitors. In March of 2017, the first shareholder visit to our production facility in Sibbhult, Sweden was arranged, with approximately 20 attendees. Since the year-end report was published February 14, 2017, the annual report has been adjusted in order to be in line with the rules for large companies in the K3 regulations. Consequently, the expenses of the company are gross reported in the income statement and the capitalized expenditures for development work is a separate item of revenue. An equivalent adjustment has been made to the comparative figures of 2015. Gross reporting in this way does not affect the previously reported operating profits. The annual and audit report are available either as an attachment to this release or under Financial reports on the webpage of Ripasso Energy, https://ripassoenergy.com/en/financial-reports/. For additional information with respect to this press release, please contact Ripasso Energy’s CEO and founder Gunnar Larsson, e-mail: ir@ripassoenergy.com. For more information about the company, visit: https://ripassoenergy.com/. This information is information that Ripasso Energy is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, at 10:00 on March 27, 2017.

Saab and Loomis Group sign Global Framework Agreement for a Secure Transport Logistic System

The framework agreement consolidates already existing agreements between Saab and Loomis Group and includes the use of the TRACK and TRACE system in four new markets. “We are excited about this new agreement and look forward to continuing our successful partnership with Loomis to jointly develop and deliver their key operational system across their global operation. Our solution will support them in consolidating their systems portfolio and standardising their operational procedures and support. The agreement also supports expansion into new markets,” says Jonas Hjelm, head of Saab business area Support and Services. Saabs offers a system called TRACK and TRACE that provides customers with a secure logistic solution for different kinds of transportation. With this solution a user can gain full control over their logistic services through a work-order based system that manages, monitors and measures all services provided for the end customer. The system also creates an operational audit trail from commitment start to final execution, which facilitates having full control throughout the entire transport logistics chain. The system can also be used on mobile platforms. For further information, please contact:Saab Press Centre,+46 (0)734 180 018presscentre@saabgroup.com www.saabgroup.com www.saabgroup.com/YouTube Follow us on twitter: @saab  Saab serves the global market with world-leading products, services and solutions within military defence and civil security. Saab has operations and employees on all continents around the world. Through innovative, collaborative and pragmatic thinking, Saab develops, adopts and improves new technology to meet customers’ changing needs.